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Abstract 
 
 The multi-functional RNA binding protein FUS was identified as an androgen down-
regulated target in a 2D proteomic screen in the LNCaP cell line. This screen was 
designed to identify novel markers and therapeutic targets for prostate cancer. Cell cycle 
analysis and growth assays revealed that increased FUS levels in LNCaP cells resulted in 
inhibition of the androgen-dependent G1-S cell cycle transition and induced apoptosis. 
This is brought about, in part, via the FUS-dependent modulation of the expression of G1-
S check-point regulatory proteins, including decreased expression of Cyclin D1.  
Therefore, we have identified FUS as a key link between androgen signalling and cell 
cycle regulation. 
FUS also modulates androgen signalling by repressing Androgen Receptor (AR) 
activity. FUS is known to interact with the DNA binding domain of some nuclear receptors, 
and a mammalian 2-hybrid interaction assay revealed a ligand-dependent interaction 
between FUS and the AR that required the FUS RNA recognition motif. Transcription 
assays demonstrated that FUS is a novel co-repressor of AR activity, and quantitative real 
time PCR showed that increasing FUS levels down-regulated androgen-regulated gene 
expression in LNCaP cells, whilst reducing FUS levels resulted in an increase of the 
androgen-regulated gene TMPRSS2.  
Investigation into the mechanism(s) by which FUS represses AR activity revealed 
that FUS contains an NH2-terminal activation domain (amino acids 1-366) that is 
consistent with the AR transcriptional repression domain. Furthermore, the FUS NH2-
terminal interacts with co-activators, including SRC-1, suggesting FUS may repress AR 
activity by competition with co-activator activity.  
 Recent studies in Dr Charlotte Bevan’s laboratory demonstrated an inverse 
correlation between FUS expression and Gleason grade in human prostate tumours. This, 
combined with these findings that FUS is an inhibitor of androgen-dependent growth which 
is, in part, via repression of the AR, suggests that FUS is a key regulator in AR signalling 
and prostate cancer progression, and may be a novel tumour suppressor.  
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1. Introduction 
 
1.1 The nuclear receptor superfamily 
 Proteins belonging to the nuclear receptor superfamily regulate diverse 
physiological functions including embryonic development, cell differentiation and 
homeostasis (Mangelsdorf et al., 1995). Many members act as ligand-activated 
transcription factors and provide a direct link between signalling molecules and 
transcriptional responses. However, a large number of nuclear receptors have no defined 
ligand and are termed ‘orphan receptors’ (Mangelsdorf et al., 1995). The nuclear receptor 
family is highly conserved between species, with 21 nuclear receptor genes identified in 
the genome of Drosphilia melanogaster (Adams et al., 2000), 270 in the nematode worm 
Caenorhabditis elegans (Sluder et al., 1999) and 48 identified in humans (Robinson-
Rechavi et al., 2001).   
 Several methods have been proposed for subdividing the nuclear receptor family, 
including phyolgenetic division, using the nuclear receptor (NR)xyz nomenclature, where x 
is the sub-family, y is the group and z is the gene (Committee, 1999; Laudet, 1997). In this 
grouping the Androgen Receptor (AR) is located in sub-family 3 in nuclear receptor group 
3C, which also includes the Glucocorticoid, Progesterone and Mineralocorticoid Receptors 
(GR, PR and MR respectively) (Committee, 1999) (Figure 1.1). Hence an alternative gene 
name for the AR gene is NR3C4.  
 Nuclear receptors have also been grouped into 4 classes based upon their 
dimerization and DNA binding properties (Mangelsdorf et al., 1995) (Figure 1.2). Class I 
nuclear receptors include the steroid hormone receptors AR, GR, PR, MR and Oestrogen 
Receptor (ER), all of which function as ligand-inducible homodimers and bind DNA half 
sites organized as inverted repeats. Class II receptors all heterodimerize with Retinoid X 
Receptor (RXR) and bind to direct repeat or symmetrical DNA binding sites. This group 
includes all other known ligand-dependent receptors. Class III and IV contain mostly 
orphan receptors, with class III receptors binding primarily as homodimers to direct repeat 
DNA binding sites, and class IV receptors binding as monomers (Mangelsdorf et al., 
1995). However, recent advances determining the three dimensional structures of nuclear 
receptor DNA binding domains and the identification of specific DNA binding elements in 
chromatin immunoprecipitation studies suggests that some nuclear receptors, such as the 
AR, can bind both direct and inverted repeat response elements, suggesting this 
classification system may not be accurate and nuclear receptor DNA binding may be
Figure 1.1. Phylogenetic tree of the nuclear receptor superfamilly in Vertebrates, Arthropods 
and Nematodes. Alignment between the DNA binding, hinge and ligand binding domains of 
nuclear receptors was performed to generate a phylogenetic tree where line length represents 
amino acid conservation. Subfamilies are represented by numbers 1-6 on far right and groups 
represented by letters. Adapted from Cell. 1999 Apr 16;97(2):161-3 and reproduced with 
permission.    
steroid receptor group 
? 
16 
? ? ? 
Class I 
steroid receptors 
Class II 
RXR heterodimers 
Class III 
dimeric orphan receptors 
Class IV 
Monomeric orphan receptors 
AR, GR, MR, PR & ER TRα/β, RARα/β/γ, VDR, PPARα/β/γ & EcR,  
RXR, USP, HNF-4 & COUP/ARF  
RXR 
NGFI-B & ELP 
Figure 1.2. Representative diagram of nuclear receptor superfamily classification according 
to ligand binding domain, DNA binding and dimerization properties. Representative receptor 
is depicted on DNA element (red arrow) indicating the DNA binding element orientation. Class 
protein members are listed below. Class I includes Androgen, Glucocorticoid, Mineralocorticoid, 
Progesterone and Oestrogen Receptors (AR, GR, MR, PR and ER respectively). Class II includes 
Thyroid, Retinoic Acid, Vitamin D, Peroxisome Proliferator activated and Ecdysone Receptors (TR, 
RAR, VDR, PPAR and EcR respectively). Class III includes Retinoid X, Hepatocyte Nuclear Factor 
4 Receptors (RXR and HNF-4 respectively), and Chicken Ovalbumin Upstream Promoter/Apolipo 
Protein A1 Regulatory Protein (COUP/ARP). Class IV includes Neuronal Growth Factor 1B and 
Ellipse Receptors (NGF-1B and ELP respectively). 
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highly variable within these classes (see sections 1.2.2 and 1.2.4, androgen response 
elements and the DNA binding domain respectively).  
 
1.2 The structure and function of the Androgen Receptor (AR)  
 The AR gene is located on chromosome Xq11-12, spanning 90Kb and contains 8 
exons encoding a protein of approximately 110KDa (Brown et al., 1989; Kuiper et al., 
1989; Lubahn et al., 1988; Marcelli et al., 1990). The AR protein shares the modular 
structure organization common to the nuclear receptor superfamily. This structure consists 
of an NH2-terminal domain containing activation function 1 (AF1) encoded by exon 1, a 
central DNA binding domain (DBD) encoded by exons 2-3, and a COOH-terminal domain, 
which contains the ligand-dependent activation function 2 (AF2) encoded by exons 4-8. 
The DBD and COOH-terminal domain are separated by a hinge region (Doesburg et al., 
1997; Robinson-Rechavi et al., 2003) (Figure 1.3).  
 
1.2.1 Androgen Receptor transcription and expression 
 The AR promoter lacks a TATA and CAAT sequence in the region 5’ to the mRNA 
transcriptional start site (Baarends et al., 1990). Transcription factor binding sites have 
been identified in the AR promoter, including conserved sites for the house keeping 
proteins Specificity Protein 1 (Sp1) (Baarends et al., 1990) and Nuclear Factor 1 (NF-1) 
(Song et al., 1999). DNA binding sites have also been identified for inducible transcription 
factors Nuclear Factor kB (NF-kB) (Zaidi & Supakar, 2003), cyclic adenosine 
monophosphate (cAMP) Response Element Binding protein (CREB) (Lindzey et al., 1993; 
Mizokami et al., 1994), MYC (Grad et al., 1999), E Twenty Six (ETS) and Activator Protein 
1 (AP-1) (as reviewed in Lee & Chang, 2003; McEwan, 2004).  
 The AR coding sequence contains two androgen response elements (AREs) 
located in exons 4 and 5 to which AR has been shown to bind, suggesting AR expression 
may be autoregulated (Dai & Burnstein, 1996; Grad et al., 1999). In support of this, 
androgens are reported to down regulate AR mRNA levels in the human prostate cell line 
LNCaP (Krongrad et al., 1991), suggesting a negative feedback mechanism limiting the 
androgen response. However, this mechanism is not fully understood since androgens are 
also reported to up-regulate AR mRNA expression in several cell lines including 
hepatocellular carcinoma (Yu et al., 1995) and osteoblasts (Wiren et al., 1997), and also 
increase AR protein levels (Krongrad et al., 1991). 
 
N-terminus (AF-1) DBD LBD (AF-2) 
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Figure 1.3. Representative diagram of the Androgen Receptor (AR) gene and modular 
protein structure. The human AR (above) consisting of 8 exons, gives rise to the AR protein 
(below). The AR protein domains are indicated, including activation function domains 1 and 2 (AF1 
and AF2), the DNA binding domain (DBD) and nuclear localization signal (NLS). Amino acid 
domain boundaries are indicated by amino acid residue numbers and  known functions of the 
domains are listed below. 
Human AR gene: Xq11-12 
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 Immunohistochemistry studies in rats have revealed that the AR is expressed in 
most tissues, including the prostate, testis, ovaries, uterus, neurons, mammary gland, skin, 
pituitary, thyroid, adrenal cortex liver, cardiac muscle, bladder and bone (Pelletier, 2000). 
 
1.2.2 Androgen response elements (AREs) 
 Steroid receptors AR, GR, PR and MR bind to the consensus DNA sequence 5’-
TGTTCT-3’ organised as hexameric inverted repeat separated by three nucleotides (Cato 
et al., 1987; Ham et al., 1988). This palidromic sequence is termed a ‘classical androgen 
response element (ARE)’ and is present in the promoter region of multiple androgen 
regulated genes including Prostate Specific Antigen (Claessens et al., 1989; Cleutjens et 
al., 1997; De Vos et al., 1991; Nelson et al., 1999; Riegman et al., 1991). AR selective 
response elements that exclusively recruit the AR have also been identified in the 
enhancers and promoters of multiple androgen regulated genes, including human 
Secretory Component (Verrijdt et al., 1999), mouse Sex-Limited Protein (Adler et al., 1991; 
Adler et al., 1993) and rat Probasin (Rennie et al., 1993). These sites resemble a direct 
repeat of the hexameric half site and comparison of the known AR selective AREs 
revealed the consensus sequence 5’ A/GGCTCTnnnA/TGTTCT/C-3’, with the main 
difference being the central base pairs of the 5’ half site (underlined) (as reviewed in 
Claessens et al., 2008; McEwan, 2004).  
 Chromatin immunoprecipitation followed by microarray identification of DNA targets 
(termed ChIP-on-chip) has identified multiple AR binding sites in prostate cells. For 
example, Wang et al., identified 90 AR binding sites on chromosome 21 and 22 in the 
LNCaP cell line (Wang et al., 2007). Only 10% of these sites were identified as classical 
AREs, however 68% were composed of either single ARE half sites or two ARE half sites 
arranged in various orientations (Wang et al., 2007). This study also reported the 
association of AR binding with DNA binding motifs for transcription factors GATA Binding 
Factor 2 (GATA2), Forkhead Box Protein A1 (FOXA1) and Octamer Binding Transcription 
Factor 1 (Oct-1) (Wang et al., 2007).  
 Massie et al., identified 1532 AR bound promoters in the LNCaP cell line, of which 
27% resembled the classical ARE (Massie et al., 2007). However, 57% of the target 
promoters contained the classical ARE half site. Also, 70% of the AR binding promoters 
contained the ETS transcription factor binding site. ETS binding has been shown to be 
androgen-dependent, suggesting ETS transcription factors may regulate AR 
transcriptional activity (Massie et al., 2007).  
 21 
 Bolton et al., performed ChIP-on-chip detection of AR DNA binding targets in the 
immortalized human prostate epithelial cell line Hpr-1AR, identifying 524 AR binding 
regions in the promoters of androgen regulated genes (Bolton et al., 2007). In contrast 
with Wang et al., and Massie et al., 69% of the identified AR binding sites were classical 
AREs (Bolton et al., 2007). Further work is needed to investigate the functional importance 
of the AR binding sites identified by ChIP-on-chip techniques (see section 1.5, Androgen 
regulated genes).   
 
1.2.3 The NH2-terminal activation function 1 (AF1) 
 The NH2-terminal domain sequence (amino acids 1-558 in the AR) is poorly 
conserved among the steroid receptor family (Lavery & McEwan, 2005). The three 
dimensional structure of the NH2-terminal domain remains unsolved, likely due to the lack 
of folded structure (McEwan et al., 2007). Spectroscopic techniques predict the AR NH2-
terminal domain to be highly disordered with limited structure (Lavery & McEwan, 2006), 
composed of 13% α-helix and 20% β-sheet structures (Reid et al., 2002a).  
 The AR primary activation function (AF1) has been mapped to the NH2-terminal 
domain by deletion and point mutation studies (Chamberlain et al., 1996; Jenster et al., 
1995; Simental et al., 1991), and this domain retains 65% of the transactivation activity of 
full length AR (Jenster et al., 1995). AF1 is divided into two transcriptional activation units 
(Tau), termed Tau1 and Tau5 (Jenster et al., 1995) (Figure 1.4). Tau1 (amino acids 100-
370) is required for the ligand-dependent activation of full length AR, whereas Tau5 
(amino acids 360-529) retains its transactivation function in a constitutively active AR with 
the LBD deleted (Jenster et al., 1995). Transcription assays demonstrated that both Tau1 
and Tau5 have autonomous transcriptional activity, and deletion analysis indicated both 
units are necessary for maximal transactivation activity of the full length AR (Callewaert et 
al., 2006). 
 Multiple co-regulatory proteins, general transcription factors and cell cycle 
regulatory proteins interact with the AR NH2-terminal domain. For example, core Tau1 
interacts with the general transcription factor TFIIF via the RAP47 subunit (McEwan, 2004; 
McEwan & Gustafsson, 1997). Additional AR NH2-terminal domain binding proteins 
include CREB Binding Protein (CBP) (Fronsdal et al., 1998), members of the p160 Steroid 
Receptor Co-activator (SRC) family (Bevan et al., 1999), TFIIIH (Lee et al., 2000), Cyclin E 
(Yamamoto et al., 2000) and Cyclin D1 (Petre et al., 2002). Spectroscopic studies 
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Figure 1.4. Representative diagram of the full length and NH2-terminal of the Androgen 
Receptor (AR). (A) The full length AR protein, with structural domains indicated and amino acid 
domain boundaries noted below. (B) Detailed representation of the NH2-terminal domain of the AR 
with functional domains indicated and amino acids domain boundaries noted below. The location of 
the functional motifs 23FQNLF27 and 183L/HX7LL192 (represented by signal amino acid code and 
amino acid position in superscript) are indicated by grey lines. Domain boundaries are as stated in 
Bennett et al., Int J Biochem Cell Biol. 2010 Jun;42(6):813-27 and Claessens et al., Nucl Recept 
Signal 2008; Jun 27:6e008.   
 
 
183L/HX7LL192  
23FQNLF27 
22 
 23 
demonstrated that the AR NH2-terminal adopts a more structured α-helical conformation 
upon binding to TFIIF, which facilitates the interaction of this domain with SRC-1, 
indicating that structural changes within the AR NH2-terminal are necessary for AF1 
function (Kumar et al., 2004). AF1 has also been shown to bind co-repressors, including 
Tab2, a component of the Nuclear Receptor Co-Repressor (NCoR) complex (Dotzlaw et 
al., 2002; Zhu et al., 2006). In the case of Tab2, this interaction occurs in the presence of 
the AR antagonist bicalutamide and is mediated by the 183L/HX7LL192 motif, located within 
Tau1 (Zhu et al., 2006).  
 The AR NH2-terminal domain mediates an androgen-dependent NH2/COOH 
terminal intramolecular AR interaction via the highly conserved 23FQNLF27 motif, which 
interacts with the agonist bound AR LBD. This interaction has been shown to be critical for 
ligand-dependent AR activity and stabilization of hormone binding (see section 1.3.3, the 
AR NH2/COOH-terminal interaction) (He et al., 1999; He et al., 2000). 
 The AR NH2-terminal domain contains trinucleotide repeat regions, including a 
polymorphic CAG nucleotide repeat which encodes a poly-glutamine stretch starting at 
amino acid 57, which can vary in length between 11-26 amino acids (Kumar et al., 2011). 
The CAG repeat is associated with Kennedy’s disease (see section 1.7, The Androgen 
Receptor and disease).  A poly-glycine stretch has also been identified in Tau5 (starting at 
amino acid 449) (Ding et al., 2005). 
 
1.2.4 The DNA binding domain (DBD) 
 The AR DBD includes 70 amino acids encoded by exon 2 and 3 and shows high 
conservation as compared to other human steroid receptors; it is 79% identical to PR, 76% 
identical to GR and 56% identical to ERα (Gelmann, 2002). The three dimensional 
structure of the AR DBD has been solved, revealing two zinc fingers that are formed from 
three α-helices (Shaffer et al., 2004). These fingers contain two zinc ions each coordinated 
to four cysteines (Luisi et al., 1991; Shaffer et al., 2004) (Figure 1.5). The first zinc finger 
contains a five amino acid proximal box (P-box) motif, which is comprised of an α-helix 
that co-ordinates specific interactions with DNA nucleotides in the DNA major groove. 
Perfect P-Box homology is observed between AR, GR, PR and MR (Zilliacus et al., 1995), 
and all of these receptors bind to the classical ARE consensus DNA sequence 5’-
TGTTCT-3’ (Claessens et al., 1996; Luisi et al., 1991; Zhou et al., 1997). The second zinc 
finger module is folded into two α-helices and contains the 5 amino acid distal box (D-box)  
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motif, which is similarly highly conserved between the AR, GR, MR and PR (Zilliacus et al., 
1995). The D-box motif forms the AR DNA dependent dimerization face, which fixes the 
position of the P-box DNA interacting amino acids (Shaffer et al., 2004).  
 Binding studies on the promoter of the androgen regulated gene Probasin identified 
the second zinc finger module containing the D-box motif and a 12 amino acid residue 
COOH-terminal extension into the AR hinge domain as essential components for the 
binding of AR to selective AREs (Schoenmakers et al., 1999) (Figure 1.5). Deletion of the 
COOH-terminal extension abolished the AR interaction with AR selective AREs 
(Schoenmakers et al., 2000).   
 The solving of the crystal structure of the AR DBD bound to DNA has revealed that 
the AR binds to a direct repeat of the classical ARE half site sequence, resembling an AR 
selective ARE, as a homodimer in a head-to-head confirmation (Shaffer et al., 2004) 
(Figure 1.6). This is in contrast to other nuclear receptor DBDs which adopt the orientation 
of the DNA binding site, i.e. head-to-tail dimerization, as observed for Vitamin D nuclear 
receptor (Shaffer & Gewirth, 2002). This demonstrates the energetically favourable 
dimerization at the AR DBD interface and suggests that dimerization plays an important 
role in AR-DNA binding.   
 
1.2.5 The hinge  
 The hinge domain is located between the last α-helix of the DBD and the first α-
helix of the LBD (amino acids 623-671 in human AR). A bipartite nuclear localization signal 
(NLS) is located spanning the hinge domain and DBD of all steroid receptors (AR amino 
acids 617-633) (Zhou et al., 1994) (Figure 1.5). The hinge domain is involved in multiple 
mechanisms of AR activation control. For example, within the AR hinge NLS resides the 
COOH-terminal extension sequence required for binding of AR to AR selective AREs, 
suggesting the hinge regulates AR DNA binding (Schoenmakers et al., 1999; 
Schoenmakers et al., 2000) (see section 1.2.4, the DNA binding domain and Figure 1.5).  
 The hinge region attenuates the transcriptional activity of the AR, since deletion of 
AR hinge amino acids 628-646 increases the ligand-dependent transcriptional activity of 
the AR in transcription assays (Haelens et al., 2007) furthermore, post-translational 
acetylation of the hinge domain also modulates AR transcriptional activity (see section 
1.3.4, post-translational modification of the AR).   
 
 
5?-A G A A C A nnn A G A A C A-3?
3?-T C T T G T nnn T C T T G A-5? 
DNA response element: 
•  Classical AR consensus 
•  Direct repeat 
DNA response element: 
•  VDR consensus  
•  Direct repeat 
5?-A G G T C A nnn A G G T C A-3?
3?-T C C A G T nnn T C C A G T-5? 
(A) 
(B) 
Figure 1.6. Comparison of the three dimensional structure of DNA binding domains of the 
Androgen Receptor and Vitamin D Receptor bound to direct repeat of consensus DNA 
binding elements. The (A) Androgen Receptor and (B) Vitamin D Receptor classical response 
DNA binding element arranged as direct repeats are shown below the representative ribbon 
structures of the (A) Androgen Receptor DNA binding domain in a homodimer head-to-head 
conformation, and (B) Vitamin D Receptor response element DND binding domain homodimer in a 
?head-to-tail? conformation. Ribbon and DNA structures are modified from Shaffer P L et al., Proc 
Natl Acad Sci USA 2004;101:4758-476 and reproduced with permission. 
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1.2.6 The ligand binding domain (LBD) 
 The structure of the LBD (amino acids 677-919) is conserved among nuclear 
receptors, as shown by 50% sequence homology between the AR and PR (Matias et al., 
2000; Sack et al., 2001). The atomic structure of the AR LBD in complex with the synthetic 
androgen metribolone and dihydrotestosterone has been solved.(Matias et al., 2000; Sack 
et al., 2001) This structure revealed an 11 α-helical anti parallel sandwich containing 2 
anti-parallel β-sheets and a central ligand binding cavity (Figure 1.7). This structure is very 
similar to that of other hormone receptor LBDs, including GR and PR (Sack et al., 2001).  
 The AR LBD structure revealed that 18 ligand binding cavity residues from helies 3, 
5 and 11 are in direct contact with bound agonist. Many of the contacts between the AR 
LBD and agonist are also conserved in the PR-agonist bound structure, including residues 
Q711, M745, R752 contacting the steroid A ring and back bone, and residues L704 and 
N705 interacting with the steroid C ring (Sack et al., 2001) (Figure 1.7). The interaction of 
the steroid C ring with T877 and D ring with N705 are unique to the AR LBD. However, AR 
LBD interaction with steroids may not be androgen specific, as other steroids including 
oestradiol-17β and progesterone are also able to transactivate the AR (Tyagi et al., 2000).  
 The mechanism of nuclear receptor LBD activation involves the ligand binding 
induced repositioning of helix 12, closing the ligand-binding cavity. This conformational 
change generates a hydrophobic surface on the LBD containing the activation function 2 
(AF2) (Bourguet et al., 2000; Matias et al., 2000; Sack et al., 2001). Unlike the ER, AF2 is 
not the prominent AF unit in the AR (Simental et al., 1991), since the AR AF2 displays only 
weak independent transcriptional activity (Jenster et al., 1995), and significant activity is 
only observed in the presence of high levels of p160 co-activator proteins (Gregory et al., 
2001a; He et al., 1999). Deletion of the LBD generates a constitutively active AR, 
suggesting AF2 may also play an inhibitory role in the regulation of AR transactivation in 
the absence of ligand (Jenster et al., 1991; Simental et al., 1991). 
 The AF2 domain is an interaction site for multiple co-regulatory proteins. Agonist-
induced LBD conformational changes generate an AF2 hydrophobic groove flanked by 
concentrated regions of negative and positively changed residues which act as a docking 
site for co-transcriptional proteins containing the conserved LXXLL nuclear receptor 
interaction motif (where L is leucine and X is any amino acid) derived from AR co-
regulatory proteins SRC-1, Receptor Interacting Protein 140 (RIP-140) and CBP (Heery et 
al., 1997). The interaction of AF2 with LXXLL motif containing co-activators, including 
5α-dihydrotestosterone  
A ring   B ring   D ring 
Figure 1.7. The three dimensional structure of the Androgen Receptor (AR) ligand binding 
domain. (A) Ribbon diagram of the AR ligand binding domain bound to agonist 5α-
dihydrotestosterone. The α-helices are numbered and represented in red, the NH2 and COOH-
terminals are indicated by N and C. Anti-parallel β-sheets are represented in green. (B) A 
representative model of the agonist 5α-dihydrotestosterone binding site. Several of the AR ligand 
binding domain residues in direct contact with agonist are depicted. Dotted lines represent 
hydrogen bonding.  Figures modified from Sack et al., 2001 Proc Natl Acad Sci USA. 
98:4904-4909 and Gelmann, 2002 J Clin Oncol. 20(13):3001-15 and reproduced with kind 
permission.  
(A) 
(B) 
C ring 
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SRC-1 and SRC-2 is weak (He et al., 1999). The AF2 displays a greater preference for 
phenylalanine rich motifs including FXXLF (where F is phenylalanine, L is leucine and X is 
any amino acid), which have been identified in AF2 binding co-activators including AR 
associated protein (ARA) 54, ARA 55 and ARA70 (He et al., 2002; He & Wilson, 2003; 
Zhou et al., 2002b). Such a motif has also been identified in the AR NH2-terminus, which 
mediates a ligand-dependent NH2/COOH-terminal intramolecular interaction (He et al., 
2000) (see section 1.3.3, the Androgen Receptor NH2/COOH-terminal interaction). 
 The AR LBD also binds heat shock proteins (hsp), including hsp90, 70 and 65 
(Marivoet et al., 1992; Veldscholte et al., 1992b), which are essential for maintaining the 
AR in a hormone responsive conformation prior to ligand binding. The AR LBD also 
contains a nuclear export signal (NES) positioned at amino acids 742-817 (Saporita et al., 
2003). This signal is dominant over the nuclear localization signal found in the DBD-hinge 
and functions in the absence of ligand (see section 1.3.2, Androgen Receptor nuclear 
translocation and export). 
 
1.3 The Androgen Receptor signalling pathway 
1.3.1 Androgen synthesis 
 Androgens are steroid hormones that are the principal determinant of male 
phenotype differentitation during embryogenesis and puberty and also maintain 
reproductive function in adulthood. This body of work will focus largely on the role of 
androgens in male reproductive tissue, however androgens also affect non-reproductive 
tissue including bone, muscle, adipose tissue and the central nervous system (as 
reviewed in Heemers & Tindall, 2007).  
 Steroid hormones, which include mineralocorticoids, glucocorticoids, progestins, 
oestrogens and androgens, are synthesized from cholesterol and share a 4 carbon ring 
structure and therefore are able to diffuse freely into cells (as reviewed in Heemers & 
Tindall, 2007). The common precursor of all steroid hormones is pregnenolone, produced 
upon the cleavage of cholesterol. Multiple pathways have been identified for the synthesis 
of steroids from cholesterol and multiple enzymes regulate these pathways (as reviewed in 
Rainey et al., 2002). Testosterone is the most prevalent androgen in males and is 
synthesized by the testes. Other androgens include dehydroepiandrosterone (DHEA), 
androstenediol and androstenedione, which are produced by the adrenal cortex and can 
be converted into testosterone in androgen target tissues (Rainey et al., 2002). Secreted 
androgens are transported in the blood stream to distant hormone-responsive tissues. The 
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majority of blood circulatory testosterone is bound to carrier proteins, including Steroid 
Hormone Binding Globulin (SHBG) (Selby et al., 1988) or Albumin, with only 1-2% existing 
unbound. Testosterone can be converted into the more potent androgen 5α-
dihydrotestosterone (DHT) by 5α-reducatase enzymes, which are expressed in androgen 
target tissues such as the prostate. DHT has a 5-fold higher affinity for AR compared to 
testosterone, and therefore is a more potent androgen (Russell & Wilson, 1994).  
 Androgen synthesis is tightly regulated by the hypothalamus-pituitary-gonadal axis 
(Figure 1.8). The hypothalamus secretes the peptide hormones Luteinizing Hormone 
Releasing Hormone (LHRH) (also known as Gonadotrophin Releasing Hormone) and 
Corticotrophin-Releasing Hormone (CRH), which trigger the release of the glycopeptide 
hormones Luteinizing Hormone (LH) and Adrenocorticotropic Hormone (ACTH) 
respectively from the anterior pituitary gland. The release of LH into the blood stream 
stimulates the synthesis of testosterone by the testicular Leydig cells, whereas ACTH 
stimulates androgen synthesis by the adrenal gland. The synthesis of androgen is 
regulated by a negative feedback loop, where high blood levels of testosterone are 
detected by the hypothalamus and anterior pituitary gland, leading to decreased LHRH 
and LH secretion (Figure. 1.8). 
 
1.3.2 Androgen Receptor nuclear translocation and export 
 Unliganded AR is cytoplasmic and exists as part of a 250-300 KDa multi-protein 
complex, including heat shock proteins (Hsp), co-chaperones and cytoskeletal proteins 
(Veldscholte et al., 1992b), which maintain the AR LBD in a stable but partially unfolded 
intermediate state with a high affinity for androgen (Bohen et al., 1995; Pratt & Toft, 1997). 
The minimum complex required for efficient folding and ligand activation of steroid 
receptors consists of Hsp70, Hsp40, Hop, HsP90 and p23 (as reviewed in Prescott & 
Coetzee, 2006). 
 The binding of androgen to the AR LBD permits folding of the AR into an active 
ligand bound state, followed by the dissociation of the receptor chaperone complex 
(Veldscholte et al., 1992b). Ligand-induced AR conformational changes also unmask the 
NLS located in the hinge (Zhou et al., 1994), which binds to the nuclear import factor 
Importin-α (Cutress et al., 2008). Ligand bound AR then enters the nucleus via the nuclear 
pore complex as an AR-Importin-α complex, upon which Importin-α dissociates (Cutress 
et al., 2008). COS-1 cells transfected with Green Fluorescent Protein (GFP) tagged AR 
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Figure 1.8. Diagram of the control of androgen synthesis and secretion in males. The release 
of Leuteinizing Hormone Releasing Hormone (LHRH) and Corticotrophin-Releasing Hormone 
(CRH) from the hypothalamus stimulates secretion of Adrenocorticotropic Hormone (ACTH) and 
Leuteinizing Hormone (LH) respectively which stimulates the synthesis of testosterone in the testes 
and the synthesis of adrenal androgens in the adrenal cortex. Diffusion of androgens into androgen 
target tissue, including the prostate, occurs via transport of  free androgen or androgen-plasma 
protein complexes in the blood stream. The hypothalamic-pituitary axis is regulated by a negative 
feedback loop whereby high blood testosterone levels are sensed by the hypothalamus, leading to 
down regulation of LHRH, LH and ACTH production.  
CRH 
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demonstrated AR nuclear translocation to distinct nuclear foci within 15 minutes of ligand 
treatment (Georget et al., 1999; Roy et al., 2001; Tyagi et al., 2000). Ligand binding also 
induces the AR NH2/COOH-terminal interaction, which is observed prior to AR-DNA 
interaction (van Royen et al., 2007) (See section 1.3.3, Androgen Receptor NH2/COOH-
terminal interaction).  
 Activated AR binds as a homo-dimer to the AREs found in regulatory elements of 
ARGs, where the AR recruits general transcriptional machinery and co-regulatory proteins 
to regulate transcription of target genes (Figure 1.9) (as reviewed in Bennett et al., 2010) 
(see section 1.4, Androgen Receptor transcription complex formation).   
 A functional AR NES (amino acids 742-817) is dominant in the absence of ligand 
and is repressed upon the addition of androgen, when the NLS signal within the hinge is 
dominant (Saporita et al., 2003). Upon androgen withdrawal, the AR can migrate back to 
the cytoplasm, and is able to re-enter the nucleus upon subsequent ligand exposure 
(Tyagi et al., 2000). AR ligand-binding induced conformational changes may provide a 
mechanism by which nuclear/cytoplasmic AR shuttling is regulated (Saporita et al., 2003).   
 
1.3.3 The Androgen Receptor NH2/COOH-terminal interaction 
 An androgen-dependent interaction between the AR NH2 and COOH-termini was 
initially identified using a mammalian 2-hybrid system (Langley et al., 1995). 
Conformational changes in the AR LBD induced upon ligand-binding generate the AF2 
interaction surface, which interacts preferentially with FXXLF like motifs, including 
23FQNLF27 and 433WHTLF437 in the AR NH2-terminal, and live cell fluorescence resonance 
energy transfer (FRET) studies demonstrated that this interaction is intramolecular, rather 
that intermolecular within the AR dimer (Schaufele et al., 2005). 
 This NH2/COOH-terminal interaction competes with LXXLL motif containing co-
activators for binding to AF2 in the presence of androgen (He et al., 2000). FRET studies 
further demonstrated that the AR AF2 domain preferentially binds the AR NH2-terminal 
domain when the ligand-bound AR is mobile, however upon DNA binding the AF2 domain 
preferentially interacts with co-activators (van Royen et al., 2007). This suggests the 
COOH/NH2-terminal interaction may prevent co-regulator interaction with ligand-bound AR 
prior to recruitment to ARGs and may explain why AF1 domain is the more potent 
activation domain in vitro (He et al., 2004; He et al., 2000; Hur et al., 2004; van Royen et 
al., 2007).  
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Figure 1.9. Schematic representation of aspects of the Androgen Receptor (AR) ligand 
binding-competent signalling pathway. The androgen testosterone diffuses through the cell 
membrane into the cytoplasm of androgen responsive tissue, for example the prostate, where the 
enzyme 5α-Reductase converts testosterone into the more potent androgen dihydrotestosterone. 
The AR is maintained in a ligand-responsive conformation by the head shock protein complex 
(HSPC) which dissociates from the AR upon the binding of dihyrotestosterone to the AR. The AR 
subsequently dimerizes and translocates to the nucleus. The AR binds to androgen response 
elements (AREs) upstream of androgen regulated gene transcriptional start sites. The AR 
transcription complex mediates transcription of androgen-regulated genes, and is formed by the 
recruitment of general transcription machinery (GTM) and RNA Polymerase II (RNAP). AR activity 
is modulated by the binding of AR co-activator proteins, including p300, CREB binding protein 
(CBP) and p300 CBP Associated Factor (P/CAF).  
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 Glutathione-S-Transferase (GST) and 2-hybrid interaction studies demonstrated 
that the AR NH2/COOH-terminal interaction is required for helix 12 stabilization upon 
ligand binding, and that this interaction slows the dissociation of ligand from AR which may 
potentiate AR transctivation (Centenera et al., 2008; He et al., 2000; Langley et al., 1998). 
In support of the functional importance of this interaction, AR mutations that disrupt the 
NH2/COOH-terminal interaction, but do not affect ligand binding, have been identified in 
androgen insensitivity syndrome patients where AR function in compromised or absent 
(Jaaskelainen et al., 2006; Thompson et al., 2001).  
 Modulation of the AR NH2/COOH-terminal interaction by co-factors is proposed to 
regulate the AR AF2 transactivation capacity (as reviewed in Centenera et al., 2008). For 
example, the AR co-repressor Cyclin D1 can competitively bind to 23FQNLF27, thus 
inhibiting the NH2/COOH-terminal interaction and reducing AR transactivation (Burd et al., 
2005). Conversely, the AR co-activator Melanoma Antigen Gene Product (MAGE-11) 
binds to 23FQNLF27 but increases overall activity by increasing p160 co-activator 
recruitment to AF2 (Bai et al., 2005). 
 Chromatin immunoprecipitation studies demonstrated the NH2/COOH-terminal AR 
interaction is critical for DNA binding, since deletion of the 23FQNLF27 motif inhibited AR 
recruitment to the Prostate Specific Antigen (PSA) enhancer ARE (Li et al., 2006). 
Furthermore, this study demonstrated the NH2/COOH-terminal interaction is essential for 
AR interaction with the chromatin remodelling complex Switch/Sucrose Non-Fermentable 
(SWI/SNF), suggesting this interaction also facilitates chromatin remodelling at AREs (Li et 
al., 2006).  
 An indirect model of NH2/COOH-terminal interaction has also been hypothesized, 
whereby co-factors act as bridging factors between the AR NH2 and COOH-terminals 
(Shen et al., 2005). In support of this, AR co-activator SRC-2 enhanced the AR 
NH2/COOH-terminal interaction 10-fold, and is able to restore AR NH2/COOH-terminal 
interaction when this AR 23FQNLF27 motif is mutated (Shen et al., 2005).  
 
1.3.4 Post-translational modification of the Androgen Receptor  
 Ligand binding is the predominant factor regulating steroid receptor transcriptional 
activity. However, all steroid receptors are subject to post-translational modifications, 
which can influence receptor transactivation potential (as reviewed in Faus & Haendler, 
2006). Known sites of AR modifications are depicted in Figure 1.10.  
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Figure 1.10. Schematic representation of the post-translational modification sites of the 
Androgen Receptor. Schematic depiction of the Androgen Receptor with NH2-terminal domain 
(NTD), DNA binding domain (DBD) and ligand binding domain (LBD) positions indicated. The 
position of activation function domains (AF) are also indicated and the amino acid number domain 
boundaries are indicated below. Known amino acid post-translational modifications (represented 
by single letter amino acid code and position number) are represented by colour, where red, green 
and blue represent phosphorylation, sumoylation and acetylation events respectively.  
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1.3.4.1 Phosphorylation  
 Radioactive methionine labelling and SDS-PAGE studies demonstrated that 15 
minutes post synthesis of the 110KDa AR protein, a 112KDa AR isoform appears (Kuiper 
et al., 1992; Kuiper et al., 1991). This is followed by a third 114KDa isoform after hormone 
treatment (Jenster et al., 1994), suggesting both constitutive and ligand-dependent 
phosphorylation of the AR. Gioeli et al., used mass spectrometry to identify constitutive 
phosphorylation at serine 94 and ligand-enhanced phosphorylation at serines 16, 81, 256, 
308, 424, and 650 in the LNCaP cell line (Gioeli et al., 2002). In another study, constitutive 
phosphorylation at serine 650 was shown to be dependent upon constitutive 
phosphorylation of serine 515 (Wong et al., 2004).  
 The kinases that regulate AR phosphorylation are known for several AR sites, 
including serine 650, which is phosphorylated by the stress kinase pathway kinases c-Jun 
NH2-terminal Kinase (JNK), Mitogen Activated Protein Kinase Kinase (MKK) 4 and 6  
which phosphorylate nuclear AR (Gioeli et al., 2006). This phosphorylation event 
enhanced nuclear export, whereas the mutation of Serine 650 to non-phosphorylatable 
alanine reduced AR nuclear export. Furthermore, reduction of MKK4 or 6 by siRNA 
increased PSA expression (Gioeli et al., 2006). Therefore, stress kinase-dependent 
phosphorylation of serine 650 can enhance AR nuclear export, leading to decreased 
expression of ARG targets such as PSA.  
 The Protein Kinase B (PKB) pathway is also implicated in AR phosphorylation. Lin 
et al., demonstrated that PKB-dependent phosphorylation of serine 210 and 790 
suppressed AR transactivation and expression of the AR target gene p21 (Lin et al., 
2001). In contrast to this, Wen et al., demonstrated that Human Epidermal Growth Factor 
Receptor 2 (Her-2) mediated activation of the PKB pathway induced serine 210 and 790 
phosphorylation and enhanced AR transactivation (Wen et al., 2000a). This suggests the 
PKB pathway has differential effects upon AR activity in various cell lines.  
 
1.3.4.2 Acetylation  
 The post-translational addition of acetyl groups to lysine residue side chains has 
been identified within the AR 630KXKK633 motif, located in the hinge region (Fu et al., 
2002). This modification is carried out by histone acetyl transferases (HATs) including TAT 
Interacting Protein 60 (Tip60) (Gaughan et al., 2002), p300/CBP Associated Factor 
(PCAF) and p300 (Fu et al., 2000). Acetylation is reported to regulate AR transactivation, 
since mutation of the AR acetylation motif repressed AR ligand-dependent function, 
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inhibited AR transactivation by co-activators including Tip60 and also enhanced the 
interaction of AR with co-repressor NCoR (Fu et al., 2000). This suggests acetylation may 
regulate AR activity via modulation of co-factor recruitment (Fu et al., 2002). AR 
acetylation may also be essential for maintaining the AR in a transactivation-competent 
conformation, since mutation of the 630KXKK633 motif resulted in impaired ligand-dependent 
nuclear translocation, misfolding and AR aggregation (Thomas et al., 2004).  
 
1.3.4.3 Sumoylation  
 Sumoylation is the covalent addition of the polypeptide Small Ubiquitin Like Modifier 
(sumo) onto target protein lysine side chains. AR sumoylation sites have been identified, 
including lysines 386 and 520 (Poukka et al., 2000). These sumoylation events are 
androgen-dependent and modulated by E3 ligases of the Protein Inhibitor Of Activated 
Signal Transducer and Activator of Transcription (PIAS) family, including PIASχα and 
hZimp (Kotaja et al., 2002; Nishida & Yasuda, 2002; Sharma et al., 2003). Sumoylation is 
reported to repress AR transactivation, since mutation of AR sumo acceptor sites 
increases AR activity at classical AREs in transcription assays, however no increase in 
activity was observed on androgen selective AREs, suggesting sumoylation may 
selectively modulate AR-DNA binding (Callewaert et al., 2004). Sumoylation also appears 
to modulate AR co-regulator recruitment, since the AR co-repressor Daxx is dependent 
upon AR sumoylation for its repressive capacity (Lin et al., 2004).  
 
1.3.2.4 Ubiquitination 
 The covalent attachment of mono or bi-ubiquitin to proteins can affect target 
protein-protein interactions or nuclear localization, whereas poly-ubiquitination of proteins 
usually targets proteins for degradation via the proteasome pathway (as reviewed in Faus 
& Haendler, 2006; Haglund & Dikic, 2005). The E3 ubiquitin ligase Murine Double Minutes 
2 (Mdm2) promotes AR poly-ubiquitination, resulting in attenuated AR activity and 
proteasomal degradation of the AR (Lin et al., 2002a). Furthermore, Mdm2 represses the 
AR activity in cooperation with Histone Deacetylase 1 (HDAC-1), which is recruited to the 
Mdm2-AR complex prior to proteasomal degradation (Gaughan et al., 2005). The de-
ubiquitination of the AR by Ubiquitin Specific Protease-10 (USP10) activates AR, possibly 
via inhibition of AR degradation (Faus et al., 2005). AR activity is, however, enhanced by 
mono-ubiquitination, which is promoted by Tumour Susceptibility Gene Product-101 
(TSG101) (Burgdorf et al., 2004).   
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1.4 Androgen Receptor transcription complex formation 
 Initiation of eukaryotic mRNA transcription requires recruitment of general 
transcription factors and RNA Polymerase II to the promoter, forming the pre-initiation 
complex, which is subsequently followed by clearance of the promoter, elongation of 
mRNA and termination of transcription (as reviewed in Proudfoot et al., 2002). The 
accurate and efficient execution of this process relies upon recruitment of general 
transcription factors, chromatin remodelling proteins, transcriptional co-regulatory proteins 
and specific transcription factors (as reviewed in Boatright et al., 2003).  
 
1.4.1 Androgen receptor interaction with basal transcription machinery 
 The ARE bound AR dimer exerts its function as a transcriptional modulator, in part, 
by direct interaction with components of the pre-initiation complex. This includes the AR 
NH2-terminal domain interaction with TATA binding protein (TBP), a protein essential for 
RNA Polymerase II recruitment to the pre-initiation complex (McEwan & Gustafsson, 
1997). The AR NH2-terminal domain also interacts with the RAP74 subunit of Transcription 
Factor IIF (TFIIF), which regulates pre-initiation complex stability and promoter escape 
(McEwan & Gustafsson, 1997; Reid et al., 2002b). This interaction increased α-helical 
structure within the AR NH2-terminal domain, facilitating interaction with the co-activator 
SRC-1 (Kumar et al., 2004). A weaker interaction has also been detected between the AR 
and RAP30 subunit of TFIIF (McEwan & Gustafsson, 1997).  
 The AR also interacts with TFIIH, a general transcription factor that facilitates DNA 
strand separation at the pre-initiation complex (Lee et al., 2000). Over-expression of the 
TFIIH subunit, Cdk Activating Kinase (CAK), enhanced AR transactivation (Lee et al., 
2000). The AR also interacts with Cyclin Dependent kinase 9 (CDK9), a subunit of the 
general transcription factor Positive Transcription Elongation Factor-b (p-TEFb) (Lee et al., 
2001). TFIIH, CAK and p-TEFb possess RNA Polymerase II COOH-terminal kinase 
activity (Marshall et al., 1996; Shiekhattar et al., 1995), and this phosphorylation event is 
necessary for transcriptional elongation by RNA Polymerase II (as reviewed in Phatnani & 
Greenleaf, 2006). For example, RNA Polymerase II is recruited to gene promoters in a 
hypo-phosphorylated state, and promoter escape requires TFIIH-dependent 
phosphorylation of the COOH-terminal, which is necessary for recruitment of the RNA 
capping apparatus (Ho & Shuman, 1999; Komarnitsky et al., 2000). Therefore, the 
interaction of AR with TFIIH and p-TEFb may increase the rate of expression of ARGs by 
enhancing RNA Polymerase II phosphorylation. In support of this AR also interacts directly 
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with RNA Polymerase II via the RPB2 subunit, and over-expression of this subunit 
enhanced ARG transcription (Lee et al., 2003). The detected interactions of AR with basal 
transcription machinery components suggests that AR mediates target gene transcription 
by regulating both transcription initiation and elongation (as reviewed in Heemers & 
Tindall, 2007). 
 
1.4.2 Androgen receptor co-regulators 
 The AR can also exert transcriptional regulatory effects through the recruitment of 
co-regulatory proteins. Co-regulators can either enhance transcriptional activity of the AR 
(co-activators), or can reduce AR transcriptional activity (co-repressors), but neither 
significantly alter the basal transcription rate nor possess DNA binding ability (as reviewed 
in Heemers & Tindall, 2007). Co-regulators instead regulate AR transactivation by 
interacting with the AR at target gene promoters, or by interacting with non-DNA bound AR 
to affect ligand and DNA binding competency (as reviewed in Heemers & Tindall, 2007; 
Heinlein & Chang, 2002). Co-regulators affect AR signalling through multiple mechanisms, 
some of which are discussed below.  
 
1.4.2.1 Androgen Receptor co-activators 
1.4.2.1.1 Chromatin remodelling 
 The nucleosome is the basic packing unit of chromatin, comprising of a core 
nucleosome octamer particle containing Histone proteins 2A, 2B, 3 and 4, around which 
146 base pairs of DNA are wrapped. Histone-DNA interactions limit the access of 
transcription factors to DNA and chromatin modification is necessary for transcription 
initiation and efficient gene transcription (as reviewed in Morales et al., 2001; Narlikar et 
al., 2002).  
 Chromatin remodelling proteins catalyse the ATP-dependent unwrapping of DNA-
histone contacts, resulting in nucleosomal reorganization and generation of euchromatin 
structure which is more permissible to interaction with transcription factors (Mellor, 2006). 
AR co-activators with direct chromatin remodelling activity have been identified, including 
Switch 3-Related Gene Product (SRG3), a component of the SWI/SNF ATP-dependent 
chromatin remodelling complex (Hong et al., 2005). SRG3 interacts with the AR hinge 
region and over-expression of SRG3 enhanced AR transactivation (Hong et al., 2005). A 
further example is AR Interacting Protein 4 (ARIP-4), a nuclear ATP-ase and member of 
the SNF-2-like family of chromatin remodelling proteins, which has also been 
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demonstrated to enhance AR transactivation and interact with the AR DBD (Rouleau et al., 
2002).  
 
1.4.2.1.2 Histone modification 
 Histones are subject to multiple post-translational modifications including 
acetylation, methylation, ubiquitination, phosphorylation, sumoylation and ribosylation and 
the majority of these modifications occur on the NH2- and COOH-terminal histone tails 
(Peterson & Laniel, 2004). The acetylation of lysine residues in the NH2-terminal of histone 
tails is positively correlated with active gene transcription, including increased Histone 3 
acetylation at lysine 9 and 14 residues in response to androgen (Kang et al., 2004). The 
acetylation of histone lysine residues neutralizes the positive charge of lysine, reducing 
histone-DNA contacts and producing a transcriptionally more permissive chromatin 
structure (as reviewed in Shahbazian & Grunstein, 2007).  
 AR co-activators that possess HAT activity have been identified, including CBP, 
p300, PCAF (Blanco et al., 1998; Ogryzko et al., 1996), SRC-1 and SRC-3 (Chen et al., 
1997; Spencer et al., 1997), all of which interact with the AR (Bevan et al., 1999; Heemers 
& Tindall, 2007; Tan et al., 2000). The histone substrate of each HAT co-activator varies, 
with SRC-1, CBP and p300 able to acetylate all histones, whilst PCAF and SRC-3 can 
acetylate Histone H3 (Davie & Spencer, 1999). The HAT activity of co-activators is also 
thought to potentiate AR transcriptional activity, since Huang et al., demonstrated that the 
p300-dependent acetylation of Histone 3 facilitates recruitment of the chromatin 
remodelling complex SWI/SNF (Huang et al., 2003). The AR co-activation by PCAF, p300 
and CBP is dependent upon their HAT activity, since HAT domain mutation diminished 
ligand-dependent AR activation (Fu et al., 2000). In addition to AR co-activation via 
histone acetylation, p300 and PCAF directly acetylate the AR hinge-DBD region, and 
mutation of these AR lysine residues results in inhibition of AR transactivation (see section 
1.3.4.2, Acetylation).  
 A further example of histone modification is methylation of lysine and arginine 
residues. In higher eukaryotes arginine residues can be mono- or dimethylated on histone 
H3 and H4, whereas lysine can be additionally trimethylated at specific locations on 
histone H3 and H4 (Bhaumik et al., 2007). Histone methylation has been linked to both 
transcriptional activation and repression. For example, H3K9 methylation is associated 
with heterochromatin formation and recruitment of the transcriptional repressor 
Heterochromatin Protein 1 (HP1) (Bannister et al., 2001). Conversely, H3K4 methylation is 
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associated with actively transcribed genes (Santos-Rosa et al., 2002), and the H3K4 
methyltransferase complex COMPASS (Complex of Proteins Associated with Set1) 
associates with the elongating form of RNA Polymerase II (Krogan et al., 2003). 
 
1.4.2.1.3 The p160 family of Steroid Receptor Co-activators (SRC) 
 The SRC family is composed of three members, SRC-1/Nuclear Receptor Co-
activator 1 (NCOA-1), SRC-2/NCOA-1/Transcription Intermediary Factor 2 (TIF-
2)/Glucocorticoid Receptor Interacting Protein 1 (GRIP-1) and SRC-3/NCOA-3/ Amplified 
In Breast Cancer 1 (AIB1)/CBP Interacting Protein (pCIP)/Receptor Associated Co-
activator 3 (RAC-2) (as reviewed in Leo & Chen, 2000). All members have been shown to 
interact with and co-activate the AR, with ligand-dependant interaction with the AR 
detected for SRC-1 and SRC-3 (Berrevoets et al., 1998; Onate et al., 1998; Tan et al., 
2000) (as reviewed in Heemers & Tindall, 2007). SRC family members share similar 
structure, including a DNA-binding basic helix-loop-helix motif and a PAS (Per/Arnt/Sim 
homology) domain that is known to mediate protein-protein interaction, however the role of 
these domains in co-activation remains unknown (as reviewed in Leo & Chen, 2000).  
 SRC members interact with the LDB AF2 domain of steroid receptors via the co-
activator interaction motif LXXLL that is conserved in the central domain of all SRC 
proteins (Heery et al., 1997; Leo & Chen, 2000; Xu & O'Malley, 2002). However, this 
interaction is weak for the AR and mutation of the SRC-1 LXXLL motif did not abrogate the 
interaction of SRC-1 and AR (Bevan et al., 1999). Further deletion studies detected a 
stronger, ligand-independent interaction between the SRC-1 COOH-terminal glutamine 
rich domain and the AR NH2-terminal domain (Bevan et al., 1999; He et al., 1999).  
 The mechanism(s) by which the SRC family co-activate the AR are best understood 
for SRC-1 and SRC-3, both of which have intrinsic HAT activity and can acetylate histones 
to enhance transcription (see section 1.4.2.1.2, histone modification). Furthermore, the 
SRC family are proposed to act as scaffold proteins and potentiate AR transactivation by 
recruiting additional AR co-activator proteins with stronger HAT activity, including p300, 
CBP and PCAF (Fu et al., 2000; Ogryzko et al., 1996). SRC-1 has also been shown to 
interact with the basal transcription machinery via TFIIB and TBP (Takeshita et al., 1996). 
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1.4.2.1.4 Androgen Receptor Associated Protein 70KDa (ARA70) 
 The ability of steroid receptors to bind ligand is determined by protein receptor 
stability and receptor folding. The cytoplasmic protein ARA70 co-activates AR, in part, by 
enhancing AR stability (as reviewed in Heinlein & Chang, 2002).  
 ARA70 contains both a LXXLL and FXXLF motif (Hsu et al., 2003; Zhou et al., 
2002b). Mutation studies demonstrate the AR-LBD interaction with ARA70 is LXXLL 
independent, whereas FXXLF mutation inhibited ARA70 ligand-dependent interaction with 
AR-LBD and reduced AR transactivation (Hsu et al., 2003; Yeh & Chang, 1996; Zhou et 
al., 2002b). Furthermore, ARA70 enhanced the constitutive activity of an AR NH2-DBD 
fragment, and this activity was independent of the ARA70 FXXLF motif (Zhou et al., 
2002b). Therefore, ARA70 co-activation of the AR results from interaction with both the 
AF1 and AF2 domains. 
 ARA70 over-expression enhanced AR transactivation in response to the weak 
androgen Δ5-androstenediol (Miyamoto et al., 1998a) and also enhanced AR 
transactivation by the oestrogen oestradiol (Han et al., 2001; Yeh et al., 1998), which 
binds AR with 100-fold lower affinity than DHT and does not usually transactivate AR. 
ARA70 slows the dissociation of AR and Oestradiol, suggesting that ARA70 mediates AR 
co-activation by stabilization of ligand-binding (Heinlein & Chang, 2002). In support of this, 
increased ARA70 expression also enabled AR transactivation in response to AR 
antagonists hydroxyflutamide and bicalutamide (Miyamoto et al., 1998b).   
 
1.4.2.2 Androgen receptor co-repressors 
 Co-repressor, like their counterparts the co-activators, utilize multiple mechanisms 
to exert their AR repressive functions (as reviewed in Wang et al., 2005a).  
 
1.4.2.2.1 Histone Deacetylases (HDACs) 
 HDACs counterbalance the activity of HATs by the catalysis of acetyl group removal 
from histone lysine residues, resulting in restored lysine positive charge and enhanced 
histone-DNA interaction, generating a more condensed chromatin structure, which is less 
accessible to transcription factors (as reviewed in Mellor, 2006).  
 HDACs usually require activation via interaction with secondary co-repressor 
proteins. For example HDAC3, a co-repressor of the AR, requires interaction with the co-
repressors Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) or 
NCoR to activate HDAC activity (Wen et al., 2000b). HDAC3 enzymatic activation requires 
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the interaction of HDAC3 with a deacetylase activating domain (DAD), present in both 
NCoR and SMRT, which has a unique 4 α-helical structure that interacts with both the NH2 
and COOH-termini of HDAC3 (Codina et al., 2005; Guenther et al., 2001). The 
conformation of this domain is essential for HDAC3 interaction and activation, since 
disruption of the DAD domain helical structure by mutation analysis abolished interaction 
with and activation of HDAC3 (Codina et al., 2005). Therefore, the interaction of HDAC3 
with nuclear transcription factors appears to permit regulation of both the location and 
activity of HDAC activity (Karagianni & Wong, 2007).  
 The AR co-repressor Cyclin D1 mediates its repressive activity by interaction with 
the AR AF1 (as described in section 1.4.2.2.2) and also HDAC3 (Lin et al., 2002b; Petre-
Draviam et al., 2003; Petre-Draviam et al., 2005). Cyclin D1-mediated repression of the 
AR is partially relieved upon the addition of the HDAC3 inhibitor tricostatin A (TSA), 
suggesting Cyclin D1 utilizes multiple mechanisms to repress the AR (Petre et al., 2002). 
The AR co-repressor Hairy/Enhancer of Split Related With YRPW Motif 1 (Hey-1) also 
mediates its AR-repressive capacity, in part, via HDAC recruitment. Hey-1 interacts with 
the AR AF1 domain and requires both the Hey-1 basic helix-loop helix motif and the Hey-1 
COOH-terminal domain to repress AR activity. The addition of HDAC class II inhibitor TSA 
diminished the repressive capacity of the Hey-1 COOH-terminal domain but had less 
inhibitory effect upon the repressive capacity of the basic helix loop helix domain, 
suggesting Hey-1 utilizes both HDAC-dependent and HDAC-independent mechanisms to 
mediate AR repression (Belandia et al., 2005).  
 
1.4.2.2.2 Inhibition of the Androgen Receptor NH2/COOH-terminal interaction 
 The AR NH2/COOH-terminal interaction is necessary for maximal AR 
transactivation and AR co-repressors have been identified that modulate this interaction. 
For example, the checkpoint protein and Ras Associated with Diabetes (Rad) family 
member, hRad9, interacts with the AR LBD via a FXXLF motif in the COOH-terminus of 
hRad9. This interaction interrupts the AR NH2-terminal interaction with the AR LBD via 
competition for the FXXLF binding groove within the AR LBD, resulting in repression of AR 
transactivation and reduced expression of the androgen-regulated gene PSA (Wang et al., 
2004). Cyclin D1 also inhibits the AR NH2/COOH-terminal interaction by binding directly to 
the AR NH2-terminal 23FXXLF27 motif. This interaction is crucial for Cyclin D1 mediated 
repression of the AR and acts in concert with Cyclin D1 recruitment of HDAC3 (Burd et al., 
2005). 
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1.4.2.2.3 Inhibition of Androgen Receptor DNA binding  
 Repression of AR transactivation can be achieved by the binding of co-repressors 
to the AR DBD, preventing AR interaction with AREs. For example, the AR co-repressor 
Calreticulin interacts with the AR DBD via the calreticulin motif KLGFFKR. This interaction 
inhibited the binding of AR to the rat Probasin ARE in gel shift assays and inhibited AR 
transactivation in transcription assays (Dedhar et al., 1994).   
 
1.4.2.2.4 Competition with Androgen Receptor co-activators 
 In addition to HDAC3 recruitment, the AR co-repressors SMRT and NCoR are also 
proposed to inhibit AR transactivation via competition for AR co-activator binding sites to 
inhibit AR co-activator recruitment. Chromatin immunoprecipitation studies demonstrated 
that the reduction of SMRT or NCoR proteins by siRNA increased recruitment of co-
activators SRC-1 and p300 to the agonist bound AR at the PSA promoter (Yoon & Wong, 
2006). In support of this, interaction studies demonstrated that NCoR interacts with the AR 
NH2-terminal domain, the primary binding site of SRC-1, and in transcription assays NCoR 
repressed the SRC-1 dependent co-activation of AR (Hodgson et al., 2005).  
 
1.4.3 Order of Androgen Receptor transcriptional complex formation 
 The assembly of the AR transcriptional complex has been most comprehensively 
studied at the PSA promoter. Three AREs have been identified within PSA regulatory 
regions, including ARE I and II which are located within 650 base pairs upstream of the 
transcriptional start site (Cleutjens et al., 1996). ARE III is located in an enhancer element 
approximately 4.2Kb upstream of the transcriptional start site (Cleutjens et al., 1997). 
Chromatin immunoprecipitation studies demonstrated that ligand bound AR is recruited 
predominantly to the enhancer ARE and more weakly recruited to the promoter AREs I 
and II. This is followed by recruitment of RNA Polymerase II and subsequent combinatorial 
recruitment of AR co-activators, including SRC-1, SRC-2, SRC-3, p300, CBP and PCAF 
(Shang et al., 2002; Wang et al., 2005b). Co-regulator and RNA Polymerase II recruitment 
to the PSA promoter peaks 16 hours after androgen treatment, after which recruitment 
declines, and this correlates with PSA expression (Wang et al., 2005b). 
 Chromatin immunoprecipitation combined with chromosomal conformation capture 
(termed CHiP-3C) demonstrated that the PSA promoter and enhancer AREs communicate 
via chromosomal looping which brings the AREs within close proximity (Wang et al., 
2005b). This chromosomal looping, mediated via the AR transcription complex, is 
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hypothesized to facilitate transcription via directing the sliding of RNA Polymerase II along 
looped DNA to the promoter ARE, or facilitate its tracking from enhancer to promoter ARE 
(Wang et al., 2005b) (Figure 1.11).  
 
1.5 Androgen regulated genes (ARGs) 
 Several cDNA microarray experiments have been performed in the androgen 
responsive prostate cancer cell line LNCaP, with the aim of identifying ARGs (for example 
DePrimo et al., 2002; Nelson et al., 2002; Velasco et al., 2004). These studies report a 
diverse range of ARG function, including genes involved in fatty acid metabolism, cell 
proliferation and differentiation, protein transport and trafficking (Nelson et al., 2002) and 
production and secretion of proteins that constitute the prostatic fluid (DePrimo et al., 
2002). Nelson et al., identified 146 genes with greater than 3-fold alteration in expression 
upon treatment of LNCaP cells with synthetic androgen R1881, 28 of which had been 
previously identified as characterised ARGs. Analysis of sequences upstream of the 
transcriptional start site identified 25 of the 28 ARGs that contained sites with homology to 
the ARE consensus binding motif, suggesting direct gene regulation by AR binding 
(Nelson et al., 2002).  
 A recent study by Ngan et al., used whole genome RNA microarrays to identify 319 
androgen up-regulated and 300 down-regulated genes in the LNCaP cell line (Ngan et al., 
2009). Pathway analysis identified strong androgen stimulation of the fatty acid synthesis 
pathway mediators, including Fatty Acyl-CoA Oxidase, and this pathway has been shown 
to stimulate prostate cancer growth (Zha et al., 2005). Ngan and co-workers also 
confirmed the androgen down-regulation of the Transforming Growth Factor (TFG)-β 
pathway via the key regulators SMAD 1,3,6 and 7. Activation of this pathway has been 
shown to inhibit growth and promote apoptosis (Ngan et al., 2009; Tang et al., 1999; Zhu 
& Kyprianou, 2005).  
 Well characterised up-regulated ARGs identified in these studies include PSA and 
Kallikrein 2 (KLK2). Both are highly homologous members of the serine protease family 
expressed by the prostate epithelial cells and secreted into the prostate lumen (Young et 
al., 1992; Young et al., 1991; Yousef & Diamandis, 2001). PSA is a major protein in 
semen, where it cleaves Semenogelin I and II, which mediate gel formation in semen 
coagulum. The blood serum level of PSA is used as a biomarker for prostate disease 
including prostate cancer, with increased serum levels correlating with prostate disease 
(as reviewed in Balk et al., 2003). 
RNAP 
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ARE III 
AR    AR 
AR    AR 
ARE I/II 
Promoter 
GTA 
GTA 
p300 
GTA 
SRC 
PSA 
Figure 1.11. Schematic representation of the formation of the Androgen Receptor (AR) 
transcriptional complex on the PSA promoter. The ligand bound AR binds predominantly to the 
PSA enhancer androgen response element (ARE) III and more weakly to the promoter AREs I and 
II located -4.2Kb and 0.65Kb upstream of the PSA transcriptional start site respectively. The AR 
transcription complex at the enhancer ARE is composed of RNAP Polymerase II (RNAP), the 
general transcription apparatus (GTA) and AR co-activators including Steroid Receptor Co-
activators (SRC), p300 and CREB Binding Protein (CBP) and interacts with the promoter ARE AR 
transcriptional complex via chromosomal looping.   
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 Multiple ChIP-on-chip studies have been performed in prostate cancer cell lines to 
map AR genomic binding sites (see section 1.2.2, Androgen response elements) (Bolton 
et al., 2007; Massie et al., 2007; Wang et al., 2007), and have provided insight into the 
location and type of AREs located in ARGs but these studies do not simultaneously map 
sites of active transcriptional activity and AR recruitment. A recent study by Massie et al., 
used ChIP-on-chip to identify 1283 candidate actively transcribed androgen target genes 
as defined by co-recruitment of the AR and RNA Polymerase II in response to androgen. 
This data was combined with detailed gene expression profile data to identify direct 
androgen-regulated target genes that recruit AR and transcription machinery (Massie et 
al., 2011). Many established androgen regulated genes were identified, including PSA and 
cell cycle regulators such as CDK6, both of which are direct up-regulated targets of the 
AR. Metabolic pathway analysis of this gene set identified enrichment of metabolic 
regulators of the glycolytic pathway including 6-Phosphofructo-2-Kinase and also enzymes 
that use glycolysis metabolites for lipid production, such as the fatty acid synthase FASN, 
thus indicating the up-regulation of anaerobic metabolic pathways in prostate cancer cells. 
The comparison of the direct AR target genes with clinical prostate tumour gene 
expression data enabled the identification of direct AR target genes that were up-regulated 
in prostate cancer tumours, for example, Calcium/Calmodulin-Dependent Protein Kinase 
Kinase 2 (CAMKK2), which can stimulate glycolysis by activation of the metabolic sensor 
AMP kinase (AMPK) (Massie et al., 2011). 
 
1.6 The Androgen Receptor and cell cycle regulation 
1.6.1 Mitogenic cell cycle overview 
 The mitogenic cell cycle is regulated by the coordinated formation and degradation 
of Cyclin Dependent Kinase (CDK)/Cyclin complexes, where CDK kinase activity is 
activated by interaction with Cyclins (as reviewed in Balk & Knudsen, 2008; Malumbres & 
Barbacid, 2005). The type of mitogenic stimuli varies between cell types, but typically 
stimulate accumulation of D type Cyclins which bind to CDK4 or 6. Active CDK4 and 6 
phosphorylate targets to facilitate transition through the Gap-1 (G1)/DNA synthesis (S) 
phase cell check point, including phosphorylation and deactivation of the Retinoblastoma 
Tumour Suppressor Protein (RB). Increased RB phosphorylation leads to increased 
expression of the RB regulated targets Cyclin E and A, which bind to and activate CDK2 to 
further promote RB phosphorylation and progression through the G1/S cell cycle check 
point. Transition through the Gap 2 (G2)/Mitosis (M) phases is controlled by the ordered 
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activation of CDK1 by Cyclin A and B. The rapid degradation of Cyclin B in anaphase 
triggers mitotic exit and cell cycle termination (as reviewed in Malumbres & Barbacid, 
2005) (Figure 1.12).  
 
1.6.2 Androgen regulation of the mitogenic cell cycle 
 Normal and cancerous prostate cells are dependent upon androgens for cell cycle 
progression (Huggins & Hodges, 1972; Jenster, 1999). Androgen-deprived prostate 
cancer cells arrest in early G1/S cell cycle phase due to altered expression and activity of 
crucial G1/S check point regulators, including decreased expression of Cyclin D1 and 
Cyclin A, decreased activity of CDK4 and CDK2, and hypophosphorylation of RB 
(Knudsen et al., 1998; Xu et al., 2006). Furthermore, androgen deprivation induces 
expression of the CDK2 inhibitor, Kinase Inhibitor Protein 27 (p27KIP) (Knudsen et al., 
1998). This suggests a model whereby androgens, via the AR, induce expression of the 
known androgen regulated target Cyclin D1 (Xu et al., 2006), resulting in increased CDK4 
and 6/Cyclin D1 complex formation and subsequent RB phosphorylation and increased 
Cyclin A and Cyclin E expression and subsequent CDK2 activation (Knudsen et al., 1998). 
Androgens also facilitate activation of CDK4 and 6 by the up-regulation of p21Cip, a factor 
known to facilitate CDK4 and 6/Cyclin D1 complex formation (Lu et al., 1999). 
Furthermore, androgens induce degradation of p27KIP, which is an inhibitor of CDK2 
activation. The androgen-regulated modulation of cell cycle regulators Cyclin D1, p21Cip 
and p27KIP results in increased RB phosphorylation and transition through the G1/S check 
point (Figure 1.12) (as reviewed in Balk & Knudsen, 2008; Knudsen et al., 1998).  
 
1.7 The Androgen Receptor and disease 
 Mutations of the AR and modulation of the androgen-signalling axis are associated 
with diseases involving androgen target tissue and also male sexual differentiation. 
Pathogenic mutations of the AR include gain of function mutations such as those observed 
in prostate cancer and spinal bulbar muscular atrophy, and also loss of function mutations 
as observed in androgen insensitivity syndrome patients.  
 
1.7.1 The prostate gland 
  The prostate is a male exocrine gland that surrounds the urethra at the base of the 
bladder (Figure 1.13). The human prostate consists of ducts lined by luminal epithelial 
cells, which are surrounded by basal epithelial cells that contact the basement membrane. 
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Figure 1.13. The human prostate structure and cellular composition. (A) Representative 
diagram of the human male reproductive and urinary organs. The image is taken from CancerHelp 
UK, the patient information website of Cancer Research UK, www.cancerhelp.org.uk, and is 
reprinted with permission. (B) A cross section of the normal adult human prostate, with nuclei 
stained blue and Androgen Receptor strained brown. Immunohistochemistry performed by 
S.Powell and reprinted here with permission. (C) Representative diagram of the cellular structure 
of the  prostate.  
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The prostate stroma encapsulates the epithelial cells and is composed of stromal, 
fibroblasts, smooth muscle, endothelial, dendritic and nerve cells in addition to blood 
vessels (Figure 1.13). During ejaculation prostate contractions force prostatic secretions 
into the ejaculate, including citric acid, calcium, zinc, magnesium and Pepsinogen II and 
PSA which aid semen liquification (Aumuller & Seitz, 1990; Owen & Katz, 2005).  
 Androgens are essential for prostate development, as well as function upon 
maturation, as demonstrated by studies of AR null mice, which show severely impaired 
prostate development (Matsumoto et al., 2003). The human prostate develops from the 
endodermal urogenital sinus (UGS), which is surrounded by connective tissue structure 
called the urogenital sinus mesenchyme (UGM). In response to foetal testicular 
androgens, produced at approximately 8 weeks post conception, the AR positive human 
male UGM induces UGS differentiation to generate prostatic secretory epithelia. The 
developing epithelium in turn induces differentiation of the UGM into prostate stroma, 
including smooth muscle and fibroblast cells (as reviewed in Cunha et al., 2004). 
Therefore, the paracrine interactions between the initially AR positive UGM and AR 
negative UGS are reciprocal during in utero prostate development (Cooke et al., 1991; 
Cunha et al., 2002). 
 Post-birth the prostate grows little until puberty when androgen-dependent growth 
resumes, mediated primarily via AR expression in the luminal epithelial cells. Post puberty 
prostate growth stops and androgens instead regulate the prostate secretory function 
(Bonkhoff & Remberger, 1996; Cunha et al., 2004). Androgens also regulate programmed 
cell death in mature prostate tissue, leading to a state of cell quiescence (Isaacs et al., 
1992). The growth quiescence of the adult prostate is maintained by the reciprocal 
homeostatic regulatory interaction of smooth muscle and epithelium (Cunha et al., 2002). 
Pathological states of the adult prostate exist where this mesenchimal-epithelial 
dependant quiescence is disrupted, resulting in the initiation of aberrant prostate growth, 
examples of which include benign prostatic hyperplasia and prostate cancer which are 
discussed below in sections 1.7.1.1 and 1.7.1.2. 
 
1.7.1.1 Benign Prostatic Hyperplasia (BPH) 
 BPH is characterised by non-malignant proliferation of the luminal epithelial and 
stromal cells of the prostate gland causing enlargement of the prostate. Symptoms of BPH 
include difficulties with and increased frequency of urination due to the pressure of the 
enlarged prostate on the urethra and bladder (as reviewed in Thorpe & Neal, 2003). 
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Treatment options include surgical resection of the prostate, or the administration of 5-α 
reductase inhibitors to inhibit the androgen stimulated growth of the prostate. α-1-
Adrenergic Receptor blockers may also be administered, which cause relaxation of 
smooth muscle and reduce the size of the prostate and pressure of the bladder (Thorpe & 
Neal, 2003; Wei et al., 2005).  
 
1.7.1.2 Prostate cancer 
 Prostate cancer accounts for 13% (~10,000) of cancer deaths and 24% of new 
cancer diagnoses in England and Wales (Rowan et al., 2008). Prostate cancer in men 
under 50 is rare, and incidence rises steeply with age (Rowan et al., 2008). For example, 
for men aged 55-64 the incidence rate is approximately 180 per 100,000 males and this 
increases 5-fold for men aged 85 and over to approximately 1000 cases per 100,000 
males (http://info.cancerresearchuk.org/cancerstats/prostate/incidence/).  
 At diagnosis, approximately 90% of prostate cancers are dependent upon 
androgens for growth (Cunha et al., 1987; Heinlein & Chang, 2004). Surgical prostate 
removal can be curative, however if the tumour has breached the prostate capsule and 
cannot be shrunk by radiotherapy, or has metastasized, then the primary treatment is 
modulation of AR activity through the deprivation of circulating androgens, reducing 
tumour growth. This can be achieved by surgical castration, which eliminates testicular 
androgen synthesis, or alterntivly achieved chemically by the use of LHRH agonists. The 
AR can be inhibited directly by anti-androgens, which are AR antagonists, for example 
bicalutamide. Often a combined approach of surgical castration or LHRH agonist with anti-
androgen is implemented, and over 80% of patients respond positively to androgen 
ablation treatment (as reviewed in Niraula & Tannock, 2011). However, this treatment 
invariably fails within a median of 12-24 months, as hormone refractory tumours develop 
(Feldman & Feldman, 2001; Heinlein & Chang, 2004). Treatment options are very limited 
and non-curative in non-organ confined hormone-refractory patients. They include 
administration of a secondary anti-androgen and/or administration of chemotherapeutic 
drugs, which may reduce the pain of metastasized tumours (Niraula & Tannock, 2011).  
 A new approach to prostate cancer treatment is suppression of androgen synthesis 
via inhibition of 17-α-Mono-oxygenase, an enzyme required for conversion of cholesterol 
to androgens, inhibition of which blocks both testicular and adrenal androgen production. 
A phase III clinical trial of Abiraterone Acetate, an inhibitor of 17-α-Mono-oxygenase, was 
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performed in patients with hormonal refractory non-organ confined prostate cancer, rising 
PSA blood levels and who had been previously treated with chemotherapy. This trial 
demonstrated that the drug prolonged survival from a median of 10.9 months to 14.9 
months, indicating that Abiraterone Acetate may therefore be a future treatment option for 
patients with hormone refractory, non-organ confined disease (de Bono et al., 2011).  
 
1.7.2 The Androgen Receptor and hormone refractory prostate cancer 
 AR expression is retained during prostate cancer progression, including progression 
from hormone responsive to hormone refractory disease in most patients (Heinlein & 
Chang, 2004; Sadi et al., 1991; van der Kwast et al., 1991), and modulation of the AR 
signalling axis is proposed as a mechanism for the development of hormone refractory 
tumours that are resistant to androgen ablation therapy (as reviewed in Feldman & 
Feldman, 2001). This can be achieved by multiple mechanisms including:  
 
 1.7.2.1 Androgen Receptor amplification 
 AR hypersensitivity to low androgen concentrations present during androgen 
ablation treatment is one of the mechanisms for progression to hormone refractory tumour 
growth and can be achieved by amplification and over-expression of the AR. In vivo 
studies showed 30% of hormone refractory tumours contained amplified copies of AR 
(Visakorpi et al., 1995). In vitro studies also demonstrated AR mRNA up-regulation as the 
only consistent change between paired androgen-dependent and independent cell lines 
(derived from serial passage in castrated nude mice), demonstrating that increased AR 
expression is sufficient to drive such progression (Chen et al., 2004). Furthermore, stable 
exogenous AR over-expression permitted growth stimulation in response to the anti-
androgen bicalutamide, although the exact mechanism by which this is achieved is not 
known (Chen et al., 2004). Increased AR stabilization and nuclear localization was also 
observed in prostate cancer cell lines expressing increased AR (Gregory et al., 2001b). 
 
1.7.2.2 Androgen Receptor co-factor modulation 
 AR hypersensitivity to low androgen concentrations may also be achieved by 
modification of co-regulator expression, and the balance of AR co-activators and co-
repressors is hypothesized to regulate AR transcriptional activity (Feldman & Feldman, 
2001). In support of this, human immunohistochemistry studies demonstrated that the AR 
co-activators SRC-1 and SRC-2 were up-regulated in prostate tumours that reoccurred 
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after androgen ablation therapy, and this increase in expression was not observed in 
androgen-dependent tumours (Gregory et al., 2001a). Modulation of AR co-repressor 
cellular location may also facilitate AR activation in the presence of low androgen 
concentration. For example, immunohistochemistry studies demonstrate that the AR co-
repressor Hey-1 is localized in the nucleus of normal prostate epithelial cells, whereas 
advanced prostate cancer tumours displayed only cytoplasmic Hey-1. This suggests that 
the cytoplasmic relocalization of Hey-1 may have diminished the AR repressive capacity of 
Hey-1 and conferred a growth advantage in tumour cells (Lavery et al., 2011).  
 
1.7.2.3 Androgen Receptor mutation 
 Many somatic mutations of the AR have been identified in prostate tumours, with at 
least 70 single-base substitutions described in prostate cancer, most in the NH2-terminal 
domain or LBD (Gottlieb et al., 2004). AR somatic mutations often result in a gain of 
function, enabling AR transactivation in the presence of low androgen concentrations, and 
this is another mechanism by which prostate tumours may acquire androgen-independent 
growth. AR mutations are rare in early stage prostate tumours, but increase in occurrence 
after progression to androgen independence suggesting AR mutation may confer a growth 
advantage. For example, the sequencing of the AR in the LNCaP cell line identified the 
LDB mutation T877A, which enables AR activation by oestrogens, progestins and anti-
androgens in addition to androgens (Veldscholte et al., 1992a). Crystallographic studies of 
the AR LDB T877A revealed that the substitution of smaller alanine for threonine in the 
LBD pocket allows the mutant AR to accommodate ligands that wild type AR cannot 
(Matias et al., 2000). This mutation was also identified in 30% of metastatic prostate 
cancer tumours in one study (Gaddipati et al., 1994). A further example is the AR LBD 
helix 11 mutation H874Y, identified in the CWR22 prostate cancer cell line, which also 
results in loss of ligand specificity and activation of the AR by progesterone, oestradiol and 
the anti-androgen hydroxyflutamide (Duff & McEwan, 2005; McDonald et al., 2000). The 
presence of the more hydrophobic tyrosine residue in the H874Y mutant disrupts helix 12 
conformation, which also enhances the interaction of p160 co-activators with AF2. 
Therefore, the H874Y mutation mediates aberrant activation of the AR by loss of ligand 
specificity and increased co-activator interaction (Duff & McEwan, 2005; McDonald et al., 
2000).  
 The AR NH2-terminal Tau1 domain mutation K179R was also identified in hormone 
refractory prostate tumours (Tilley et al., 1996) and enhanced transcriptional activity of the 
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AR 4-fold in the presence of androgens (Callewaert et al., 2006). Tau1 is an essential 
domain for the NH2/COOH-terminal AR intramolecular interaction and deletion studies 
suggest Tau1 can reduce the interaction of the NH2-terminal domain with p160 co-
activator SRC-1. Therefore, it is possible that enhanced activity of the K179R mutant AR 
may be due to increased co-factor recruitment to the LBD (Bergerat & Ceraline, 2009; 
Callewaert et al., 2006).   
 
1.7.2.4 Promiscuous Androgen Receptor activation 
 Truly ligand-independent activation of the AR can enhance AR transactivation in 
post anti-androgen recurrent tumours, inducing AR target genes in the absence of ligand. 
For example, the growth factor Insulin Like Growth Factor 1 (IGF-1) induced a 5-fold rise in 
PSA expression in the LNCaP cell line (Culig et al., 1994). Whether the AR is activated by 
IGF-1 directly, or indirectly via the activation of a down stream effector of the AR signalling 
pathway is unknown (Culig et al., 1994). 
 
1.7.3 Androgen Insensitivity Syndrome (AIS) 
 Male sexual differentiation and acquisition of secondary sexual characteristics at 
puberty are androgen-dependent (as reviewed in Hughes & Deeb, 2006). AIS is an X-
linked disease often caused by loss of function mutation of the AR, resulting in partial or 
complete absence of AR activity, leading to target tissue resistance to androgens despite 
normal or high serum androgen concentrations (Jaaskelainen, 2011). Complete AIS 
(CAIS) patients have the external appearance of a female despite an XY genotype, this 
includes female external genitalia, breast development and absence of prostate, seminal 
vesicles and testicles. Partial AIS (PAIS) patients usually display a more masculinized 
phenotype including a micropenis and undescended testes. The extent of feminization of 
AIS patients is dependent upon residual AR activity (as reviewed in Brinkmann, 2001; 
Hughes & Deeb, 2006; Wilson et al., 1974).  
 More than 300 different loss of function AR mutations associated with AIS have 
been identified and are located throughout the length of the AR, with approximately 65% in 
the LBD, 20% in the DBD and small number in the NH2-terminus (as reviewed in Gottlieb 
et al., 2004; Hughes & Deeb, 2006). The most common type of mutation is a single base 
substitution resulting in a single amino acid change, or the generation of a premature stop 
codon (Gottlieb et al., 2004). However, complete and partial gene deletion and frame shift 
mutations have also been identified in patients. The AR mutations reported in AIS patients 
 56 
result in aberrant AR activity by either incomplete synthesis of AR protein or failure of AR 
to transactivate ARGs (Jaaskelainen, 2011).  
 
1.7.4 Spinal Bulbar Muscular Atrophy (SBMA) 
 SBMA, also known as Kennedy’s disease, is an X-linked hereditary adult male 
onset neurodegenerative disease of the lower motor neurons. Patients typically present 
with symptoms in the 4th-5th decade of life, with juvenile cases being extremely rare 
(Echaniz-Laguna et al., 2005). SBMA is caused by expansion of the CAG trinucleotide 
repeat, coding for the amino acid glutamine, in the AR NH2-terminal domain (La Spada et 
al., 1991). The AR CAG repeat is polymorphic, with a normal range between 11-26 
repeats, whereas SBMA patients have a range of 40-52 CAG repeats (La Spada et al., 
1991). SBMA patients display mild AIS symptoms, including reduced fertility and breast 
enlargement, suggesting partial loss of AR function (Dejager et al., 2002; Ranganathan & 
Fischbeck, 2010). However, it has been hypothesized that a toxic gain of function of the 
AR is the primary cause of neurodegenerative SBMA symptoms (Thomas et al., 2006), 
since an extended CAG repeat causes AR aggregation and nuclear inclusion in AR 
positive motor neurons, which is proposed to cause neurotoxicity via aberrant protein 
interaction of the AR resulting in transcriptional dysregulation (Thomas et al., 2006).  
 
1.8 The TET protein family 
 FUS is a member of the mammalian TET protein family (TLS/FUS, EWS and 
TAF15), also known as the FET family (FUS/TLS, EWS and TAF15) (Bertolotti et al., 
1996). The family is comprised of three structurally and functionally related mammalian 
proteins; Fused in Liposarcoma (FUS) also known as Translocated In Liposarcoma (TLS) 
(Crozat et al., 1993; Rabbitts et al., 1993), Ewing’s Sarcoma (EWS) also known as Ewing’s 
Sarcoma Break Point Region 1 (EWSR1) (Delattre et al., 1992) and TATA-Binding Protein 
Associated Factor 15 (TAF15), also known as hTAFII68 (Bertolotti et al., 1996) (Figure 
1.14). The TET proteins are defined by the presence of an NH2-terminal serine-glycine-
glutamine-tyrosine rich domain, a Cys2/Cys2 zinc finger, a highly conserved RNA 
recognition motif (RRM) and at least one arginine-glycine-glycine rich region. The TET 
family have significant primary amino acid sequence similarity, ranging from 36-46% upon 
comparison of full length proteins (Guipaud et al., 2006). The RRM domain shares even 
greater similarity, with a maximal amino acid similarity of 80% between FUS and TAF15 
(Figure 1.15) (Guipaud et al., 2006). 
Figure 1.14. Schematic diagram of TET family modular structure. (A) The human FUS gene 
(above) that encodes the FUS protein, the structure of which is shown below. (B) The protein 
structure of additional TET family members EWS and TAF15. Structural domains are indicated 
including the zinc finger binding domain (ZnF) and RNA recognition motif (RRM). Amino acid 
number domain boundaries are indicated below and are as defined by Guipaud et al., Proteomics. 
2006 Nov;6(22):5962-72, Iko et al., J Biol Chem. 2004 Oct 22;279(43):44834-40, Tan & Manley,J 
Mol Cell Biol. 2009 Dec;1(2):82-92 and Pubmed protein search tool (http://www.ncbi.nlm.nih.gov).  
1 6 5 7 8 9 10 Exon number: 2 3 4 11 12 13 14 15 
R/G rich RRM ZnF G rich S/Y/G/Q rich R/G rich 
1                                 165                  265 288             366         426     449         526 Amino acids: 
FUS 
R/G rich RRM ZnF G rich S/Y/G/Q rich R/G rich 
1                                         285  300            240 363           444  454     518    548         656 
1                                    208    232            314           353   379                                589 
R/G rich RRM ZnF S/Y/G/Q rich R/G rich 
EWS 
TAF15 
(B) 
FUS 
chromosome 16(p11.2) 
(A) 
57 
(A) ENTIRE PROTEIN SEQUENCE 
FUS      EWS      TAF15                     FUS      EWS      TAF15 
   (B) RNA RECOGNITION MOTIF 
 
 
EWS             46%            X             X     55 %             X               X ?   
                                                                        
 
TAF15          46%           36%          X                       80%             54%           X 
% AMINO ACID IDENTITY 
Figure 1.15. (A) Primary amino acid sequence comparison between TET family members 
FUS, EWS and TAF15 and (B) TET family RNA recognition motif.  Swiss prot accession 
numbers are P35637(FUS variant 2), Q01844 (EWS variant 2) and Q92804 (TAF15 variant 2). 
Adapted from Guipaud et al., Proteomics. 2006 Nov;6(22):5962-72.    
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 A Drosophilia TET family homologue, Sarcoma-Associated RNA Binding Fly 
Homolog (SARFH), has been identified as a putative TET family member by similarity of 
SARFH and TET family RRM domains (Immanuel et al., 1995; Stolow & Haynes, 1995), 
suggesting the TET family of proteins are highly conserved. Furthermore, homologues of 
TET family members were found in many mammalian species, for example the chicken 
genome contains homologues of FUS, EWS and TAF15 with 88%, 87% and 85% similarity 
to their human protein counterparts respectively (http://www.ncbi.nlm. nih.gov/UniGene).  
 
1.9 FUS structure and expression 
1.9.1 FUS genomic and protein structure 
 The FUS gene is located on chromosome 16p11.2 (Crozat et al., 1993; Rabbitts et 
al., 1993) and spans approximately 12Kb, and is comprised of 15 exons (Aman et al., 
1996; Morohoshi et al., 1998) (Figure 1.14). The FUS promoter lacks a TATA box and 
contains binding sites for the transcription factors Activator Protein 2 (AP-2) and Sp1  
qhich are typically found in promoters of house keeping genes (Aman et al., 1996).  
 Full length FUS cDNA encodes a 526 amino acid protein, with a predicted 
molecular weight of 53KDa (Prasad et al., 1994). FUS contains a NH2-terminal serine-
glycine-glutamine-tyrosine rich region encoded by exons 2-5, a glycine rich region 
containing multiple arginine-glycine-glycine repeats encoded by exon 6, a RRM domain 
encoded by exons 9-11, a Cys2/Cys2 zinc finger motif encoded by exons 12-13 and a 
further arginine-glycine-glycine domain encoded by exon 14 (Figure 1.14A). The 5’ 
untranslated region and several amino acids of the FUS NH2-terminus are encoded by 
exon 1 and the 3’ untranslated region and several COOH-terminal FUS amino acids are 
encoded by exon 15 (Iko et al., 2004; Morohoshi et al., 1998; Prasad et al., 1994).  
 The tertiary structure of FUS has not been determined, however primary sequence 
analysis reveals the presence of a highly conserved 90 amino acid RRM that is found in 
both prokaryotic and eukaryotic proteins and over 500 humans proteins (Crozat et al., 
1993). The tertiary structure of the RRM has been solved for multiple proteins, for example 
the human Small Ribonulceoprotein U1A, and it is composed of two α-helices and four 
anti-parallel β-sheets in the order of βαββαβ (Nagai et al., 1990). The RRM contains two 
consensus sequences called RNA recognition proteins-1 (RNP-1) and the less conserved 
RNP-2, their amino acids sequences are Lys/Arg-Gly-Phe/Tyr-Gly/Ala-Phe/Tyr-Val/Ile/Leu-
X-Phe/Tyr and Ile/Val/Leu-Phe/Tyr-Ile/Val/Leu-X-Asn-Leu (where X represent any amino 
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acids) respectively (as reviewed in Maris et al., 2005). The RNP motifs are involved in 
RNA recognition of both single stranded RNA and DNA, and have also been shown to 
mediate protein-protein interactions (Cassola et al., 2011; Maris et al., 2005). All members 
of the human TET family contain RNP sequences that are distinct from the consensus 
RNP sequences, for example TET family members contain a large extended loop linking 
α-helix 1 and β-sheet 2 and contain an acidic residue substitutions at position +2 and a 
threonine substitution at position +4 of the RNP-1 sequence (Bertolotti et al., 1996; Crozat 
et al., 1993) (Figure 1.16).   
 Primary sequence analysis also categorized the FUS zinc finger as a Ran-Binding 
Protein type zinc finger which is highly conserved across many eukaryotic species, 
including proteins in rat, mouse and Drosphilia and was originally identified as a Ran 
GTPase-binding domain (Higa et al., 2007; Iko et al., 2004; Nakielny et al., 1999; 
Plambeck et al., 2003). Nuclear magnetic studies of the isolated FUS zinc finger domain 
confirmed the presence of a tetrahedral coordinated zinc ion in C4 conformation within the 
FUS zinc finger domain amino acids 398-468 (Iko et al., 2004). The FUS zinc finger 
domain has 44% amino acid similarity to the Ran-Binding Protein zinc finger domain found 
in ZNF265, a human splicing factor that interacts with Cyclin B1 mRNA via its Ran-Binding 
domain, and for which the structure is resolved, revealing two β-hairpins that each 
containing two cysteine residues (Iko et al., 2004; Plambeck et al., 2003) (Figure 1.17). 
Comparative homology modelling of the FUS zinc finger domain to that of ZNF265 showed 
near identical positioning of one asparagine, one tryptophan and 4 cysteines that are 
highly conserved between the TET family members, suggesting these residues may be 
important for mediating the interaction of FUS with RNA (Iko et al., 2004) (Figure 1.17) 
(see section 1.10.2, FUS binds DNA and RNA).   
 Proteolysis studies coupled with circular dichroism suggests the RRM and zinc 
finger domains form a rigid core structure connected by a flexible glycine rich linker, whilst 
the rest of the protein is relatively unstructured (Iko et al., 2004). 
 
1.9.2 FUS expression 
 Immunohistochemistry studies using a tissue microarray containing 35 human 
organs identified almost ubiquitous expression of the TET family in all human cell types 
including prostate, with the exception of cardiac muscle, cardiac endothelium cells and 
skin melanocytes (Andersson et al., 2008). Nuclear expression was observed in almost all
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Figure 1.17. Homology model of FUS zinc finger domain. (A) The predicted three-dimensional 
structure of the zinc finger domain based upon the homology with ZNF265 zinc finger domain 
structure. The Zinc ion is represented in purple and β-strands in green. Cysteine residues 
coordinated with zinc ions are shown by stick models. (B) Alignment of of zinc finger domains of 
the TET family and closely related SARFH and ZNF265.  Red * represent residues that are 
identical in all sequences and green : represent those with conserved substitutions. Reprinted with 
kind permission from the Iko et al., J Biol Chem. 2004 Oct 22;279(43):44834-40. 
(A) 
(B) 
62 
 63 
FUS positive cell types, and this was accompanied by cytoplasmic staining in several cell 
types, including prostate, kidney, and breast, whilst exclusively cytoplasmic FUS 
expression was observed in hepatocytes (Andersson et al., 2008).  
 In support of the observed nuclear and cytoplasmic FUS expression in most cell 
types, Zinszner et al., report FUS engages in rapid nuclear-cytoplasmic shuttling in 
heterokaryon cells formed between human HeLa and mouse NIH-3T3 cells in vitro 
(Zinszner et al., 1997b), suggesting FUS has both a nuclear and cytoplasmic function. 
FUS contains both nuclear localization and export signals, shown to regulate its cellular 
localization. A nuclear localization signal has been identified at the FUS COOH-terminus, 
amino acids 514-526 (Dormann et al., 2010; Lee et al., 2006), which is necessary and 
sufficient for FUS nuclear import (Dormann et al., 2010). This process is dependent upon 
the nuclear import receptor, Transportin (Dormann et al., 2010). FUS also contains a 
nuclear export signal at amino acids 289-298, and mutation of this motif resulted in 
exclusive nuclear expression (Lanson et al., 2011).   
 
1.10 The diverse physiological roles of FUS 
1.10.1 Transcriptional regulation  
 FUS is a multifunctional protein, with reported involvement in splicing, genomic 
stability, neuronal morphology, disease pathology and transcriptional regulation (as 
reviewed in Tan & Manley, 2009; Yang et al., 2010).  
 Studies of the role of FUS as a transcriptional regulator were prompted by the 
observed intrinsic transcriptional activation potential of FUS NH2-terminal amino acids 1-
273, which when recruited to a luciferase reporter via a GAL4-DBD tag, enhanced 
transcriptional activity in trans (Uranishi et al., 2001; Zinszner et al., 1994). Furthermore, 
the fusion of the FUS NH2-terminal amino acids 1-252 to the transcription activation 
domain of Insulin Enhancer Binding Protein (IEBP) enhanced the transcriptional activity of 
IEBP on an IEBP responsive reporter construct (Sanchez-Garcia & Rabbitts, 1994).    
 FUS has subsequently been identified as a transcriptional modulator, either by 
interacting directly with both general and specific transcription factors and/or by binding to 
the regulatory promoter region of genes to mediate either transcriptional activation or 
repression.  
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1.10.1.1 FUS associates with general transcription factors  
 FUS associates with the general transcription factors TATA Binding Protein (TBP) 
(Tan & Manley, 2010) and TFIID (Bertolotti et al., 1996). TFIID is comprised of TBP and 
various TBP Associated Factors (TAFs). This complex is necessary for activated 
transcription and nucleates pre-initiation complex formation, and different TAF components 
may have differential effects upon transcription (Roeder, 1996). It is hypothesized that 
TFIID-associated proteins may affect recruitment of co-factors to the promoter via the 
general transcription machinery (Bertolotti et al., 1996; Tan & Manley, 2009), suggesting 
FUS may influence transcription initiation. FUS also interacts with RNA Polymerase II, and 
this interaction is mediated by the FUS NH2-terminal, further implementing FUS in 
transcriptional regulation (Yang et al., 2000). 
  
1.10.1.2 FUS acts as a transcriptional activator 
 FUS acts as a co-activator for multiple transcription factors. One example is p65 
(Uranishi et al., 2001), a member of the NF-κB family of transcription factors that regulate 
immune and inflammatory responses and cell proliferation (Ghosh et al., 1998). The 
transcriptional competence of p65 is regulated by interaction with co-regulatory proteins 
including CBP, p300, TBP and TFIIB (Uranishi et al., 2001). FUS associates with the p65 
trans-activation domain and co-activates p65 transcriptional activation of a NF-κB reporter 
construct in vitro, while increased FUS expression also up-regulates expression of the p65 
regulated gene ICAM-1 (Uranishi et al., 2001).  
 FUS also co-activates the transcription factor Y-Box Binding Protein 1 (YB-1) (Law 
et al., 2006). YB-1 is recruited to promoter elements of target genes upon cytotoxic stress 
to influence expression of multiple cell growth and death regulatory genes, including CDK 
inhibitors and Cyclins (Jurchott et al., 2003; Kohno et al., 2003; Lu et al., 2005). FUS 
interacts with YB-1 (Chansky et al., 2001), and reporter assays demonstrate FUS co-
activates the expression of the YB-1 regulated gene Matrix Metalloprotease I (MMP-1) in 
vitro (Law et al., 2006; Mertens et al., 1997).  
 FUS also enhances expression of Survivin, a member of the inhibitor of apoptosis 
gene family (Altieri, 2010; Du et al., 2011). FUS increased transcription at the Survivin 
promoter in synergy with Protein Arginine Methyltransferase 1 (PRMT1) in transcription 
assays (Du et al., 2011; Tang et al., 2000). Furthermore, PRMT binds to and increases the 
methylation state of FUS (Du et al., 2011). The functional consequences of FUS 
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methylation remains to be elucidated, however PRMT-1 is necessary for the FUS-
dependent increase in Survivin transcription, suggesting a possible link between post-
translational modification and the regulation of FUS transcriptional regulatory capacity (Du 
et al., 2011).  
 
1.10.1.3 FUS acts as a transcriptional repressor 
 FUS also has transcriptional repressive activity. For example, increased FUS levels 
resulted in repression of RNA Polymerase III-regulated gene expression, and chromatin 
immunoprecipitation identified FUS association with the promoter of all three classes of 
RNA Polymerase III genes, suggesting FUS mediates transcriptional repression via 
recruitment to regulatory promoter regions (Tan & Manley, 2010). Interaction studies 
demonstrate that FUS interacts with TBP and RNA Polymerase III subunit RPC155, and 
the FUS-mediated repression of RNA Polymerase III activity may involve inhibition of TBP 
recruitment, since chromatin immunoprecipitation studies demonstrated increased TBP 
recruitment to RNA polymerase III regulated promoters in the presence of reduced FUS 
expression (Tan & Manley, 2010).   
 FUS also represses transcription of the G1/S cell cycle regulatory protein Cyclin D1, 
via recruitment of FUS to multiple regions of the Cyclin D1 promoter (Wang et al., 2008). 
FUS repressive activity is regulated by non-coding RNA (ncRNA) transcribed from the 5’ 
regulatory region of Cyclin D1 in response to DNA damage. The ncRNA binds to the FUS 
COOH-terminal and relieves an intramolecular NH2/COOH-terminal interaction. This 
allosteric modification facilitates the recruitment of FUS to the ncRNA transcribed regions 
of the Cyclin D1 promoter. Here the FUS NH2-terminal interacts with co-activators CBP 
and p300 and inhibits their HAT activity, therefore repressing Cyclin D1 transcription 
(Wang et al., 2008) (Figure 1.18). 
 GST interaction studies demonstrate FUS associates with transcription factors 
RUNX-1 and 2 (Li et al., 2010), which regulate soft tissue development and 
tumourigenesis (Blyth et al., 2005). FUS also co-represses the transcriptional activity of 
RUNX-1 and 2 responsive luciferase reporters, suggesting FUS may function as a 
negative regulator of RUNX transcription factor activity possibly via inhibition of RUNX 
recruitment to DNA, since interaction studies suggest FUS binds to the highly conserved 
Runt DNA binding domain within RUNX-2 (Li et al., 2010).  
Cyclin D1 CREB CREB 
p/CAF 
CBP p300 
Cyclin D1 
CREB CREB 
p/CAF 
CBP p300 
DNA damage 
FUS intramolecular 
interaction 
FUS 
ncRNA Cyclin D1 expressing region 
(A) 
(B) 
Figure 1.18. Non-coding RNA Cyclin D1 negatively regulates Cyclin D1 transcription by 
recruiting FUS to the Cyclin D1 promoter (Wang et al., 2008). (A) Cyclin D1 transcription is 
dependent upon the histone acetyl transferase (HAT) activity of co-activators, including CBP and 
p300. (B) DNA damage induces the transcription of non-coding RNA from 5? regulatory region of 
the Cyclin D1 promoter. The FUS COOH-terminus binds to ncRNA Cyclin D1, releasing a repressive 
intramolecular COOH/NH2-terminal FUS interaction (represented by a red dotted line). Upon 
ncRNA Cyclin D1 dependent allosteric modulation FUS is recruited to ncRNA Cyclin D1 synthesizing 
regions of the Cyclin D1 promoter, where the FUS NH2-terminal interacts with CBP and p300 and 
inhibits their HAT activity, subsequently repressing Cyclin D1 transcription.  
ncRNA Cyclin D1 expressing region 
ncRNA Cyclin D1 
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 FUS also interacts with β-catenin, suggesting FUS may play a role in the 
modulation of the Wnt signaling pathway, in which β-catenin is a down stream effector. 
FUS also co-represses transcription of the β-catenin regulated gene T-Cell Factor 
(TCF)/Lymphoid Enhancer-Binding Factor-1 (LEF) in transient transcription assays (Sato 
et al., 2005). 
 Further support for the role of FUS as a transcriptional co-repressor is the 
interaction of FUS with transcription factor Purine-rich Binding Protein 1 (PU.1), an ETS 
protein that is required for differentiation of macrophages and B cells during normal 
haemotopoiesis (Hallier et al., 1998; McKercher et al., 1996; Scott et al., 1994). FUS 
represses the transcriptional activity of PU.1 on a reporter plasmid in transcription assays. 
Furthermore, electromobility shift assays demonstrate FUS COOH-terminal amino acids 
271-526 are sufficient to prevent PU.1 from binding to its cognate responsive element, 
suggesting FUS co-represses PU.1 transcriptional activity by inhibiting DNA binding 
(Hallier et al., 1998). See Table 1.1 for a summary of FUS interacting proteins.  
 
1.10.2 FUS binds DNA and RNA  
 Cross-linking studies demonstrate that full length FUS and the FUS COOH-
terminus interact with RNA. Deletion studies suggest the RRM is dispensable for this 
interaction (Crozat et al., 1993; Zinszner et al., 1997b). The addition of RNA Polymerase II 
inhibitors rapidly diminished FUS association with RNA, suggesting that the RNA involved 
may be a product of this polymerase (Zinszner et al., 1997b). FUS also preferentially binds 
poly-G homopolymer RNA oligonucleotides, and full length FUS is needed for this binding 
selectivity (Prasad et al., 1994). Further RNA interaction studies demonstrate FUS 
preferentially binds to the RNA sequence GUGG, and this specificity requires both the 
RRM and flanking RGG domains (Lerga et al., 2001). However, subsequent NMR analysis 
of isolated FUS domains suggests binding to GUGG is via the zinc finger domain, whereas 
the RRM domain showed no RNA interaction, which indicates the RGG rich domains 
flanking the RRM domain are necessary for RRM-RNA interaction (Iko et al., 2004).  
 Therefore, the specific mechanism(s) by which FUS interacts with RNA and the 
FUS domains that mediate this interaction in vivo have yet to be fully elucidated. However 
an increasing number of FUS binding RNA targets have been identified. For example, 
Wang et al., demonstrated the FUS COOH-terminus interacts with ncRNA transcribed 
from the Cyclin D1 promoter (Wang et al., 2008). FUS also binds to a 493 nucleotide long 
Table 1.1. Summary of FUS interacting proteins: FUS interacting protein name (listed on left) 
and reference reporting interaction (listed on the right).  
FUS interacting partn e r  Reference 
 
TBP  Tan & Manley, 20 1 0  
TFII D  Bertolotti et al., 1996 
CBP  Wang et al., 2008  
P300  Wang et al., 2008  
P 6 5  Uranishi et al., 2001  
YB - 1  Law et al., 2006 
PRMT-1  Du et al., 20 1 1  
RNA Polymerase III  Tan & Manley, 20 1 0  
RUNX-1 and RUNX - 2  Li et al., 2010 
-catenin Sato et al., 2005 
PU.1  Hallier et al., 199 8  
RNA Polymerase II Yang et al., 2000 
TFIIF Kameoka et al., 2004 
p54
nrb
 Kameoka et al., 2004 
hnRNP A1 Zinszner et al., 1994 
hnRNP C1/2 Zinszner et al., 1994 
SC35  Meissner et al., 2003 
TASR Yang et al., 1998 
PTB Meissner et al., 2003 
SRm160 Meissner et al., 2003 
Drosha Gregory et al., 2004 
NMDA receptor adhesion 
complex 
Husi et al., 2000 
Nd1-L Fujii & Takumi, 2005 
Androgen Receptor Haile et al., 2011 
Retinoid-  Receptor 
Oestrogen Receptor  
Glucocorticoid Receptor 
Thyroid Receptor 
Powers et al., 1998 
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sequence in the 3’ untranslated region of the mRNA transcript of the actin stabilizing 
protein Nd1-L, which does not contain the GUGG motif. This suggests FUS may bind to 
additional RNA motifs or recognize RNA conformation (Fujii et al., 2005). In support of this, 
FUS also binds non-GUGG containing human telomeric RNA (UUAGGG)4 (Takahama et 
al., 2008) and to single stranded telomeric DNA (TTAGGG)4 (Takahama et al., 2009), 
suggesting a role in telomeric binding and recognition.  
 FUS also binds to a DNA oligonucleotide containing a zinc finger binding consensus 
sequence in vitro (Perrotti et al., 1998). The DNA binding capacity of FUS may play a role 
in DNA double strand break repair, since it has been shown that FUS is involved in D-loop 
formation in vitro, which is essential for double strand break repair during homologous 
recombination. During D-loop formation FUS binds both single and double stranded DNA 
and mediates annealing of complementary DNA strands (Baechtold et al., 1999).  
 
1.10.3 The role of FUS in splicing regulation 
 FUS was identified as the heterogeneous nuclear ribonucleoprotein (hnRNP) P2 
(Calvio et al., 1995), which is a component of a pre-mRNA complex identified in vitro 
(Dreyfuss et al., 1993; Pinol-Roma et al., 1988). The hnRNP family are implemented in the 
regulation of multiple stages of RNA metabolism, including mRNA splicing (Chou et al., 
1999) and 3’-end processing (Kessler et al., 1997) to generate mature mRNA (Chaudhury 
et al., 2010; Hocine et al., 2010). The identification of FUS as hnRNP2 suggests FUS may 
participate in the regulation of RNA processing.  
 In support of this, proteomic studies identified FUS as a component of the 
spliceosome (Hartmuth et al., 2002; Zhou et al., 2002a), which is comprised of small 
nuclear (sn) RNA, snRNPS and multiple splicing factors, which function to regulate the 
splicing of pre-mRNA (Will & Luhrmann, 2010). Furthermore, FUS also associates with a 
large transcription-splicing complex bound to the 5’ splice site of pre-mRNA in Hela cells, 
in complex with RNA Polymerase II, snRNPs and multiple transcription and splicing 
factors, including TFIIF and Nuclear RNA Binding Protein p54 (p54nrb) (Kameoka et al., 
2004). FUS also associates with specific splicing factors including hnRNP A1 and C1/2 
(Zinszner et al., 1994), YB-1 (Rapp et al., 2002), Serine Arginine Proteins (SC35 and TLS 
Associated Serine-Arginine Protein (TASR)) (Meissner et al., 2003; Yang et al., 1998), 
Polypyrimidine Tract Binding Protein (PTB) (Meissner et al., 2003) and SRm160 (Meissner 
et al., 2003).  
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 The interaction of FUS with multiple splicing factors suggests FUS regulates 
splicing and this has been demonstrated for H-Ras pre mRNA, whereby increased FUS 
levels favoured the generation of the alternatively spliced H-Ras product containing an 
alternative exon termed intron-D-exon (IDX) (Camats et al., 2008). 
 Further implicating FUS as a regulator of RNA metabolism is the identification of 
FUS as a component of the Drosha multi-protein complex (Gregory et al., 2004). Drosha is 
a RNA Polymerase III that is involved in the processing of microRNA, which are a family of 
small non-protein coding genes involved in multiple cell functions including proliferation 
and cell death regulation. The association of FUS with this Drosha complex suggests FUS 
may also play a role in microRNA processing (Gregory et al., 2004). See Table 1.1 for a 
summary of FUS interacting proteins. 
 
1.10.4 FUS may couple splicing and transcription 
 FUS is able to interact directly with transcription factors, functioning as both a 
transcriptional co-activator and co-repressor, and also interacts with splicing factors and 
has been identified as a component of the spliceosome complex. It is hypothesized that 
FUS may bridge the processes of transcription and splicing via the interaction of FUS with 
RNA Polymerase II and general transcription factors TFIID and TBP, and components of 
the splicing and transcription machinery (Law et al., 2006). The exact mechanism(s) by 
which FUS couples splicing and transcription remain to be determined and this would 
require the identification of specific mRNA targets for which both transcription and splicing 
are coupled by FUS.  
 
1.10.5 The role of FUS in development and genome maintenance 
 Two independent FUS knock out mice have been created via the insertion of gene-
trap constructs in exon 8 or 12 respectively (Hicks et al., 2000; Kuroda et al., 2000). The 
phenotype of FUS-/- mice is dependent upon genetic background. Inbred FUS-/- mice die 
within 16 hours of birth and are small with major defects in B lymphocyte development. In 
addition, embryonic fibroblasts from these mice displayed genomic instability (Hicks et al., 
2000). However, out bred FUS-/- mice survived until adulthood but were sterile due to 
defects in spermatogenesis. These mice displayed enhanced sensitivity to ionizing 
radiation, suggesting genomic instability (Kuroda et al., 2000).   
 The genomic instability in both FUS-/- mouse models suggests FUS has a role in 
genomic maintenance, and this is suggested by its role in D-loop formation, an essential 
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step in DNA repair by homologous recombination (Baechtold et al., 1999). FUS is also a 
target of Ataxia Telangiectasia Mutated (ATM), a kinase induced by double stranded DNA 
breaks (Baechtold et al., 1999). Furthermore, FUS serves as a sensor of DNA damage 
signals by binding to Cyclin D1 damage-induced ncRNA, which initiates the FUS-
dependent repression of Cyclin D1, suggesting FUS may function to regulate cell cycle 
progression in response to DNA damage signals (Wang et al., 2008). It is hypothesized 
that cells lacking FUS may therefore have reduced DNA repair ability and transcription 
regulation of cell cycle, resulting in the observed chromosomal instability (Tan & Manley, 
2009). 
 
1.10.6 Cytoplasmic function of FUS 
 In addition to its nuclear function and splicing, FUS appears to function in the 
cytoplasm. It is observed to shuttle between the nucleus and cytoplasm in heterokaryons 
(Zinszner et al., 1997b) and immunohistochemistry studies demonstrate FUS is expressed 
in the cytoplasm and nucleus of most human tissues (Andersson et al., 2008).  
 The physiological role of cytoplasmic FUS has been studied in neuronal cells, 
where proteomic studies indicate cytoplasmsic FUS is in complex with RNA transporting 
granules in association with Kinesin, a microtubule transporter protein (Kanai et al., 2004). 
RNA transporter granules mediate the transport of RNA and proteins including hnRNPs to 
dendrite synapses, where they influence local mRNA translation which affects neuronal 
plasticity (Kanai et al., 2004). Furthermore, FUS has been identified in complex with the N-
Methyl-D-Aspartate (NMDA) receptor adhesion complex, (Husi et al., 2000; Selamat et al., 
2009) which regulates mRNA translation and plasticity of neuronal glutamate excitatory 
synapses. Inhibitor studies demonstrate the transport of FUS to neuronal dendrites is 
dependent upon actin filaments (Fujii et al., 2005), Myosin-Va (Yoshimura et al., 2006) and 
Myosin VI  (Takarada et al., 2009), and FUS transport is stimulated upon activation of  the 
neurotransmitter receptor Metabotropic Glutamate Receptor 5 (mGluR5) (Fujii et al., 
2005). These results suggest cytoplasmic FUS may play a role in modulation of neuronal 
plasticity by facilitating mRNA transport and local translation at synaptic membranes. 
 Cytoplasmic FUS may also regulate cell morphology, since FUS null neurons 
displayed abnormal morphology (Fujii et al., 2005). In support of this, FUS binds to mRNA 
encoding Actin stabilizing protein Nd1-L (Fujii & Takumi, 2005), suggesting FUS may 
regulate Actin reorganization. Furthermore, FUS localizes to cell spreading initiation 
centres which are focal-adhesion like complexes that are observed to exist in the early 
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stages of cell spreading in adherent cell lines (Andersson et al., 2008; de Hoog et al., 
2004). The spreading initiation complex is distinct from focal adhesion complex due to the 
presence of RNA binding proteins, RNA and an Actin sheath surrounding the complex in 
addition to focal adhesion markers such Viniculin (de Hoog et al., 2004). The addition of 
FUS antibody during cell adhesion led to increased cell radii, indicating these centres 
regulate cell spreading and that FUS may play a role in the regulation of this process (de 
Hoog et al., 2004). 
 FUS has also been identified as a component of cytoplasmic RNA stress granules, 
which are induced upon cellular stress when translation is impaired (Anderson & 
Kedersha, 2009; Andersson et al., 2008). Stress granules are a complex of mRNA, 
translation initiation components and multiple proteins involved in RNA metabolism, and 
are thought to function as regulators of translation (Anderson & Kedersha, 2009; 
Andersson et al., 2008) and apoptosis (Arimoto et al., 2008; Buchan & Parker, 2009). The 
physiological role FUS plays upon incorporation into RNA stress granules remains 
unknown.  
 
1.11 Post-translational modification of FUS 
 FUS contains multiple post-translational modification sites (Figure 1.19), including 
sites of methylation and phosphorylation. For example, Western blot analysis 
demonstrated that FUS is tyrosine phosphorylated in response to treatment with Fibroblast 
Growth Factor (FGF) 2, Epidermal Growth Factor (EGF) and Platelet Derived Growth 
Factor (PDGF) in murine brain endothelial cells (Klint et al., 2004). Furthermore, cell 
fractionation studies demonstrate FGF-2 induced phospho-FUS is localized in the 
cytoplasm, suggesting FUS may play a cytoplasmic role in the regulation of cell growth 
(Klint et al., 2004). FUS is also phosphorylated by the kinase Ataxia Telangiectasia 
Mutated (ATM) at serine 42 in response to double stranded DNA breaks (Gardiner et al., 
2008). Further FUS phosphorylation sites at serine 256, 439 and 513 and tyrosine 479 
were identified in a human lymphoblastoid cell line by 2D SDS-PAGE followed by mass 
spectrometry (Guipaud et al., 2006).  
 FUS serine 256 is a phosphorylation target of Protein Kinase C β-II (PKCβII), and 
this phosphorylation event is necessary for the binding of FUS to an oligonucleotide 
containing a zinc finger recognition consensus motif in vitro (Perrotti et al., 1998). The 
phosphorylation of FUS serine 256 by PKCβII also inhibits the c-Jun-dependent 
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Figure 1.19. Schematic representation of several post-translational modification sites of 
FUS. Schematic depiction of the FUS protein structure, with structural domains depicted, including 
the RNA recognition motif (RRM) and zinc finger (ZnF) domains. The FUS domain amino acid 
boundaries are indicated below. Examples of known amino acid post-translational modifications 
(represented by single letter amino acid code and position number) are represented by colour, 
where blue represents di-methylation sites and pink represents phosphorylation sites.  
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proteasomal degradation of FUS in myeloid cells (Perrotti et al., 1998; Perrotti et al., 
2000), demonstrating that FUS levels are regulated by post-translational phosphorylation. 
 Mass spectrometry identified that FUS is di-methylated at arginines 216, 218, 242 
and 394 in Hela cells (Du et al., 2011). FUS arginine methylation increased upon over-
expression of Protein Arginine Methyltransferase 1 (PRMT-1), suggesting FUS is arginine 
methylated by PRMT-1. The functional consequence of this methylation has yet to be fully 
explained, however, FUS and PRMT1 synergistically activate transcription at the Survivin 
promoter, suggesting that FUS arginine methylation may regulate its transcriptional activity 
(Du et al., 2011).  
 
1.12 The role of FUS in disease 
1.12.1 Neurodegenerative disease 
 FUS is implicated in the pathobiology of neurodegerative diseases via the 
identification of FUS mutations in a subset of patients with familial amyotrophic lateral 
sclerosis (ALS) (Kwiatkowski et al., 2009; Vance et al., 2009), an adult onset fatal 
neurodegerative disease which is characterized by the loss of upper and lower motor 
neurons, progressive muscle weakening and paralysis (Lagier-Tourenne et al., 2010). The 
average ALS patient age at diagnosis is 60 years and most die due to respiratory failure 1-
5 years after disease onset (Vance et al., 2009). Although most cases are sporadic, 
approximately 10% of ALS patients have disease familial history, caused by dominant 
mutation in either TAR DNA Binding Protein 43 (TDP-43), CuZn Superoxide Dismutase 
(SOD1), Angiogenin (ANG) or FUS. To date approximately 26 FUS mutations have been 
identified, accounting for approximately 4% of familial ALS cases, and FUS mutations are 
also found in rare sporadic cases (Belzil et al., 2009; Blair et al., 2009; Chio et al., 2009a; 
Chio et al., 2009b; Corrado et al., 2009; Damme et al., 2009; Drepper et al., 2009; 
Kwiatkowski et al., 2009; Lagier-Tourenne et al., 2010; Tateishi et al., 2009; Ticozzi et al., 
2009; Vance et al., 2009; Waibel et al., 2010). The majority of FUS mutations are found in 
exon 15, which contains the COOH-terminal NLS sequence, and the remainder in exons 3, 
5, 6 and 14 (Dormann et al., 2010) (Figure 1.20). 
 The common pathological hallmark of ALS patients is the presence of cytoplasmic 
inclusions in neurons (Lagier-Tourenne et al., 2010). Postmortem immunohistological 
studies showed FUS localized to cytoplasmic inclusions in lower motor neurons (Vance et 
al., 2009), and ALS-associated FUS mutants expressed in vitro localize to the cytoplasm in  
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Figure 1.20. Amyotrophic lateral sclerosis patient FUS mutations. Schematic diagram of 
FUS with structural domains indicated, including the RNA recognition motif (RRM) and zinc 
finger (ZnF) domains and the amino acids number of the domain boundaries are indicated 
above. The amino acid location of  FUS mutations identified in familial amyotrophic lateral 
sclerosis patients are indicated below FUS. Amino acid mutations found within the COOH-
terminal nuclear localization signal (amino acids 514-526) are depicted below (Waibel et al., 
2010; Lagier-Tourenne et al., 2010).  
nuclear localization signal 
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neuronal cells (Kwiatkowski et al., 2009; Vance et al., 2009). FUS is hypothesized to gain 
cytoplasmic toxic function or lose nuclear function, or both in ALS (Ju et al., 2011).  
 Dormann et al., demonstrated that familial ALS mutations located within the FUS 
COOH-terminal NLS signal disrupt the Transportin-dependent nuclear import of FUS, 
resulting in cytoplasmic accumulation and mRNA stress granule formation (Dormann et al., 
2010). Therefore, a two hit ALS pathological model is proposed requiring a defect in 
nuclear import of FUS resulting in cellular mislocalization, and the addition of cellular 
stress, which may be sufficient for the formation of stress granules (Dormann et al., 2010).  
 FUS immunoreactive inclusion bodies are present in other neurodegenerative 
diseases, including polyglutamine expansion diseases (Doi et al., 2010), neuronal 
intermediate filament inclusion disease (NIFID) (Neumann et al., 2009b) and a subset of 
frontotemporal lobar degenerative disease (Neumann et al., 2009a), suggesting a possible 
common pathological role of FUS in neurodegeneration.  
 
1.12.2 FUS oncogenic fusion proteins 
 FUS forms oncogenic fusion proteins with several transcription factors including 
CCAAT Enhancer Binding Protein Homologous Protein (CHOP) in myxoid liposarcoma 
(Crozat et al., 1993; Rabbitts et al., 1993), ETS Regulated Gene (ERG) (Ichikawa et al., 
1994) and Fifth Ewing Variant (FEV) (Ng et al., 2007) in Ewing’s sarcoma and human 
myeloid leukemia, CREB3L2 (Storlazzi et al., 2003) and CREB3L1 (Mertens et al., 2005) 
in low-grade fibromyxoid sarcoma and to Activating Transcription Factor 1 (ATF-1) in 
angiomatoid histiocytoma (Waters et al., 2000). In all FUS fusion products, the 
translocation results in expression of the FUS NH2-terminus fused to a transcription factor 
DNA binding domain, with its expression driven by the FUS promoter (Tan & Manley, 
2009). The oncogenic translocation of FUS with CHOP and ERG is discussed in sections 
1.12.2.1 and 1.12.2.2.   
 
1.12.2.1 FUS-CHOP  
 FUS was originally identified as part of the FUS-CHOP oncogenic translocation 
protein, formed as a result of the chromosomal translocation t(12;16)(q13.3;p11.2) (Crozat 
et al., 1993; Rabbitts et al., 1993) and comprised of the FUS NH2-terminal amino acids 1-
266 fused to full length CHOP (amino acids -27 to 169, including 27 amino acids encoded 
by CHOP 5’ untranslated region) (Figure 1.21). The RRM and zinc finger domains of FUS 
are replaced by the leucine zipper DNA binding domain of CHOP (Crozat et al., 1993; 
R/G rich RRM ZnF G rich S/Y/G/Q rich R/G rich 
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Figure 1.21. Schematic representation of the oncogenic FUS-CHOP fusion protein that 
arises as a result of a t(12;16)(q13;p11) translocation. The FUS and CHOP and FUS-CHOP 
structural domains are indicated, including the zinc finger binding domain (ZnF), RNA recognition 
motif (RRM) and basic leucine zipper domain (bZIP). A part of the 5? untranslated region of CHOP 
that is translated in FUS-CHOP is depicted by a black box (bottom diagram). Amino acid number 
domain boundaries are indicated below.  
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Rabbitts et al., 1993). The mechanisms by which FUS fusion proteins contribute to cellular 
transformation are best understood for FUS-CHOP. The expression of FUS-CHOP is 
proposed to be the primary cause of myxoid liposarcoma due to its high frequency and 
specificity of expression in the disease as it is reported that 90% of myxoid liposarcomas 
express FUS-CHOP (Antonescu et al., 2000).  
 Expression of either the FUS or CHOP separate fusion domains are not sufficient to 
transform fibroblasts nor induce tumours in mice (Perez-Losada et al., 2000b; Zinszner et 
al., 1994), whereas transgenic mice ubiquitously expressing FUS-CHOP develop myxoid 
liposarcoma, suggesting FUS-CHOP expression alone is sufficient for cell type specifc 
transformation (Perez-Losada et al., 2000a). In vitro expression studies demonstrated that 
FUS-CHOP is expressed exclusively in the nucleus (Zinszner et al., 1997a), which is 
hypothesized to result in deregulation of gene expression, leading to inhibition of adipocyte 
differentiation and liposarcoma development (Tan & Manley, 2009). The isolated FUS 
fusion domain (amino acids 1-266) is capable of autonomously activating reporter gene 
expression (Prasad et al., 1994; Sanchez-Garcia & Rabbitts, 1994; Uranishi et al., 2001; 
Zinszner et al., 1994), suggesting the FUS domain provides a trans-activation function 
contributing to FUS-CHOP aberrant transcriptional regulation.  
 Several FUS-CHOP regulated genes have been identified including DOL54, which 
is up-regulated by FUS-CHOP in vitro (Domoto et al., 2002; Kuroda et al., 1999). DOL54 is 
associated with the regulation of adipocyte differentiation and increased DOL54 
expression is associated with adipocyte tumourigenicity (Kuroda et al., 1999). FUS-CHOP 
also up-regulated expression of Platelet Derived Growth Factor-α (PDGFα), which 
promotes growth and migration of mesenchymal cells in vitro (Riggi et al., 2006). This 
suggests FUS-CHOP mediates cell transformation by the stimulation of growth and 
disruption of adipocyte differentiation regulation.  
 
1.12.2.2. FUS-ERG 
 Another example of a FUS oncogenic fusion protein is FUS-ERG, which is formed 
by the (16;21)(p11.2;q22.2) translocation which results in the NH2-terminal domain of FUS 
fusing to the COOH-terminal of ERG, a protein essential for maintenance of the 
haematopoietic stem cell and normal haematopoiesis (Loughran et al., 2008). FUS-ERG is 
expressed in acute myeloid leukaemia and Ewing’s tumour, where multiple translocation 
junctions have been identified within the FUS-ERG fusion protein, all of which result in the 
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replacement of the RNA binding domain of FUS with the DNA binding domain of ERG 
(Ichikawa et al., 1994; Shing et al., 2003).  
 The contribution of FUS-ERG to oncogenic transformation is less well studied than 
that of FUS-CHOP. However, over-expression of FUS-ERG in vitro results in the 
transformation of the mouse fibroblast cell line NIH3T3 (Ichikawa et al., 1994) and also 
blocks differentiation of a mouse myeloid progenitor cell line (Pan et al., 2008). The in vitro 
ectopic expression of FUS-ERG is not sufficient to induce leukaemia in pre-haematopoietic 
progenitor cells derived from human umbilical cord, suggesting additional genetic events 
are required to initiate leukaemia (Tsuzuki et al., 2011; Warner et al., 2005). In vitro 
studies also demonstrated that FUS-ERG may contribute to oncogenic transformation by 
the disruption of RNA splicing, since increased expression of FUS-ERG in the human 
erythroleukemic cell line K562 resulted in altered CD44 mRNA splice variants (Yang et al., 
2000). CD44 encodes an adhesion protein and altered CD44 splicing isoforms have been 
found in multiple cancers (Goodison et al., 1998). Furthermore, cell cycle regulatory 
protein CDK1 is up-regulated upon over-expression of FUS-ERG in a mouse myeloid 
progenitor cell line, which is proposed to contribute to the inhibition of terminal 
differentiation (Pan et al., 2008). 
 
1.12.3 Altered FUS expression in cancer 
 FUS expression is altered in several cancers, including prostate cancer, and Brooke 
et al., reported an inverse correlation between FUS expression in prostate tumours and 
tumour Gleason grade (a measure of prostate cancer progression and aggressiveness), 
and also demonstrated that patients with higher FUS levels were less likely to have 
metastatic bone tumours and were more likely to live longer (Brooke et al., 2011). 
Paradoxically, increased FUS expression in cancer is also reported, for example in 
invasive breast lobular carcinoma where genomic profiling of patient tumour samples 
revealed increased FUS expression (Stange et al., 2006). Immunositochemistry studies 
also reported increased FUS expression in colon cancer tumours (Lepourcelet et al., 2005; 
Sato et al., 2005).  
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1.13 FUS project background  
 Dr Greg Brooke identified FUS as an androgen down-regulated target in a 2D SDS-
PAGE protein screen performed in the LNCaP cell line, where androgen stimulation for 16 
hours induced a 35% decrease in FUS expression (Figure 1.22, unpublished data from Dr 
Charlotte Bevan’s laboratory). This regulation was confirmed by Western blot analysis, 
with the down-regulation of FUS expression observed after 24 hours of androgen 
treatment (Brooke et al., 2011). 
 GST interaction studies demonstrated that FUS interacts with the Retinoid-α and 
Thyroid nuclear receptors and also with the steroid nuclear receptors ERα and GR 
(Powers et al., 1998). Deletion studies indicate that the FUS NH2-terminus mediates 
interaction with the Thyroid Receptor DBD, but does not inhibit Thyroid Receptor 
recruitment to DNA (Powers et al., 1998). GST interaction assays were performed to 
investigate the interaction of FUS with AR domains (Figure 1.23, unpublished data from Dr 
Charlotte Bevan’s laboratory). A strong interaction was evident between FUS and the AR 
DBD, which is in agreement with the reported interaction of FUS with the DBD of additional 
steroid receptors GR and ERα (Powers et al., 1998). FUS was also shown to interact with 
the AR LBD and LBD-hinge in the presence of the anti-androgen bicalutamide. A weak 
interaction with AR AF1 was also observed (Figure 1.23, unpublished data from Dr 
Charlotte Bevan’s laboratory).  
 
1.14 Project hypothesis and aims 
 FUS is an androgen down-regulated target and also interacts with the AR, therefore 
it is hypothesized that FUS plays an important role in the regulation of the androgen 
signalling axis, and FUS regulation may link androgen signalling to prostate cell division.  
 
Project aims are; 
1. to investigate the role of FUS in androgen-dependent cell cycle progression and 
proliferation;  
2. to determine whether FUS is a regulator of AR activity; and 
3. to explore the mechanism(s) by which FUS affects AR activity. 
 
Figure 1.22. Identification of FUS as a protein down regulated by androgen in a 2-Dimensional 
(2D) SDS PAGE analysis of protein regulation in response androgen. LNCaP cells were exposed to 
10nM mibolerone (MIB) or control ethanol for 16 hours and harvested. (A) whole cell lysates were 
separated by isoelectric focusing (18cm linear pH3-10 strip, Amersham) and then separated by 
molecular weight using SDS-PAGE. Gels were stained with SyproRuby (BioRad) and visualised using a 
Typhoon Phosphoimager (Amersham). Significant differences in spot intensity between treatments were 
identified using PDQuest v6.2.1 (Biorad) and protein identities determined using mass spectrometry. 
Results are the mean of 4 independent experiments ±1SD. (B) Densitometry was performed on the 
protein bands identified as FUS. * P<0.05 (Student’s T test). This data is unpublished and the 
experiments were performed by Dr Greg Brooke and published here with his permission.  
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GST tagged AR constructs used: 
Input 
Empty vector 
AF1 
AF2 + ethanol 
AF2 + mibolerone 
AF2 + bicalutamide 
AF2-hinge + Ethanol 
AF2-hinge + mibolerone 
AF2-hinge + bicalutamide 
DBD  
FUS 
AF-1 
LBD/AF-2 
LBD/AF-2 Hinge 
DBD 
1                                                     559      624     676                                919 
AF-1 DBD LBD/AF-2 Hinge 
Figure 1.23. Glutathione-S-Transferase (GST) pull down to investigate interaction between 
Androgen Receptor (AR) and FUS in PC3wtAR. The structure of GST tagged AR constructs are 
depicted including the DNA binding domain (DBD), ligand binding domain (LBD) and activation 
function (AF) domains 1 and 2 and the amino acid number of domain boundaries are indicated. 
GST tagged AR domains (as depicted on right) were immobilized on a glutathione column and 
PC3wtAR whole cell lysates were applied. Where indicated the cell lysates were incubated with 
10nM mibolerone, 1µM bicalutamide or ethanol. Bound proteins were eluted and resolved by SDS-
PAGE and subjected to Western blot analysis, using antibodies   specific for FUS. Unpublished 
data from Dr Bevan’s laboratory, produced by Dr Deepa Chotai and Dr Vik Reebye.  
Full length AR 
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82 
 83 
2. Materials and methods 
 
2.1 Reagents, buffers and solutions 
Table 2.1 Preparation of reagents, buffers and solutions. All chemicals are from 
Sigma-Aldrich unless otherwise stated. dH2O = distilled water, ddH2O = MilliQ water 
(18MΩ-cm). 
Reagent Recipe Sterilization Storage 
 
General buffers 
 
   
PBS (Phosphate buffered 
saline) 
1 tablet (Oxoid) in a total of 100ml dH2O. Autoclaved 4°C 
    
Protease inhibitors Protease inhibitor cocktail, dissolved in 
dimethyl sulfoxide (DMSO). 5µl/ml used 
for mammalian cell lysates. 
Autoclaved -20°C 
    
PMSF 
(phenylmethylsulphonyl 
fluoride) 
Stock solution made to 100mM in 
ethanol and used at a final concentration 
of 1mM. 
Autoclaved -20°C 
    
RIPA lysis buffer 
(Radio-
immunoprecipitation assay) 
50mM TrisHCl pH 7.4, 150mM NaCl, 
2mM EDTA, 1% NP-40 and 0.1% SDS. 
0.22µm filter 4°C, use within a 
month 
    
5M NaCl 29.22g NaCl in total of 100ml ddH2O. Autoclaved Room temp 
    
2.5M glycine 187.7g glycine in total of 1l ddH2O.    
    
Doxycycline Sterile stock made up to 4mM in ddH2O 
and diluted as required. 
0.22µm filter -20° 
    
1M TrisHCl pH 7.4 121.14g Tris base dissolved in 800ml 
ddH2O. HCl added to pH 7.4 and 
solution made to 1l. 
 
Autoclaved Room temp 
 
 
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and Western blotting 
buffers 
 
10% SDS (sodium dodecyl 
sulphate) 
50g SDS in total of 500ml ddH2O. Autoclaved Room temp 
 
    
Water saturated  
butan-2-ol 
200ml butan-2-ol added to 200ml ddH2O 
and shaken vigorously. Mixture allowed 
to separate into two distinct phases and 
top phase used. 
Autoclaved Room temp 
 
 84 
 
Reagent Recipe Sterilization Storage 
    
5 x SDS running buffer 0.96M glycine, 0.12M Tris and 0.05% 
SDS made up to 2l in dH2O (144g 
glycine, 30g Tris, and 10g SDS).  
- 4°C.  Diluted to 1x 
with dH2O when 
needed 
    
Semi-dry transfer buffer 0.15M glycine, 0.02M Tris and 200ml 
methanol, made up to 1l with dH2O 
(11.26g glycine and 2.44g Tris base).  
- 4°C 
 
    
Wash buffer  
(PBS-0.1% tween) 
0.5ml tween-20 added to 500ml PBS. 
 
- Room temp 
    
Blocking buffer  
(5% Marvel in PBS-0.1% 
tween) 
5% dried skimmed milk powder (Marvel) 
in PBS-0.1% Tween-20.  
 
- Used immediately 
    
SDS-PAGE  
loading buffer 2x 
 
11.50ml glycerol, 4.5ml Tris-HCL pH6.8, 
1g SDS, 2ml β-mercaptoethanol. Made 
up to 40ml with ddH2O with a few grains 
of bromophenol blue. 
- 4°C 
    
1.5M Tris-HCl pH 8.8 181.7g Tris base dissolved in 800ml 
ddH2O. HCl added to pH 8.8 and 
solution made to 1l.  
Autoclaved Room temp 
    
1.5M Tris-HCl pH 6.8 181.7g Tris base dissolved in 800ml 
ddH2O. HCl added to pH 6.8 and 
solution made to 1l. 
Autoclaved Room temp 
    
10% APS  
(ammonium persulfate) 
1g APS dissolved in ddH2O to a final 
volume of 10ml. 
- 4°C 
    
 
 
Table 2.2 Gel components for SDS-PAGE Western blot analysis 
 
Gel components 10% SDS-PAGE gel 
(10ml) 
Stacking Gel (5ml) 
   
ddH2O 4ml 2.8ml 
   
30% acrylamide (National 
Diagnostics) 
3.3ml 0.85ml 
   
1.5M Tris-HCl pH 8.8 2.5ml - 
   
1.5M Tris-HCl pH 6.8 - 1.25ml 
   
10% SDS 100µl 50µl 
   
10% APS 100µl 50µl 
   
TEMED (N,N,N’,N’-
tetramethyl-ethylenediamine  
(Pharmacia Biotech) 
 
10µl 
 
5µl 
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Table 2.3 Mammalian cell culture 
 
Cell Type Media Additives Storage 
    
Normal growth media 
 
COS-1 
 
 
DMEM (Dulbeccos 
modified eagles 
media)  
2mM glutamine, 100units/ml penicillin, 
0.1mg/ml streptomycin and 10% FBS 
(Fetal Bovine Serum, First Link UK 
Ltd). 
4°C, used within 1 
month 
    
LNCaP 
PC3wtAR 
RPMI (Roswell Park 
Memorial Institute)-
1640 
2mM glutamine, 100 units/ml 
penicillin, 0.1mg/ml streptomycin and 
10% FBS.  
4°C, used within 1 
month 
 
LNCaP-FUS 
LNCaP-TR2 
RPMI (Roswell Park 
Memorial Institute)-
1640 
2mM glutamine, 100 units/ml 
penicillin, 0.1mg/ml streptomycin, 
10% tetracycline free FBS 
(Clonetech) and 12mg/ml blasticidin 
(Invitrogen). 
4°C, used within 1 
month 
    
Starvation (androgen-deprivation) media 
 
COS-1 
 
Phenol red free 
DMEM (Gibco) 
2mM glutamine, 100unit/ml penicillin, 
0.1mg/ml streptomycin and 5% sFBS 
(double charcoal stripped fetal bovine 
serum, First Link UK Ltd). 
4°C, used within 1 
month 
    
LNCaP 
PC3wtAR  
Phenol red free 
RPMI-1640 (Gibco) 
2mM glutamine, 100units/ml penicillin, 
0.1mg/ml streptomycin and 5% sFBS. 
4°C, used within 1 
month 
 
LNCaP-FUS 
LNCaP-TR2 
Phenol red free 
RPMI-1640 (Gibco) 
2mM glutamine, 100units/ml penicillin, 
0.1mg/ml streptomycin, 5% sFBS and 
12 mg/ml blasticidin (Invitrogen). 
 
 
Wash media 
 
COS-1  Phenol red free 
DMEM 
2mM glutamine, 100units/ml penicillin, 
0.1mg/ml streptomycin and 2% sFBS. 
4°C, used within 1 
month 
 
Trypsin solution for cell passaging 
 
Trypsin-EDTA 
(Ethylenediamine
tetra acetic acid 
disodium salt) 
0.02% EDTA 5ml Trypsin at a concentration of 
25g/l in 0.9% NaCl in 50ml 0.02% 
EDTA. 
 
4°C, used within 1 
month 
    
Freezing media    
    
COS-1 
LNCaP  
PC3-wtAR 
90% FBS, 10% 
DMSO  
10% 
- 50ml aliquot 
-20°C 
    
LNCaP-TR2 
LNCaP-FUS 
90% Tetracycline free 
FBS, 10% DMSO 
- 50ml aliquot 
-20°C 
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Table 2.4 Bacterial culture 
 
Reagent  Recipe Sterilization Storage 
 
LB (Luria-Bertani) 25g LB Broth mix (Fisher Scientific) 
in total of 1l dH2O.  
Autoclaved 4°C 
    
LB-Agar 20g LB Broth mix (Fisher Scientific) 
and 8g Agar (Acros organics) in 
total of 1l dH2O. 
Autoclaved 4°C 
    
Ampicilin (100mg/ml) 1g Ampicillin in total of 10ml ddH2O 0.22µ filter -20°C 
    
Ampicillin resistant 
selection media/agar 
100mg/ml Ampicillin added to LB 
medium/agar to give final 
concentration of 100µg/ml 
Added under 
flame 
Stored at 4°C 
and used within 
1 week 
    
 
 
Table 2.5 Calcium phosphate and FuGENE 6 transfection of mammalian cells 
 
Reagent Recipe Sterilization Storage 
 
2.5M CaCl2 277.5g CaCl2 in total of 1l ddH2O. 0.22µm filter -20°C  
 
2 X BBS  
(BES buffered solution) 
0.05M BES (N,N-bis[2-
Hydroxyethyl]-2] 
aminoethanesulfonic acid), 280nM 
NaCl and 1.5mM Na2HPO4, pH 
adjusted to pH 6.95 using 1M 
NaOH. Made to a total of 1l in 
ddH2O. 
0.22µm filter -20°C  
 
FuGENE 6 transfection 
reagent (Roche) 
- - 4°C 
    
 
 
Table 2.6 DNA gel electrophoresis 
 
Reagent Recipe Sterilization Storage 
 
TAE  
(Tris Acetate EDTA) (50x) 
242g Tris, 57.1ml glacial acetic 
acid, 100ml 0.5M EDTA pH8.0 
made to a total of 1l with dH2O. 
- Room temp, 
diluted to 1x  
when required 
    
DNA loading buffer 40g sucrose and 100mg of Orange 
G made to 50ml with ddH2O. 
- Room temp 
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Table 2.7 Antibodies used in Western blot analysis and immunohostochemistry 
 
 
Table 2.8 Antibodies used in chromatin immunoprecipitation assays 
 
 
 
     
Antibody Species 
raised in 
Production company and 
Catalogue number  
Concentration Dilution 
     
Western blot analysis     
     
Monoclonal IgG to Beta 
Actin  
Mouse Abcam  
8226 
1mg/ml 1:20000 
     
Polyclonal IgG to AR (N-20)  Rabbit Santa Cruz 
sc-816 
200µg/ml 1:1000 
     
Monoclonal IgG1 to human 
FUS/TLS  
Mouse Santa Cruz 
4H11   
200µg/ml 1:5000 
     
Polyclonal IgG to TAF15  Rabbit GeneTex GTX77901  1mg/ml 1:1000 
     
Monoclonal IgG1 to EWS  Mouse Santa Cruz 
G-5   
200µg/ml 1:1000 
     
Polyclonal IgG to acetyl 
histone 3 
Rabbit Upstate 
H306-599  
1mg/ml 1:1000 
     
Polyclonal IgG to mouse 
IgG - HRP conjugated (horse 
radish peroxidase) 
Goat Dako 
P0447 
0.25 g/l 1:2000 
     
Polyclonal IgG to rabbit IgG 
HRP conjugated    
Goat Dako  
P0448 
0.25 g/l 1:2000 
     
Immunohistochemistry     
     
Polyclonal IgG to GAL4 
DNA binding domain 
Rabbit Santa Cruz 
SC-577 
200µg/ml 1:200 
     
Polyclonal IgG to Rabbit 
IgG (Alexa Fluor 488)  
Goat Invitrogen 
A31628 
2mg/ml 1:200 
     
Antibody Species 
raised in 
Production company 
and Catalogue number  
Concentration Number of µ l 
for 2µg  
     
Polyclonal IgG to AR (N-20) Rabbit Santa Cruz 
sc-816 
200µg/ml 10µl 
     
Monoclonal IgG1 to human 
FUS/TLS 
Mouse Santa Cruz 
4H11 
200µg/ml 10µl 
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Table 2.9 Chromatin immunoprecipitation buffers 
 
Chromatin 
immunoprecipitation 
buffer 
Recipe Sterilization and storage 
   
Lysis buffer 1% SDS, 10mM EDTA and 50mM Tris HCL pH 
8.0 in ddH2O.  
 
0.22µm filter 4°C 
warm to room temp before use 
 
Dilution buffer 1% Triton X100, 2mM EDTA, 150mM NaCl and 
20mM Tris-HCL pH 8.0 in ddH2O. 
 
0.22µm filter 
4°C 
Low salt wash 0.1% SDS, 1% Triton X100, 2mM EDTA, 
20mM Tris-HCL pH 8.0, 150mM NaCl in 
ddH2O.  
  
0.22µm filter 
4°C 
High salt wash 0.1% SDS, 1% triton X100, 2mM EDTA, 20mM 
Tris-HCL pH 8.0 and 500mM NaCl in ddH2O. 
 
0.22µm filter 
4°C 
LiCl wash 0.25M LiCl, 1% NP40, 1% deoxycholate, 1mM 
EDTA and 10mM Tris-HCL pH 8.0 in ddH2O. 
 
0.22µm filter 
4°C 
TE buffer 10mM Tris-HCL pH 7.5 and 1mM EDTA in 
ddH2O. 
 
0.22µm filter 
4°C 
 
Elution buffer 0.1% SDS and 1mM NaHCO3 in ddH2O. 0.22µm filter 
Room temp 
 
 
 
 
 
 
 
 
 
 
Table 2.10 Receptor ligands 
 
Steroid receptor Agonist  Antagonist 
   
Androgen Receptor 
(AR) 
Mibolerone (DuPont, NEN) 
10mM stock in 100% ethanol. Final 
concentration 0.01nM, 0.1nM, 1nM or 
10nM.  
Bicalutamide 1mM stock in 100% 
ethanol. Final concentration 1µM. 
 
   
Glucocorticoid 
Receptor (GR) 
Dexamethasone 10µM stock in 100% 
ethanol. Final concentration 10nM. 
- 
   
Oestrogen Receptor 
(ER) 
17β-Oestradiol 10µM stock in 100% 
ethanol. Final concentration 10nM. 
- 
   
Progesterone 
Receptor (PR) 
Progesterone 10µM stock in 100% 
ethanol. Final concentration 10nM. 
- 
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Table 2.11 Histone deactylase (HDAC) inhibitors  
 
HDAC inhibitor Solution Storage 
   
Sodium butyrate 1M stock in 100% ethanol. Used at 
5mM final concentration. 
-20°C 
 
Nicotinamide 1M stock solution in ddH2O. Used 
at 5mM final concentration. 
-20°C 
 
Valproic acid 1M stock solution in ddH2O. Used at 
final 5mM concentration. 
-20°C 
 
Tricostatin A 100µM stock in 100% ethanol. Used 
at 100nM final concentration. 
-20°C 
   
 
 
2.2. Bacterial cultures, transformation and DNA preparation 
2.2.1 Bacterial cultures and transformation 
 All plates and media suspensions contained the appropriate selection antibiotic 
unless otherwise stated. Bacterial media suspensions were incubated at 37oC with 
shaking at 220rpm, and bacterial plates incubated at 37oC without shaking. Max efficiency 
DH5α competent Esherichia coli (Invitrogen) were used for transformation of ligated 
plasmids as stated, whereby 50µl competent cells per transformation were thawed on ice 
and incubated with approximately 50ng plasmid DNA or 2µl of ligation reaction for 30 
minutes on ice. Cells were heat shocked at 42°C for 45 seconds prior to incubation with 
450µl super optimal catabolite (SOC) media (Invitrogen) for 1 hour. Up to 100µl of 
transformed culture was spread onto LB plates and incubated overnight at 37oC.  
 
2.2.2 DNA preparation 
 Where small quantities of plasmid were required (for example, sequencing or 
diagnostic restriction enzyme digestion), a single bacterial colony was used to inoculate 
5ml of LB broth under sterile conditions, cultures were incubated overnight and plasmid 
DNA harvested using a miniprep kit (Qiagen). For harvesting high yield plasmid DNA, 5ml 
cultures grown for 8 hours were used to inoculate 250ml of fresh LB broth and incubated 
overnight. Plasmids were harvested using a maxiprep kit (Qiagen) and DNA resuspended 
in ddH2O unless otherwise stated. The concentration of all DNA was determined by 
measuring the absorbance at λ260 nm, and purity by measuring λ260/280nm. For long-
term storage of bacteria transformed with verified plasmids, glycerols were created by 
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mixing 200µl of glycerol with 800µl of LB-cell suspension under sterile conditions, and 
stored at -80°C. 
 
2.3 Plasmid creation 
Table 2.12 Mammalian expression plasmids used in this study. All vectors contained 
the ampicilin resistance gene. 
 
Plasmid From/created by Reference 
   
PDM-LAC-Z-βGAL Valentine J (Boer et al., 1990) 
pSG5-EMPTY Stratagene - 
pSG5-SRC-1 Parker M (Belandia et al., 2002) 
pSG5-ER Parker M (Belandia et al., 2002) 
pSVAR Brinkmann A (Brinkmann et al., 1989) 
pSG5-GR Kalkhoven F (Kalkhoven et al., 1994) 
TAT-GRE-EIB-LUC Jenster G 
PROBASIN-PROM-LUC Jenster G 
(Verrijdt et al., 2000) 
Verrijdt et al., 2000) 
ERE-LUC Parker M  (Belandia et al., 2002) 
pGL2-LEXA-GAL4-LUC Parker M 
pSG5-LEXA-VP16 Parker M 
(Christian et al., 2004) 
(Christian et al., 2004) 
pM-GAL4-FUS FULL, A, B1, B2, 
B3, C,D, E and F 
Culley R - 
pSG5-ARΔLBD Brinkmann  A (Jenster et al., 1991) 
pSG5-FUS Brooke G - 
pM-GAL4-EMPTY Clonetech - 
5-GAL-LUC Karo Bio - 
AR∆τ1 and AR∆τ5 Jenster G (Jenster et al., 1995) 
pM-GAL4-MAD Brooke G - 
pTER-EMPTY Invitrogen - 
pTER-GUGG Brooke G - 
pM-GAL4-FXXLF Brooke G - 
pSG5-ARA70 Bevan C - 
cMVB-p300 Heery D - 
pRSIR-SV-MC-CBP-HA Heery D - 
pSG5-TAF15 Culley R - 
pCMV-HA-EWS Cohen P (Klevernic et al., 2009) 
pTL-TAF15 Tora L (Bertolotti et al., 1999) 
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2.3.1 DNA restriction enzyme digestion, de-phosphorylation, gel extraction and 
ligation 
 Restriction enzymes were purchased from Roche Diagnostics. Digestions were 
performed at 37°C, using appropriate enzyme volume, buffer and incubation times in 
accordance with the manufacturer’s recommendations. Where dephosphorylation of 
expression vectors was necessary, digestion with restriction enzymes was followed by 
addition of 2µl Shrimp Alkaline Phosphatase and the necessary volume of the appropriate 
buffer, and incubated for an additional 30 minutes at 37°C. Digested DNA was separated 
by agarose gel electrophoresis and DNA bands of the correct size were excised form the 
gel using a sterile scalpel under UV illumination. DNA was purified from the agarose gel 
using the QIAquick gel extraction kit (Qiagen). Ligations were performed using a rapid 
ligation kit (Roche). All ligations were performed using 50ng of vector and 3x molar excess 
of insert where possible, and performed in accordance with manufacturer’s protocols.  
 
2.3.2 The sub-cloning of full length and truncated FUS into plasmid pM-GAL4  
 Primers were designed for polymerase chain reaction (PCR) amplification of full 
length and truncated forms of FUS, with the addition of a 5’ BamH1 and 3’ Xba1 restriction 
enzyme recognition sequence (Table 2.13). Primer pairs used and the sub-cloning 
scheme are depicted in Figure 2.1. PCR reactions were carried out using template 
expression plasmid pSG5-FUS. PCR was carried out using pre-aliquoted reddymix PCR 
master mix (Thermo Scientific) and a Peltier Thermal cycle PCR machine (DNA engine 
DYAD). PCR products were identified by gel electrophoresis. Plasmid pM-GAL4 and FUS 
PCR products were digested with BamH1 and Xba1, products identified by gel 
electrophoresis and purified using gel extraction kit. Plasmid pM-GAL4 was additionally 
dephosphorylated using Shrimp Alkaline Phosphorylase. FUS inserts were ligated into the 
pM-GAL4 plasmid and transformed into DH5α Max Efficiency Escherichia coli (Invitrogen). 
All plasmids were verified by a diagnostic BamH1 and Xba1 restriction enzyme digestion 
and DNA sequencing.   
 
 
 
 
EcoR1-Sma1-BamH1-SaI1-Mlu1-Pst1-HindIII-Xba1 
PCR products inserted here 
B) 
Figure 2.1. Sub-cloning scheme for the generation of pM-GAL4-FUS constructs. (A) 
Primers were designed for the PCR amplification of full length and truncated FUS products 
(FULL-E) for which the amino acid numbers are listed. The location of the FUS RNA recognition 
motif (RRM) and zinc finger binding domain (ZnF) are depicted. Primers were designed to 
incorporate 5? BamH1 and 3?Xba1 restriction enzyme sites for all FUS PCR products. (B) 
Diagram depicting the pM-GAL4 expression plasmid, containing 1-146 amino acid GAL4 DNA 
binding domain (DBD) upstream of the multiple cloning site (MCS). Plasmid pM-GAL4 and PCR 
inserts were digested with BamH1 and Xba1, and the 5?BamH1 and 3?Xba1 tagged FUS PCR 
products  ligated into the pM-GAL4 MCS at the BamH1 and Xba1 restriction enzyme sites 
underlined.  
MCS 
pM-GAL4 DBD 
expression plasmid 
A) 
FULL 
A 
B1 
B2 
B3 
C 
D 
E 
F 
RRM ZnF 
RRM 
RRM ZnF 
RRM ZnF 
ZnF 
ZnF 
RRM 
RRM 
288 366 426 449 1 526 AA 
288 
288 
288 
366 
366 
425 
367 425 
449 
426 
526 
526 
526 367 
1 
1 
Full forward + full reverse 
full forward + A reverse 
D forward + B reverse 
D forward + A reverse 
F forward + B reverse 
full forward + C reverse 
D forward + full reverse 
E forward + full reverse 
F forward + full reverse  
Primers used: pM-GAL4-FUS construct: 
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Table 2.13 PCR primers used for the generation of GAL4 DNA binding domain 
tagged FUS constructs by sub-cloning. Primers were supplied by MWG Biotech. The 
DNA recognition sites for the restriction enzymes BamH1 (GGATCC) and Xba1 (TCTAGA) 
are indicated in bold.  
 
PCR primer name Primer DNA sequence Restriction enzyme site 
   
FUS full forward 5’ CGGGATCCCGATGGCCTCAAACGAT BamH1 
FUS full reverse 5’ GCTCTAGAGCTAATACGGCCTCTCC Xba1 
FUS A reverse 5’ GCTCTAGAGCGACCTTGATAGGATT Xba1 
FUS B reverse 5’ GCTCTAGAGCGTCACCAGCTCGCTG Xba1 
FUS C reverse 5’ GCTCTAGAGCGGCCTTACACTGGTT Xba1 
FUS D forward 5’ CGGGATCCCGTTTGTGCAAGGCCTG BamH1 
FUS E forward 5’ CGGGATCCCGTGGAAGTGTCCTAAT  BamH1 
FUS F forward 5’ CGGGATCCCGCTATTTGCTACTCGC  BamH1 
   
 
 
2.3.3 The sub-cloning of TAF15 into the expression plasmid pSG5 
 Primers were designed to PCR amplify full length TAF15 and to add a 5’ BamH1 
and 3’ Xma1 restriction enzyme recognition sequence (Table 2.14). PCR amplification was 
carried out using template expression plasmid pTL-TAF15, which was a gift from Dr Laszlo 
Tora, University of Strasbourg. PCR amplification and product purification were carried out 
as previously described. Plasmid pSG5 and TAF15 PCR product were digested with 
BamH1 and Xma1, and the products purified and ligated as previously described in 
section 2.3.2. Plasmid pSG5-TAF15 was verified by a diagnostic BamH1 and Xma1 
restriction enzyme digestion and DNA sequencing.   
 
Table 2.14 PCR primers used for the generation of pSG5-TAF15 by sub-cloning. 
Primers were supplied by MWG biotech. The DNA recognition sites for the restriction 
enzymes BamH1 (GGATCC) and Xma1 (CCCGGG) are indicated in bold. 
 
PCR primer 
name 
Primer DNA sequence Restrictions enzyme site 
   
TAF 15 FWD 5’ TCCCCCCGGGGGGAACCATGTCGGATTCT Xma1 
TAF15 REV 5’ CGGGATCCCGTCAGTATGGTCG BamH1 
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2.3.4 DNA agarose gel electrophoresis 
 1-1.5% agarose gels were made using agarose (Severn Biotech) dissolved in an 
appropriate volume of 1x TAE. The mixture was heated in a microwave until fully 
dissolved, allowed to cool before the addition of ethidium bromide to a final concentration 
of 10µg/ml, and then poured. DNA loading buffer was added to the samples and run along 
side a 1Kb DNA ladder (GeneRuler, Bioline). Gels were run in 1x TAE at 80 volts. Bands 
were visualized and photographed under UV light.    
 
2.4 Mammalian cell culture and freezing  
2.4.1 Mammalian cell culture 
 All cell lines were obtained form the American Type Culture Collection, unless 
otherwise stated. All cells were cultured at 37oC in 5% CO2. Mammalian cells were 
routinely grown to 70-80% confluence in T75 or T150 cell culture flasks before passaging, 
usually twice a week. For passaging, cells were washed with warm PBS, and then 
incubated with up to 1ml Trypsin-EDTA until cells had detached from the flask. Appropriate 
growth media was used to dilute and plate cells as required into fresh flasks or plates.  
 The human prostate cancer cell lines LNCaP and PC3wtAR, both derived from 
metastatic prostate cancer lesions, were used in this body of work (Horoszewicz et al., 
1983; Kaighn et al., 1979). The LNCaP cell line expresses endogenous AR with the ligand 
binding domain point mutation T877A which alters the AR ligand binding specificity, 
leading to AR activation in response to androgens and other hormones, including 
oestrogen and progesterone, and antiandrogens such as hydroxyflutamide (Veldscholte et 
al., 1992a). The PC3wtAR cell line was generated by the stable transfection of the AR 
negative parental PC3 cell line (Kaighn et al., 1979) with a constitutively expressed human 
wild-type AR construct (Peterziel et al., 1999). 
 
2.4.2 Mammalian cell freezing 
 Cells were washed in PBS then trypsinised, and trypsin neutralized with addition of 
media. Cells were pelleted at 1400rpm for 4 minutes at room temperature, and 
resuspended in freezing media.  Vials were stored at -80°C for at least 48 hours before 
being transferred to liquid nitrogen storage. To re-establish cell lines, vials were defrosted 
at 37°C, cells were pelleted and resuspended in fresh media prior to being transferred to a 
fresh flask.  
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2.5 Transient transfection of mammalian cells 
 For all mammalian transient transcription assay transfections, cells were plated in 
24 well plates and grown to approximately 80% confluence in starvation media for 24 
hours prior to transfection.  
 
2.5.1 Transient transfection using calcium phosphate 
 The calcium phosphate method previously described by others (Chen & Okayama, 
1987) was used for transfection of COS-1 cells. In FUS over-expression assays, 50ng of 
nuclear receptor expression vector (pSG5-PR, pSG5-ER, pSG5-GR, pSVAR, pSG5-
ARΔLBD, AR∆τ1 and AR∆τ5), and 1µg of luciferase reporter construct (TAT-GRE-E1B-
LUC or PROBASIN-PROM-LUC was used for pSG5-GR, pSVAR, pSG5-PR, pSG5-
ARΔLBD, AR∆τ1, AR∆τ5, and ERE-LUC was used for pSG5-ER). In the co-activator 
interaction assay, cells were additionally transfected with either 200ng of pSG5-ARA70, 
pSG5-SRC-1, pRSIR-SV-MC-CBP-HA or cMVB-p300.  
 For the trans-activation/repression and mammalian 2-hybrid assays cells were 
transfected with 1µg of luciferase reporter (pGL2-LEXA-GAL4-LUC or 5-GAL-TATA-LUC 
respectively) and 200ng of pM-GAL4-FUS (FULL-E). For the mammalian 2-hybrid assays 
cells were co-transfected with 100ng AR-VP16 and, as a positive control for this assay, 
cells were co-transfected with 200ng pM-GAL4-FXXLF. For the trans-repression assays 
cells were co-transfected with 100ng LEXA-VP16 and, as a positive control for 
transcriptional repression in this assay, cells were co-transfected with 200ng pf pM-GAL4-
MAD. In all transcription assays cells were co-transfected with 100ng of PDM-LACZ-βGAL, 
and up to 400ng of pSG5-FUS or pM-GAL4-FUS (FULL-E) per well. The amount of DNA 
added to each well was made equal by the addition of pSG5-empty or pM-GAL4-EMPTY. 
 DNA was made to a total of 45µl with ddH2O per well of a 24 well plate. To the DNA 
mix 5µl of 2.5M CaCl2 was added, followed by 50µl of 2x BES buffered saline (BBS). Both 
were added to the DNA slowly and mixed thoroughly by pipetting. The mixture was 
incubated at room temperature for 20 minutes, inverted to re-suspend and added to cells 
in a dropwise manner. Cells were incubated for 24 hours and then washed twice with wash 
media before addition of starvation media to which hormone, bicalutamide, HDAC 
inhibitors or vehicle control treatment were added. Cells were incubated for 16 hours, then 
washed twice with cold PBS and lysed with 60µl of reporter lysis buffer (Promega), 
incubated at -80oC for 15 minutes, then thawed. Luciferase assays (LucLite Plus, Packard 
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Bioscience) and β-galactosidase assays (Galacto-light plus, Tropix) were performed using 
20µl and 10µl of cell lysates respectively, following the instructions provided and 
luminescence read on a luminometer (1420 Luminesence counter VICTOR light, Perkin 
Elmer).  
 
2.5.2 Transient transfection using FuGENE 6 
 DNA was added directly to starvation media (with no added antibiotics or FBS) 
containing FuGENE 6 (Roche), and transfection carried out in accordance with 
manufacturer’s instructions. For every 1µg of DNA used, 3µl of FuGENE 6 was added. In 
FUS over-expression assays performed in PC3wtAR cells, 250ng of TAT-GRE-E1B-LUC, 
25ng of PDM-LACZ-βGAL and up to 400ng of pSG5-FUS were added per well. The 
amount of DNA added to each well was made equal by the addition of pSG5-EMPTY. 
Following transfection, cells were incubated for 24 hours before treatment with mibolerone 
or ethanol as vehicle control. Cells were incubated for 16 hours, washed twice in cold 
PBS, lysed and luciferase and β-galactosidase assays carried out as described for calcium 
phosphate transfections (as described in section 2.5.1).  
 
2.6 Western blot analysis 
2.6.1 Cell harvesting and lysis 
 Where cell lysates were required for Western blotting, cells were collected in PBS, 
pelleted (2000rpm for 4 minutes at 4°C) and lysed in RIPA buffer (containing 5µl/ml 
protease inhibitor cocktail and 1mM PMSF). Cells were sonicated for 2 minutes at 20 
second intervals on high power before cell debris was pelleted (13,000rpm for 15 minutes 
at 4oC), and the supernatant transferred to fresh tubes. Where Western blot analysis was 
performed using cell lysates from transient transfection assays, surplus cell lysates were 
pooled after β-galactosidase and lucferase assays (as described in section 2.5) were 
complete. 
 
2.6.2 DC protein assay 
 To determine the protein concentration of cell lysates, 5µl of either known 
concentration (0.625, 1.25, 2.5, 5, 10, 15, 20 and 40µg/µl) of bovine serum Albumin (BSA) 
in appropriate lysis buffer or protein sample was used in the DC protein assay (Bio Rad). 
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Assays were carried out in accordance with the manufacturer’s instructions in a 96 well 
plate and read at a wavelength of 750nm on a spectrophotometer (Spectra MAX 190).  
 
2.6.3 Sodium dodecyle sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blot analysis 
 Following protein concentration determination by DC protein assay, 15µg of protein 
was mixed with 2x SDS-PAGE loading buffer and appropriate cell lysis buffer to a volume 
of 20µl. Protein samples were heated to 100oC for 5 minutes and chilled on ice for 5 
minutes before loading onto a 10% SDS polyacrylamide gel alongside a rainbow 
molecular weight marker (Amersham Biosciences). Proteins were separated by 
electrophoresis at 100 volts. Proteins were transferred onto a nitrocellulose membrane 
(Bio-Rad) at 35V and 150mA for 2 hours using a multiphor II semi-dry blotter (Amersham 
Bioscience) and semi-dry transfer buffer.  
 Membranes were blocked for 15 minutes in 5% Marvel in PBS-0.1% tween 
(hereafter termed blocking buffer) before the addition of antibody (see Table 2.7) diluted in 
blocking buffer, and left for 1 hour at room temperature with rocking. Membranes were 
washed 3 times with PBS-0.1% tween for 5 minutes, then blocked for 15 minutes in 
blocking buffer before the addition of suitable secondary antibody (see Table 2.7), also 
diluted in blocking buffer and incubated for 1 hour at room temperature while rocking. 
Membranes were washed three times with PBS-0.1% tween for 5 minutes and washed 
once with PBS. Proteins were detected by autoradiography using ECL (enhanced 
chemiluminescence) plus detection kit (Amersham Bioscience), following the 
manufacturer’s instructions.  
 
2.7 Increased exogenous FUS expression in the LNCaP-FUS cell line 
 A stable LNCaP cell line (hereafter termed LNCaP-FUS) with FUS expression 
under the control of a doxycycline inducible promoter was generated using the T-REX 
system (Invitrogen) by Dr Greg Brooke. To determine optimal conditions for maximal 
exogenous FUS expression, LNCaP-FUS cells were plated at 60% confluence in 6 well 
plates and incubated with increasing concentration of doxycycline in full growth media for 
72 hours and FUS expression levels determined by Western blot analysis (as described in 
section 2.6). 
 98 
 Where LNCaP-FUS gene expression was analysed by quantitative real time PCR 
(qRT-PCR), cells were grown to 60% confluence in starvation media in 6 well plates for 72 
hours prior to treatment with 10nM mibolerone or ethanol vehicle control and in the 
presence or absence of 10nM doxycycline. Cells were harvest 24 and 48 hours after 
ligand treatment and qRT-PCR performed to determine the expression of Ribosomal 
Protein Gene-L19 (L19), FUsed In Sarcoma (FUS), Kallikrein-2 (KLK2), Differentiation-
Related Gene-1 (DRG1), Prostate Specific Antigen (PSA) and Transmembrane Protease 
Serine-2 (TMPRSS2) (as described in section 2.9).  
 
2.8 Depletion of endogenous FUS using siRNA FUS in LNCaP cells 
 The ability of a small inhibitory RNA (siRNA) pool of 4 FUS oligonucleotides and 
single deconvoluted siRNA FUS oligonucleotides (A, B, D and D) to decrease endogenous 
FUS expression in the LNCaP cell line was investigated. 0.4 million cells were plated in 6 
well plates in full media for 16 hours and changed into androgen deprivation media prior to 
transient transfection with either 100nM final concentration of siRNA FUS oligonucleotide 
pool (Dharmacon LU-009497-00-0002), single siRNA FUS (A, B, C or D) (Dharmacon J-
009497-07/08/09/10), siRNA scrambled (Dharmacon D-001819-10-20) or mock 
transfected with transfection reagent DharmaFECT-2 in accordance with the 
manufacturer’s protocol. Cells were incubated for 72 hours prior to collection and lysis and 
lysates were resolved by Western blot analysis. The alteration in FUS expression was 
determined by densitometry analysis of Western blot images using ImageJ software 
(http://rsbweb.nih.gov/ij/). This demonstrated that the pool was able to deplete FUS by 
approximately 80% (Figure 2.2A). Of the single oligonucleotides, FUS-A (Thermo Scientific 
J009497-07) achieved greatest reduction in exogenous FUS expression, depleting FUS 
levels to a similar extent as the pool (Figure 2.2A).  
 To establish the lowest concentration of siRNA FUS-A necessary to induce maximal 
reduction of endogenous FUS expression in the LNCaP cell line, cells were transiently 
transfected with 100nM, 50nM and 25nM final concentration of siRNA FUS-A as described 
above, and FUS expression levels determined by Western blot analysis (Figure 2.2B). This 
demonstrated an approximate 80% reduction in endogenous FUS expression upon 
transient transfection with 25nM siRNA FUS-A. Therefore, 25nM final concentration siRNA 
FUS-A (hereafter called siRNA FUS) was used in subsequent experiments.  
 To analyze AR target gene expression by qRT-PCR, LNCaP cells were similarly 
plated and transfected with siRNA FUS-A oligonucletide or scrambled siRNA as described 
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above. Cells were treated with 10nM mibolerone or ethanol vehicle control 72 hours post 
transfection, harvested 4 or 8 hours after treatment and qRT-PCR performed to determine 
expression of L19, FUS, KLK2, DRG1, PSA and TMPRSS2 (as described in section 2.9).   
 
2.9 Quantitative real time PCR (qRT-PCR) 
 Where qRT-PCR was performed using LNCaP and LNCaP-FUS template cDNA, 
cells were lysed with QIAshredders, and RNA recovered using an RNAeasy kit with the 
additional DNAse step (both Qiagen). cDNA was synthesized via reverse transcription 
from 500ng RNA, using a Super Script II kit (Invitrogen). qRT-PCR was performed to 
determine the expression of L19, FUS, AR, KLK2, DRG1, PSA and TMPRSS2 using 
primers listed in Table 2.15. The optimal concentration of primers used per PCR reaction 
was determined in accordance with Fast SYBR-green master mix (Applied Biosystem) 
manufacturer’s protocol. Each qRT-PCR reaction contained 5µl Fast SYBR-green master 
mix, 2µl cDNA and 2µl forward and reverse primer per reaction (see Table 2.15 for final 
concentration of primers used). Reaction volume was adjusted to 10µl with ddH2O and 
qRT-PCR performed using an ABI 900HT real time PCR machine (Applied Biosystems). 
Each qRT-PCR reaction was carried out in triplicate and results normalized to L19 
expression.  
 
Table 2.15 qRT-PCR primers used for LNCaP and LNCaP-FUS cell lines 
 
PCR primer name Primer DNA sequence Final primer concentration 
   
AR-forward 
AR-reverse 
5’ CGCGACTACTACAACTTTCCACTGG 
5’ ACCACCACACGGTCCATACAACTGG 
500nM 
500nM 
KLK2-forward 
KLK2-reverse 
5’ CCTCAGGTTCTGGCATCACTT 
5’ CGGCCAGGTGAGTTCCAA 
500nM 
500nM 
TMPRSS2-forward 
TMPRSS2-reverse 
5’ AATCGGTGTGTTCGCCTCTAC 
5’ GCGGCTGTCACGATCC 
300nM 
300nM 
DRG1-forward 
DRG1-reverse 
5’ GCAGCACACACTTCACAAAGC 
5’ CCAGGCACCCGTTTGAAC 
500nM 
500nM 
PSA-forward 
PSA-reverse 
5’ TTGTCTTCCTCACCCTGTCC 
5’ AGCTGTGGCTGACCTGAAAT 
500nM 
500nM 
L19-forward 
L19-reverse 
5’ GCAGCCGGCGCAAA 
5’ GCGGAAGGGTACAGCCAAT 
300nM 
300nM 
FUS-forward 
FUS-reverse 
5’GCAGGGAGAGGCCGTATTA 
5’CTTGGGTGATCAGGAATTGG 
500nM 
500nM 
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2.10 Caspase and growth assays  
 LNCaP-FUS and parental LNCaP-TR2 cells were seeded 1000 cells per well in 96 
well plates in starvation media and treated with 10nM mibolerone or ethanol vehicle 
treatment control in the presence of absence of 10nM doxycycline. Cells were grown for 0-
8 days prior to performing cell proliferation assays using the WST-1 assay (Roche), in 
accordance with the manufacturer’s instructions.  
 For Caspase 3, 7 and 8 activity assays LNCaP-FUS and parental LNCaP-TR2 cells 
were similarly seeded and Caspase 3, 7 and 8 activity assayed using Caspase-Glo assays 
(Promega). Caspase activity was normalized to cell proliferation measured simultaneously 
using the WST-1 assay on identical cell plates.  
 
2.11 Growth assay in FUS-depleted LNCaP cells 
 Where growth assays were performed in FUS-depleted LNCaP cells, 1000 cells 
were seeded per well of a 96 well plate and transfected with FUS siRNA or scrambled 
siRNA for 72 hours as in described in section 2.8. Cells were then treated with increasing 
concentrations of mibolerone (0.01-10nM) or ethanol as vehicle control. Cell proliferation 
was measured using WST-1 reagent (as described in section 2.10) at 3 and 6 days post 
ligand treatment. 
 
2.12 Chromatin immunoprecipitation in the LNCaP-FUS cell line 
 LNCaP-FUS cells were grown to approximately 70% confluence in starvation media 
for 72 hours in T75 flasks, in the presence or absence of 10nM doxycycline. Cells were 
then treated for 2 hours with either 10nM mibolerone or ethanol vehicle control. A T75 
flask seeded simultaneously was counted to establish the number of cells per flask. The 
treated cells were cross-linked with 405µl formaldehyde per 15ml of media, for 10 min at 
37°C. The cross-linking reaction was quenched upon the addition of 750µl 2.5M glycine 
per 15ml media for 5 minutes at 37°C.  
 To all buffers (Table 2.9) used throughout the protocol protease inhibitor cocktail 
(5µl/ml) and 1mM PMSF were added prior to use. Cells were washed twice with ice-cold 
PBS and harvested using cell scrapers into 1ml PBS. Cells were pelleted by centrifugation 
at 2000rpm at 4°C for 2 minutes, resuspended in lysis buffer (200µl per 1x106 cells) and 
incubated on ice for 10 minutes. Cells were sonicated in 200µl aliquots for 10 minutes in 
20 second intervals on high power using a BIORUPTOR VCD-ZOOM. The sonicator water 
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bath was replaced with ice cold water every five 5 minutes. Lysates were pooled and 
200µl re-aliquoted into fresh tubes, to which 1.8ml of dilution buffer was added and 50µl 
sonicated cell lysate reserved for input samples. The lysates were pre-cleared by the 
addition of 50µl Dynabeads (Invitrogen) per sample, and incubated for 30 minutes with 
rotation at 4°C. For lysates to be immunoprecipitated with rabbit antibody Dynabead-
protein A was added, and for lysates to be immunoprecipitated with mouse antibody 
Dynabead-protein G was added. Dynabeads were blocked in 2mg/ml herring sperm DNA 
and 5mg/ml BSA in dilution buffer for 30 minutes prior to addition to the lysates.  
 Beads were pelleted using a magnetic rack (Invitrogen) and supernatants removed 
to new tubes, to which 2µg of either mouse monoclonal IgG1 to FUS (Santa Cruz, 4H11), 
rabbit polyclonal IgG to AR (N-20) (Santa Cruz sc-816) (Table 2.8) or appropriate species 
matched IgG control were added, and incubated at 4°C with rotation overnight, after which 
50µl of the pre-blocked dynabeads (protein A or G conjugated as appropriate) were 
added. Samples were incubated with the beads for 1 hour at 4°C with rotation. The 
supernatant was removed and pellets washed sequentially with 1ml of low salt buffer, high 
salt buffer and LiCl wash buffer. Pellets were then washed twice with TE wash buffer (to 
which no protease inhibitor or PMSF were added). At each wash stage pellets were 
incubated for 5 minutes at 4°C with rotation.  
 DNA and protein complexes were eluted from the dynabeads using 200µl freshly 
prepared elution buffer and incubated for 15 minutes at room temperature with rotation. 
Supernantants were removed to clean tubes and the elution step repeated prior to reverse 
cross-linking of protein-DNA complexes by addition of 16µl 5M NaCl and incubating at 
65°C for 4 hours. For the 50µl of lysate reserved for input samples, 350µl elution buffer 
was added per sample and reverse cross-linking performed as for the immunoprecipitated 
samples. Remaining protein was degraded with the addition of 8µl 0.5M ETDA, 16µl 1M 
Tris-HCL (pH 6.5) and 2µl of 10mg/ml Proteinase K, and incubated at 45°C for 1 hour. 
DNA was recovered using a PCR clean up kit (Qiagen).  
 
2.12.1 qRT-PCR amplification of chromatin immunoprecipitated DNA 
 Chromatin immunoprecipitation recovered DNA was diluted 1:4 with ddH2O and 2µl 
was used per qRT-PCR reaction. qRT-PCR was carried out as described previously in 
section 2.9.  qRT-PCR was performed using primers specific for TMPRSS2 androgen 
response elements I, II, III, IV and V as specified by Wang et al., and the PSA enhancer 
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androgen response element as described by Shang et al. (Shang et al., 2002; Wang et al., 
2007). An additional primer set was designed to PCR amplify a PSA androgen response 
element negative region (Table 2.16).  
 
Table 2.16 PCR primers used for qRT-PCR amplification of PSA androgen response 
element negative region. Primers were supplied by MWG biotech. 
 
PCR primer name Primer DNA sequence Primer concentration 
  
PSA ARE negative forward 5’ TCCACTCCAGCTCTAAGATGGT 1000nM 
PSA ARE negative reverse 5’ CAGGTAAACTCCAAGCACAGTGA 1000nM 
  
 
2.13 Fluorescent activated cell sorting (FACS) analysis 
 Half a million LNCaP-FUS or parental LNCaP-TR2 cells were seeded in full growth 
media in 10 cm2 dishes. After 24 hours media was replaced with starvation media for 72 
hours. Cells were then treated with either 10nM mibolerone or ethanol vehicle control in 
the presence or absence of 10nM doxycycilne. Cells and media were collected at 48 hours 
intervals for 8 days and pelleted at 2000rpm for 2 minutes at 4°C. Cells were resuspended 
in 200µl cold PBS and then fixed in cold 70% ethanol, with the addition of ethanol drop 
wise, whilst gently vortexing cells. 
  To prepare cells for FACS analysis, cells were washed twice in cold PBS and then 
treated with 100µl of Ribonuclease A (100µg/ml). DNA was stained by the addition of 
200µl propidium iodide (50µg/ml). The DNA content was measured by assessing 
propidium iodide fluorescence using a BD FACS Canto machine. For each experiment 
10,000 events were counted and the percentage of cells in each stage of the replication 
cycle determined from DNA histograms obtained for each cell sample. 
 
2.14 Confocal imaging 
 COS-1 cells were grown in starvation media for 24 hours to 20% confluence on 
cover-slips in 24 well plates. Cells were transfected with 200ng of plasmid pMGAL4-FUS 
(FULL-F) using FuGENE 6 (as described in section 2.5.2). After 24 hours the cells were 
washed twice with cold PBS by shaking at room temperature, and fixed with 0.5ml of 1% 
formaldehyde-PBS for 10 minutes. Cells were washed twice with cold PBS and 
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permeabilized with 0.5ml of 0.1% Triton-PBS for 15 minutes and then washed three times 
with PBS.  
 Cells were incubated with 10% goat serum-PBS for 30 minutes and then for 1 hour 
with rabbit polyclonal anti-GAL4 DNA binding domain antibody, diluted 1:200 in 10% goat 
serum-PBS. Cells were washed 3 times with PBS before incubation with 10% goat serum-
PBS for 15 minutes. Cells were incubated for 1 hour in the dark with secondary antibody 
Alexa Fluor 488 goat anti-rabbit IgG, diluted 1:200 in 10% goat serum-PBS. Cells were 
washed 3 times with PBS before cover slips were mounted on slides with vectorshield 
which contained 4',6-diamidino-2-phenylindole (DAPI) stain (Vector Laboratories) and then 
sealed with nail varnish. Cells were visualized using a confocoal microscope (Meta 510, 
Zeiss).  
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3. Results-Part 1 
FUS mediates androgen-dependent cell cycle progression and LNCaP cell 
growth 
 
 Androgens regulate critical processes involved in the normal development, growth 
and mature function of the prostate gland. Androgens are also involved in the 
development and progression of several diseases of the prostate including prostate 
cancer, since most prostate cancers, at least initially, are dependent upon androgens for 
growth and survival with androgen withdrawal causing prostate cancer cell cycle arrest or 
cell death (Agus et al., 1999; Balk & Knudsen, 2008; Huggins & Hodges, 1972; Isaacs et 
al., 1992; Knudsen et al., 1998). Androgen ablation therapy is used for treatment of non-
organ confined prostate cancer, causing tumour regression (Klotz, 2000; Tammela, 2004). 
Invariably however, androgen ablation therapy fails after a median of 2-3 years, and 
patients progress to incurable hormone refractory prostate cancer (Feldman & Feldman, 
2001).  
 The biological effects of androgens are mediated through the Androgen Receptor 
(AR), a ligand-dependent transcription factor belonging to the nuclear receptor super-
family (Evans, 1988; Trapman & Brinkmann, 1996). Hormone refractory prostate cancer 
development and growth is usually dependent upon the AR signalling pathway, despite 
androgen depletion via ablation therapy (Chen et al., 2004; Feldman & Feldman, 2001; 
Taplin & Balk, 2004; Trapman & Brinkmann, 1996). The aberrant re-activation of the AR 
signalling pathway can occur by multiple mechanisms, such as AR amplification, AR 
mutation and altered AR transcriptional co-factor expression (Taplin & Balk, 2004). Due to 
the dependence of prostate cancer cell survival on the AR signalling axis, a greater 
understanding of the mechanisms by which the AR exerts its cellular proliferative effects 
would be beneficial in understanding prostate cancer development and progression, and 
could potentially lead to the identification of further drug targets for the treatment of 
hormone refractory prostate cancer.  
 One approach used to gain further insight into the mechanisms by which the AR 
mediates its proliferative effects is the identification of androgen-regulated proteins. A 2D 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) proteomic study 
performed by Dr Greg Brooke identified FUS, an RNA binding protein and member of the 
TET family (TLS, EWS and TAF15), as a protein down-regulated in response to androgen 
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in the LNCaP androgen responsive prostate cancer cell line (Figure1.22), and this was 
confirmed by Brooke et al., by Western blot analysis of LNCaP cells (Brooke et al., 2011). 
  
3.1 Androgen regulation of the TET protein family 
 Western blot analysis was used to confirm the observed down-regulation of FUS in 
response to androgen and investigate the effect of androgen upon expression of the 
additional TET protein family members, EWS and TAF15. LNCaP cells were androgen-
deprived for 48 hours prior to treatment with 10nM mibolerone (a synthetic androgen) or 
100% ethanol as treatment vehicle control. Cells were harvested 0, 8, 16, 24, 48, and 72 
hours after ligand incubation and cell lysates resolved by SDS-PAGE and subjected to 
Western blot analysis, probing with antibodies specific for EWS, FUS, TAF15 and β-actin, 
with β-actin used as a control for equal protein loading (Figure 3.1). 
 This preliminary Western blot analysis shows no clear change in expression of the 
TET family members FUS and TAF15 in the absence of mibolerone, and a potential 
decrease in EWS expression. EWS and TAF15 also show no discernible change in 
expression with 10nM mibolerone treatment, while FUS expression is down-regulated by 
10nM mibolerone treatment at 48 hours and is almost absent at 72 hours of treatment 
(Figure 3.1), confirming the androgen down-regulation reported by Brooke, et al. (Brooke et 
al., 2011).   
 
3.2 Characterization of FUS and AR expression in the LNCaP-FUS cell line 
 The addition of androgen to the prostate cancer cell line LNCaP induces growth 
(Horoszewicz et al., 1983) and the down-regulation of FUS at both the protein (Figure 1.22 
and Figure 3.1) and RNA level (Brooke et al., 2011). This data leads to the hypothesis that 
FUS may be involved in the suppression of androgen-dependent cell growth. To investigate 
this hypothesis Dr Greg Brooke generated a LNCaP cell line with exogenous FUS 
expression under the control of a doxycycline-inducible promoter, hereafter called LNCaP-
FUS (Brooke et al., 2011).   
 The LNCaP-FUS cell line was generated using the T-REX system (Invitrogen), 
whereby LNCaP cells were stably co-transfected with a plasmid expressing the Tet 
repressor (TetR) under the transcriptional control of the constitutively active human 
cytomegalovirus (CMV) promoter (a kind gift from Dr Yoshi Kawano), and a plasmid 
containing the FUS cDNA sequence under the control of both the CMV promoter and Tet 
 
 
Figure 3.1. Western blot analysis of androgen regulation of the TET protein family (FUS, 
EWS and TAF15) in the LNCaP cell line. Cells were androgen deprived for 48 hours prior to 
treatment with 10nM mibolerone or ethanol vehicle control. Cells were incubated with ligand for the 
time indicated prior to cell colelction and lysis. Cell lysate proteins were resolved by SDS-PAGE 
and subjected to Western blot analysis, probing with EWS, FUS, TAF15 and β-actin specific 
antibodies. Western blot displayed is a representative result of two experimental repeats.  
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Operator 2 sequence (TR2), to which TetR binds and represses exogenous FUS 
transcription (see chapter 2 section 2.7). Treatment of LNCaP-FUS cells with doxycycline 
releases TetR from the Tet operator upstream of exogenous FUS, resulting in doxycycline-
inducible exogenous FUS expression (Figure 3.2A).   
 The concentration of doxycycline necessary to induce maximal exogenous FUS 
expression was determined by the treatment of LNCaP-FUS cells with doxycycline 
concentrations ranging from 0nM to 1000nM for 72 hours prior to cell harvesting and lysis. 
Cell lysates were resolved by SDS-PAGE and subject to Western blot analysis, 
immunoblotting with FUS and β-actin specific antibodies. An increase in FUS expression was 
observed upon treatment with 1nM doxycycline and maximal FUS expression was detected 
with 10nM and above doxycycline treatment (Figure 3.2B). The incubation time necessary to 
induce maximal FUS expression in LNCaP-FUS cells with 10nM doxycycline was 
determined by the treatment of LNCaP-FUS cells with 10nM doxycycline for times ranging 
between 0 and 48 hours prior to harvesting and lysis. Cell lysates were resolved by SDS-
PAGE and subject to Western blot analysis, immunoblotting with FUS and β-actin specific 
antibodies. Maximal FUS expression was observed from 24 hours treatment with 10nM 
doxycycline (Figure 3.2C).  
 To determine whether increased exogenous FUS expression had any effect on AR 
expression levels, LNCaP-FUS cells were androgen-deprived for 48 hours prior to treatment 
with 10nM mibolerone in the presence or absence of 10nM doxycycline for 72 hours, after 
which cells were harvested and lysed. Cell lysates were resolved by SDS-PAGE and subject 
to Western blot analysis, immunoblotting with AR, FUS and β-actin specific antibodies. 
Endogenous FUS expression was down regulated by 72 hours of androgen treatment in the 
absence of doxycycline, and exogenous FUS expression successfully induced upon 10nM 
doxycycline treatment. AR levels in LNCaP-FUS cells are unaltered by exposure to 10nM 
doxycycline treatment and subsequent increased exogenous FUS expression (Figure 3.2D).  
 
3.3 Increased exogenous FUS expression inhibits androgen-dependent growth in 
LNCaP cells 
 The LNCaP-FUS cell line enables doxycycline-inducible expression of increased 
exogenous FUS, and was used to investigate the effect of increased exogenous FUS 
expression on androgen-dependent LNCaP cell growth. LNCaP-FUS cells were androgen-
deprived for 48 hours prior to induction of increased exogenous FUS expression with 10nM 
doxycycline treatment, in the presence or absence of 10nM mibolerone or ethanol vehicle 
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Figure 3.2. Characterization of the LNCaP-FUS cell line. (A) Schematic representation of the 
doxycycline inducible FUS promoter in the LNCaP-FUS cell line. (B-D) Western blot analysis of 
FUS and Androgen Receptor (AR) expression in the LNCaP-FUS cell line. (B) LNCaP-FUS 
were treated with increasing concentrations of doxycycline (DOX) as indicated for 24 hours. (C) 
LNCaP-FUS were treated with 10nM DOX for 0-48 hours as indicated. (D) LNCaP-FUS were 
androgen deprived for for 72 hours prior to treatment with 10nM mibolerone and 10nM DOX for 72 
hours. Cells were lysed and lysates were resolved by SDS-PAGE and subjected to Western blot 
analysis probing with antibodies specific for FUS, β-actin and AR as indicated. B-D Figures are a 
representative result of two experimental replicates.  
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control. The cells were imaged with a phase contrast light microscope at 2 day intervals for 8 
days. Increased exogenous FUS expression (doxycycline treatment) in the presence of 
10nM mibolerone caused LNCaP-FUS cells to appear rounder by day 4, and reduced in cell 
number by day 6. Cell rounding was also observed after 8 days of increased exogenous 
FUS expression in the presence of ethanol (Figure 3.3). 
 To quantify the reduction in LNCaP-FUS cell number observed after 6 days treatment 
with doxycycline and mibolerone (Figure 3.3), cell proliferation assays were performed 
whereby LNCaP-FUS cells were treated as in Figure 3.3 and assayed for cell proliferation at 
2 day intervals for 8 days (Figure 3.4A). A reduction in cell proliferation was observed from 2 
days of increased exogenous FUS in the presence of 10nM mibolerone, and fewer 
proliferating cells were present by day 8 than seeded at day 0, suggesting cell death had 
occurred. A normal increase in cell proliferation in response to androgen was observed in the 
absence of doxycycline (Figure 3.4A). To ensure the observed reduction in androgen-
dependent proliferation was not due to doxycycline exposure, identical cell proliferation 
assays were performed on the LNCaP-FUS parental cell line, LNCaP-TR2 (LNCaP cells 
stably transfected with the TetR expression plasmid). No inhibition of ligand-dependent 
proliferation was observed in the presence of 10nM doxycycline (Figure 3.4B), 
demonstrating that the inhibition of androgen-dependent LNCaP-FUS proliferation is a FUS-
specific effect.  
 A difference in rate of androgen-dependent proliferation was observed between 
LNCaP-FUS and LNCaP-TR2 in the absence of doxycycline, with LNCaP-TR2 having a 
greater ligand-induced growth response compared to LNCaP-FUS (Figure 3.4A and B). The 
proliferative difference may be due to clonal selection of the LNCaP-FUS cell line. 
 Fluorescence activated cell sorter (FACS) analysis was used to investigate the effect 
of increased exogenous FUS expression on LNCaP cell cycle progression. LNCaP-FUS and 
parental LNCaP-TR2 cells were treated as in Figure 3.4, and harvested at 2 or 4 day 
intervals for LNCaP-FUS and LNCaP-TR2 respectively. The harvested cells were propidium 
iodide stained and the DNA content of cells established by measuring propidium iodide 
fluorescence by FACS analysis. The percentage of cells in each stage of the cell replication 
cycle (Table 3.1A and Table 3.2A) was determined from DNA histograms obtained for each 
sample (Figure 3.5).   
 The AR can exert its effect on the cell cycle through the regulation of proteins involved 
in the gap 1(G1)/synthesis (S) cell cycle transition (as reviewed in Balk & Knudsen, 2008), 
and androgen withdrawal results in accumulation of cells in G1 phase (Gamble et al., 2004; 
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Figure 3.3. Phase contrast microscope images of the LNCaP-FUS cell line. LNCaP-FUS cells 
were androgen deprived for 48 hours prior to treatment with 10nM mibolerone or ethanol, and ± 
10nM doxycycline. Images were taken at 20x magnification with a phase contrast microscope at 
the time points indicated (bars = 100µm).   
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Figure 3.4. The effect of increased exogenous FUS expression upon LNCaP cell 
proliferation. LNCaP-FUS (A) and LNCaP-TR2 cells (B) were androgen deprived for 48 hours 
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Figure 3.5. Fluorescent activated cell sorting (FACS) analysis of LNCAP-FUS and parental 
LNCaP-TR2 cell lines. LNCaP-FUS (A) and LNCaP-TR2 (B) cells were androgen deprived for 48 
hours prior to treatment with ±10nM doxycycline (DOX) and ± 10nM mibolerone (MIB) for the 
indicated times. Cells were fixed, propidium iodide stained and cell cycle analyzed using FACS. 
Data was analyzed using FlowJo v8.8.6 (Tree Star). Data shown here represents one repeat of the 
experiment which was performed in triplicate. 
LNCaP-TR2 
LNCaP-FUS 
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(A) 
    
Table 3.1. Fluorescent  activated cell sorting (FACS) analysis of LNCAP-FUS cells. Cells were 
androgen deprived for 48 hours prior to treatment with ± 10nM doxycycline (DOX) and  ± 10nM 
mibolerone for the indicated times. Cells were fixed, propidium iodide stained and cell cycle 
analyzed using FACS. Numbers in panel (A) shows percentage distribution of cells in stages of the 
cell cycle. Panel (B) shows the percentage distribution of cells in stages of the cell cycle, excluding 
the sub G1 population. Results presented are the mean of three independent experiments ± 1 
standard error. P (Student?s T Test) values are between data in the presence and absence of 
doxycycline, indicated by * =p≤0.05) and **=p≤0.005).  
  G1  S   G2 / M  
Ethanol 
DOX   -  +  -  +  -  +  -  +  
4 days   4.5 ± 0.4   4.1 ± 0.2 90.2 ± 0.5  90.5 ± 0.4  1.4 ± 0.2  1.1 ± 0.1  4.0 ± 0.2  4.2 ± 0.1   
8 days   2.9 ± 0.3   3.9 ± 0.5 90.2 ± 0.3   89.5 ± 0.9  1.1 ± 0.0   1.0 ± 0.1   5.8 ± 0.2  5.5 ± 0.4     
Sub - G1  
    Mibolerone   
  Sub - G1  G1  S   G2 / M  
DO X  -  +  -  +  -  +  -  +  
4 days   1.9 ± 0. 2   4.3 ± 0.2  88.3 ± 0.4  88.4 ± 0.2  2.9 0.0   1.4 0.1   7.0 ± 0.2   5.8 ± 0.2   
8 days 
  
2.7 ± 1.1   31.1 ± 2.5  78.1 ± 0.3  56.3 ± 2.2  4.7 ± 0.0   3.7 0.3   14.4 ± 1.4  8.8 ± 0.4   
± ± 
±   
  
± ± ± ± ± ± 
  
  Mibolerone   
  G1  S   G2 M  
DO X  -  +  -  +  -  +  
4 days  89.9 ± 0.3  92.5 ± 0.2  2.9 0.0  1.4 0.1   7.1 0.2  6.1 ± 0.2 
8 days 
  
79.2 0.0 
  
81.9 0.6 
  
4.7 0.0 
  
5.3 0.2 
  
16.1 0.1 
  
12.8 0.4 
G1  S   G2 / M  
  -  +  -  +  -  +  
4 days  94.4 0.1   94.4 ± 0.2  1.4 ± 0.2   1.2 ± 0.1  4.2 ± 0.3  4.4 ± 0.1   
8 days 
  
92.9 0.2 
  
93.2 0. 5 
  
1.1 0.0 
  
1.1 0.1 
  
6.0 0.2 5.7 0.4 
  
± 
  
Ethanol 
(B) 
DOX
± ± 
± 
± 
± 
± 
± 
± 
/ 
± 
** 
** ** ** 
** ** ** * 
** ** * 
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Table 3.2. Fluorescent  activated cell sorting (FACS) of LNCAP-TR2 cells. Cells were 
androgen deprived for 48 hours prior to treatment with ± 10nM doxycycline (DOX) and  ± 10nM 
mibolerone for the indicated times. Cells were fixed, propidium iodide stained and cell cycle 
analyzed using FACS. Numbers in panel (A) shows percentage distribution of cells in stages of the 
cell cycle. Panel (B) shows the percentage distribution of cells in stages of the cell cycle, excluding 
the sub G1 population. Results presented are the mean of three independent experiments ± 1 
standard error. 
  
  sub G1  G1  S  G2 /M  
DO X  -  +  -  +  -  +  -  +  
4 days  
      
  sub G1  G1  S  G2 /M  
DO X  -  +  -  +  -  +  -  +   
4 days  
    
(B) 
1.6 ± 0.2 2.1 ± 0.0 80.4 ± 1.1 78.8 ± 0.8 3.8. ± 0.4 3.8 ± 0.4 14.0 ± 0.8 15.1 ± 0.4 
0.9 ± 0.0 1.5 ± 0.2 73.2 ± 0.8 73.8 ± 0.7 6.5. ± 0.3 5.9 ± 0.5 19.1 ± 0.6 18.6 ± 0.8 
(A) 
G1  S  G2 /M  
DO X  -  +  -  +  -  +  
4 days   
  
Ethanol 
82.0±1.1 80.8±0.8 3.8±0.4 3.9±0.4 14.3±0.8 15.4±0.4 
Ethanol 
Mibolerone 
    Mibolerone   
  G1  S  G2 /M  
DO X  -  +  -  +  -  +  
4 days   75.0±0.9 75.1±0.7 6.6±0.3 6.0±0.5 19.3±0.7 18.9±0.8 
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Knudsen et al., 1998; Taneja et al., 2001). In agreement with these published studies, the 
accumulation of LNCaP-FUS cells in G1 phase was observed in the absence of both 
mibolerone and doxycycline treatment. This G1 accumulation was released upon addition of 
mibolerone (decreasing from 90.2% to 88.3% of cells at day 4 and 90.2% to 78.1% at day 8) 
as the cells progress to S phase (increasing from 1.4% to 2.9% of cells at day 4 and 1.1% to 
4.7% at day 8) and gap 2 (G2)/mitosis (M) phase (increasing from 4.0% to 7.0% of cells at 
day 4 and from 5.8% to 14.4% at day 8) (Table 3.1A).  
 In the presence of 10nM mibolerone the increased exogenous FUS levels (10nM 
doxycycline treatment) resulted in the accumulation of LNCaP-FUS cells in the sub-G1 
phase  (increasing from 1.9% to 4.3% of cells at 4 days and 2.7% to 31.1% of cells at 8 
days) (Table 3.1A). FACS data was re-calculated to exclude the sub-G1 population and 
reveal the effect of doxycycline (and therefore increased exogenous FUS expression) on the 
active cell cycling population (Table 3.1B and Figure 3.6). It was evident from the sub-G1 
excluded data that increased exogenous FUS expression (doxycycline treatment) decreased 
the mibolerone-dependent cell cycle progression from G1 into S and G2/M phases. In the 
presence of mibolerone, the increased exogenous FUS expression (doxycycline treatment) 
at 4 days increased the G1 phase population from 89.9% of cells to 92.5%, and this was 
accompanied by a decrease in S phase population (from 2.9% of cells to 1.4%) and G2/M 
phase cell population (from 7.1% of cells to 6.1%) (Table 3.1B and Figure 3.6). The same 
trend was observed at day 8 for G1 and G2/M LNCaP-FUS cell populations, but no 
significant decrease in the S phase population was detected (Table 3.1B).  
 FACS analysis of LNCaP-FUS cells was performed at 4 days following treatment.  
This time point appears to be the most informative with regards to the role of FUS in the 
regulation of androgen-dependent cell cycle progression since time course experiments 
(Figure 3.5) demonstrated that only a small proportion of cells were apoptosing at 4 days 
compared to that evident at 6 and 8 days. 
 FACS analysis performed on the parental LNCaP-TR2 cell line revealed that 
doxycycline treatment had no effect upon the cell cycle (Table 3.2 A and B, and Figure 3.6), 
therefore confirming that the observed cell cycle differences in the LNCaP-FUS cell line are 
due to exposure to increased exogenous FUS expression.  
 
3.4 Increased FUS exogenous expression induces apoptosis in LNCaP 
 FACS analysis indicates that increased exogenous FUS expression inhibits 
mibolerone-dependent LNCaP cell cycle progression and increases the sub-G1 population 
LNCaP-FUS LNCaP-TR2 
Figure 3.6. Fluorescent  activated cell sorting (FACS) analysis of cell cycling population in 
LNCaP-FUS and parental LNCaP-TR2 cells. (A) LNCaP-FUS and LNCaP-TR2 cells (B) were 
androgen deprived for 48 hours prior to treatment with ± 10nM doxycycline (DOX) and ± 10nM 
mibolerone (MIB) for 4 days. Cells were fixed, propidium iodide stained and cellular fluorescence 
measured using FACS. The percentage distribution of cycling cells was calculated by excluding 
the sub G1 population, and is shown for LNCaP-FUS (A) and parental LNCaP-TR2 cells (B). 
Results presented are the mean of three independent experiments ± 1 standard error. Student T-
test, *=p<0.05 and**=p<0.005.  
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(Table 3.1 and Figure 3.6). The observed increase in the sub-G1 population is indicative of 
an increase in cell death. Brooke et al., demonstrated by Western blot analysis that after 4 
days of increased exogenous FUS expression in the presence of mibolerone, the expression 
of the cleaved 85KDa fragment of poly ADP ribose polymerase (PARP), which is generated 
by cleavage of PARP by apoptosis executioner caspases including Caspase 3 and 7 
(Germain et al., 1999; Nicholson et al., 1995; Soldani & Scovassi, 2002), was increased in 
LNCaP-FUS cells (Brooke et al., 2011).  
 To investigate further the increased exogenous FUS-dependent initiation of apoptosis, 
Caspase 3 and 7 activity was assayed in LNCaP-FUS cells. Caspases 3 and 7 are a 
convergence point of the intrinsic and extrinsic apoptotic pathways (as reviewed in Boatright 
et al., 2003). LNCaP-FUS cells were treated as in Figure 3.4A, and the Caspase 3 and 7 
activity of cells was assayed after 0, 4 and 8 days of treatment. The Caspase 3 and 7 activity 
was normalized to cell proliferation data obtained simultaneously from duplicate cell 
samples. Increased exogenous FUS expression in the presence of mibolerone increased 
Caspase 3 and 7 activity (increasing 2.6-fold at 4 days and 30.5-fold at 8 days) (Figure 
3.7A). Identical Caspase 3 and 7 assays performed in the LNCaP-FUS parental cell line 
LNCaP-TR2 showed no corresponding induction of Caspase 3 and 7 activity (Figure 3.7A), 
indicating that Caspase 3 and 7 activation is due to increased exogenous FUS expression. 
The observed activation of Caspase 3 and 7 and the reported increase in expression of 
cleaved PARP in response to increased exogenous FUS expression in the presence of 
mibolerone (Brooke et al., 2011) therefore confirms that FUS induces apoptosis in LNCaP 
cells.   
 To gain further insight into the mechanism by which FUS induces apoptosis, Caspase 
8 activity was measured in LNCaP-FUS cells treated as in Figure 3.7A. The activation of 
Caspase 8 is via the extrinsic apoptotic pathway, whereby stimulation of extracellular death 
receptors results in the recruitment and activation of Caspase 8, which cleaves and activates 
effector Caspase 3 (Fulda & Debatin, 2006). A 3.3-fold increase in Caspase 8 activity was 
detected after 8 days of increased exogenous FUS expression (10nM doxycycline treatment) 
in the presence of mibolerone. No corresponding increase in Caspase 8 activity was 
observed in the LNCaP-FUS parental cell line LNCaP-TR2, indicating Caspase 8 activation 
is a FUS-specific effect (Figure 3.7B). However, since no increase in Caspase 8 activity was 
evident prior to 8 days, it is unlikely that FUS-dependent apoptosis is initiated via the 
extrinsic pathway, since increased Caspase 3 and 7 activity and cleaved PARP detection 
(Brooke et al., 2011) precede detection of Caspase 8 activity (Figure 3.7A).   
Figure 3.7. Increased exogenous FUS expression promotes apoptosis of the LNCaP cell 
line.Cells were androgen deprived for 48 hours prior to treatment with ± 10nM doxycycline (DOX) 
and ± 10nM mibolerone (MIB). Cells were assayed for evidence of caspase 3 and 7 (A) and 
caspase 8 (B) activity at times indicated using Caspase-Glo activity assays (Promega). Caspase 
activity was normalized to cell proliferation using WST-1 cell proliferation agent (Roche) on 
simultaneously treated duplicate cells. Graphs (A) and (B) show fold change of caspase activity in 
response to DOX treatment relative to non DOX treatment of cells for each time point. Experiments 
were repeated in triplicate, and mean value is presented ± 1 standard error. Student?s T-test, 
*=p<0.05 and**=p<0.005.  
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3.5 Reduction of FUS by siRNA enhances androgen-dependent growth of LNCaP 
cells 
 Having observed that increased exogenous FUS expression inhibited androgen-
dependent growth, the reciprocal experiment was performed whereby endogenous FUS was 
reduced in LNCaP cells by transient transfection with a single small interfering RNA (siRNA)  
FUS oligonucleotide, and growth assays performed to explore further the role of FUS in 
androgen-dependent growth.  
 The specificity of siRNA FUS was established by the transient transfection of LNCaP 
cells with siRNA FUS containing a single FUS siRNA oligonucleotide sequence, or a non-
targeting scrambled siRNA oligonucleotide pool (hereafter called scrambled) as a siRNA 
transfection negative control (see Chapter 2 section 2.8). LNCaP cells were harvested 48 
hours after transfection, RNA extracted and cDNA reverse transcribed. Quantitative real time 
PCR (qRT-PCR) was used to determine RNA expression levels of FUS and AR (relative to 
L19 RNA expression), and detected no alteration in AR RNA expression (Figure 3.8A) and a 
75% reduction in FUS RNA expression (Figure 3.8B) upon transfection with siRNA FUS. 
Western blot analysis of LNCaP harvested 72 hours after transfection with siRNA FUS 
confirmed successful reduction of FUS protein expression (Figure 3.8C).   
 To assess the effect of reduced endogenous FUS expression on LNCaP androgen-
dependent cell growth, LNCaP cells were transiently transfected with either siRNA FUS or 
scrambled for 72 hours in androgen-deprived media prior to treatment with increasing 
mibolerone concentrations (ranging from 0-10nM). Proliferation assays were performed 3 
and 6 days after incubation with ligand. Cells transfected with siRNA FUS showed a 
significant increase in androgen-dependent growth 3 days after treatment with 10nM 
mibolerone, and at 6 days with 1nM and 10nM mibolerone treatment (Figure 3.9). Therefore, 
the reduction of endogenous FUS confers an enhanced proliferative response to androgen in 
LNCaP cells. 
 
3.6 FUS regulates the expression of factors involved in mitogenic cell cycle 
progression 
 FUS has been shown to negatively regulate Cyclin D1 expression in RAW264.7 cells 
in response to DNA damage (Wang et al., 2008), indicating the involvement of FUS in the 
regulation of the progression through the  G1/S cell cycle check point. In support of this, the 
manipulation of FUS levels in LNCaP cells affected androgen-dependent growth, since 
increased exogenous FUS expression inhibited the androgen-dependent G1/S cell cycle
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Figure 3.8. Validation of FUS expression reduction in LNCaP cells by small inhibitory RNA 
(siRNA). LNCaP cells were transiently transfected with 25nM siRNA FUS or siRNA scrambled 
oligonucleotides in androgen deprived media. Cells were harvested 48 hours after transfection, RNA 
extracted and cDNA generated by reverse transcription. The RNA expression levels of (A) AR and (B) 
FUS was confirmed by quantitative real time PCR (qRT-PCR) using AR and FUS specific primers 
respectively. Data was plotted relative to L19 RNA expression, which was also determined by qRT-PCR. 
Results are the mean of 1 experiment repeated in triplicate ± 1 standard error. **= P<0.005 (Student’s T 
test). (C) 72 hours after siRNA transfection cells were harvested and lysed, and cell lysates resolved by 
SDS-PAGE. Western blot analysis was performed immunoblotting with  FUS, AR and β-actin specific 
antibodies. 
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progression and prompted G1 arrest and apoptosis, whereas decreased endogenous FUS 
expression enhanced LNCaP proliferation. A panel of cell cycle regulators involved in G1/S 
and G2/M cell cycle check points were examined for changes in expression in response to 
increased exogenous FUS expression, in an attempt to gain further insight into the 
mechanism(s) by which FUS affects cell cycle progression.  
 LNCaP-FUS cells were androgen deprived for 48 hours prior to increased exogenous 
FUS expression (10nM doxycycline treatment) in the presence of 10nM mibolerone. Cells 
were harvested after 72 hours of ligand treatment and subject to Western blot analysis 
(performed in collaboration with Dr David Mann and Dr Greg Brooke), immunoblotting with 
multiple antibodies specific for proteins involved in the regulation of cell cycle progression 
(as indicated in Figure 3.10) and β-actin. 
 The increased exogenous FUS levels altered the expression of several factors 
involved in the regulation of G1/S check point, specifically decreasing the expression of 
Cyclin D1, CDK6 and slightly decreasing phosphorylated Retinoblastoma Tumour 
Suppressor Protein (pRB) and increasing the expression of Kinase Inhibitor Protein p27 
(p27KIP). The increased exogenous FUS expression had little effect upon the expression of 
the additional G1/S cell cycle regulatory proteins CDK2, Cyclin D3 and RB, neither did 
increased exogenous FUS expression affect the expression of Cyclin A2, which has been 
shown to be involved in the regulation of both the G1/S and G2/M cell cycle check points. 
Interestingly, increased exogenous FUS expression also increased expression of Cyclin E, 
which is required in late G1/S phase. However, no increase in its cognate kinase, CKD2, 
was observed (Figure 3.10).   
 Therefore, the observed increased expression of p27KIP and decreased expression of 
CDK6 and Cyclin D1 in response to increased exogenous FUS expression in the presence 
of mibolerone suggest that FUS may, in part, inhibit the androgen-dependent G1/S cell cycle 
progression by regulating the expression of specific G1/S regulatory proteins to negate the 
growth stimulatory effect of androgen and prompt G1 arrest of LNCaP cells.   
 
 
 
 
 
 
 
 
10nM DOX 
 
10nM DOX 
Figure 3.10. FUS regulates factors involved in cell cycle progression. LNCaP-FUS cells were 
androgen deprived for 48 hours prior to treatment with 10nM mibolerone (MIB) and ± 10nM 
doxycycline (DOX). Cells were harvested and lysed 72 hours after treatment. Cells lysates were 
resolved by SDS-PAGE and subjected to Western blot analysis, probing for antibodies indicated. 
Western blotting was performed in collaboration with Dr David Mann.  
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3.7 Discussion 
3.7.1 FUS is an androgen-regulated target 
 The growth and development of prostate cancer is almost always dependent upon 
the AR signalling pathway, hence AR is a key target of prostate cancer therapies. A 
greater knowledge of AR downstream targets is critical for understanding disease initiation 
and progression, which may lead to increased treatment options for non-organ confined 
and hormone refractory prostate cancer. The observation that FUS is down-regulated in 
response to androgen treatment (Brooke et al., 2011) led to the hypothesis that FUS may 
be involved in the negative regulation of prostate cancer growth. Comparable androgen-
regulated expression of the remaining TET family members, EWS and TAF15, was not 
observed in Western blot analysis of LNCaP cells (Figure 3.1), suggesting that FUS is 
unique within the TET family in having a role in androgen-regulated signalling. Little is 
known about the regulation of TET family members, however all are down-regulated at the 
protein level during the differentiation of human embryonic stem cells and neuroblastoma 
(Andersson et al., 2008). It appears that the androgen-mediated down-regulation of FUS is 
unique to this TET family member and may provide a further example of differential 
function within the TET family. 
 The TET family share distinct structural characteristics, with both EWS and TAF15 
sharing 46% primary amino acid identities with FUS and the RRM domains sharing even 
greater identity of 55% and 80% respectively (Guipaud et al., 2006) (Figure 1.13). TET 
family members display overlapping expression patterns in human tissues, showing 
almost ubiquitous nuclear expression, with FUS and TAF15 also expressed in the 
cytoplasm of most cell types, whilst cytoplasmic EWS was rarely found in secretory cell 
types (Andersson et al., 2008).  
 The TET family members have several physiological roles in common; for example 
they are all identified as binding partners of RNA Polymerase II (Bertolotti et al., 1996; 
Bertolotti et al., 1998; Hoffmann & Roeder, 1996) and CBP (Wang et al., 2008) and are 
also all included in oncogenic fusion proteins (as reviewed in Tan & Manley, 2009). 
However, recent studies suggest TET family members also have separate biological 
functions, including the identification of FUS as a negative regulator of Cyclin D1 
expression (Wang et al., 2008).  
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3.7.2 FUS blocks cell cycle progression 
 In support of its involvement in androgen-mediated signalling, increased exogenous 
FUS expression inhibited the androgen-dependent growth of LNCaP cells by inducing G1 
cell cycle arrest and increasing the sub-G1 population (Table 3.1 and Figure 3.5). 
Conversely, decreased levels of endogenous FUS increased the androgen-dependent 
proliferative potential of LNCaP cells (Figure 3.9).  
 The AR is reported to exert its growth stimulatory effects by regulating progression 
through the G1/S cell cycle check point, since removal of androgen results in an increase 
in the G1 cell population (Knudsen et al., 1998). In agreement with this, androgen deprived 
LNCaP-FUS and LNCaP-TR2 cells accumulated in G1, and this accumulation was 
decreased upon addition of androgen and was accompanied by an increase in both the S 
and G2/M cell populations (Figure 3.6). FUS was found to block the G1/S transition, since 
increased exogenous FUS expression in the presence of mibolerone increased the G1 cell 
population and decreased both the S and G2/M cell populations (Figure 3.6).  
 
3.7.3 FUS regulates several factors involved in G1/S transition 
 The AR mediates androgen-dependent growth and cell cycle progression via 
regulation of proteins essential for transition through the G1/S cell cycle check point (Balk 
& Knudsen, 2008; Knudsen et al., 1998). For example, AR up-regulates translation of 
Cyclin D1 via activation of Mammalian Target of Rapamycin (mTOR) (Xu et al., 2006). 
Androgens have also been shown to regulate the expression of Cyclin A and the activity of 
CDK2, since androgen withdrawal diminished Cyclin A expression and increased the 
expression of the CDK inhibitor p27KIP in LNCaP cells, contributing to the inhibition of 
CDK2 activity (Knudsen et al., 1998).  
 FUS is reported to negatively regulate the transcription of the G1/S cell cycle 
regulator Cyclin D1, via a non-coding RNA (ncRNA) dependent mechanism in RAW264.7 
cells (Wang et al., 2008). FUS is directed to the promoter of Cyclin D1 by ncRNA 
transcribed from regulatory regions of Cyclin D1 in response to DNA damage. At the 
promoter FUS binds to and inhibits the HAT activity of co-activators CBP and p300, 
resulting in repression of Cyclin D1 transcription (Wang et al., 2008). Dr Charlotte Bevan’s 
laboratory has also shown that Cyclin D1 is negatively regulated by FUS in LNCaP cells, 
since increased FUS expression resulted in decreased Cyclin D1 expression (Brooke et 
al., 2011). Furthermore FUS is also recruited to the promoter of Cyclin D1 in LNCaP cells 
(Brooke et al., 2011).  
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 Since FUS is a negative regulator of the G1/S regulatory protein Cyclin D1, the 
expression of several cell cycle regulatory proteins was examined in LNCaP cells in 
response to increased FUS expression (doxycycline treatment) to explore the mechanism 
by which FUS blocks androgen-dependent cell cycle progression. Western blotting of 
lysates from the LNCaP-FUS cell line demonstrated that FUS altered the expression of 
several such factors. The Cyclin D1-CDK6 active complex produced early in G1 is 
necessary for the progression through the early G1/S check point (as reviewed in Balk & 
Knudsen, 2008), and both were identified by Western blot analysis as being down-
regulated in response to increased exogenous FUS expression (doxycycline treatment) in 
the presence of mibolerone (Figure 3.10). 
 Further implicating FUS in the mibolerone-dependent G1/S cell cycle arrest was the 
observed up-regulation of the CDK inhibitor p27KIP in response to increased exogenous 
FUS expression (Figure 3.10). p27KIP has been shown to bind and inhibit CDK2 and CDK4 
in early and late G1 respectively and p27KIP deactivation or p27KIP degradation is 
necessary for progression through the G1/S cell cycle check point (Vervoorts & Luscher, 
2008). 
 The increased exogenous expression of FUS had no effect upon the expression 
levels of RB, a key modulator of the G1/S cell cycle checkpoint. However, the 
phosphorylation of RB by the G1/S check point active Cyclin-CDK complexes, including 
Cyclin D1-CDK2, is necessary for transition through the G1/S cell cycle check point 
(Knudsen & Wang, 1997; Knudsen et al., 1998). Exogenous FUS expression did slightly 
decrease the levels of phosphorylated RB (pRB) (Figure 3.10), possibly contributing to 
FUS-dependent G1 arrest of LNCaP-FUS cells in the presence of mibolerone. The 
decrease in pRB is most likely due to decreased expression of CDK6 and Cyclin D1 
expression and an increase in expression of the CDK4 and CDK2 kinase inhibitor 
p27KIP in response to increased exogenous FUS expression. This data is in agreement 
with Knudsen et al., who showed that G1 arrest due to androgen deprivation resulted in 
a decrease in expression of pRB (Knudsen et al., 1998).  
 In agreement with the FACS data demonstrating inhibition of G1/S transition 
(Figure 3.6) the expression of the G2/M regulatory protein Cyclin A2 was unchanged 
upon increased FUS expression, suggesting the FUS inhibition of the androgen- 
dependent cell cycle is G1/S specific. However, little change was observed in the 
expression of additional G1/S cell cycle regulators including CDK2, Cyclin D3 and RB, 
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suggesting the FUS-mediated inhibition of G1/S transition is targeted to specific G1/S 
regulatory proteins.  
 The observation that FUS down-regulates the G1/S cell cycle check point activators 
Cyclin D1 and CDK6, and increased the G1/S cell cycle check point repressor p27KIP, 
suggests that a cell cycle regulatory pathway may exist, whereby mitogenic androgen 
treatment causes the down regulation of FUS, which mediates the regulation of G1/S 
check point cell cycle regulatory proteins to facilitate the androgen-dependent progression 
of cells through the G1/S check point. It is of note that Cyclin D1 has multiple functions in 
addition to the activation of CDK2 and CDK4 including the reported transcriptional 
repression of the androgen receptor (Burd et al., 2005; Petre-Draviam et al., 2005; 
Schiewer et al., 2009). It may therefore be possible that complex functional regulatory 
interactions exist between AR, FUS and Cyclin D1 to modulate cell cycle progression, and 
this warrants further investigation. 
 
3.7.4 Mechanism(s) by which increased exogenous FUS expression induces 
apoptosis 
 The concerted action of caspases leads to the proteolytic cleavage of specific 
targets, which is necessary for cellular apoptosis and performed by the executioner 
caspases such as Caspases 3, 6, and 7. Initiator caspases activate executioner caspases 
in response to extracellular or intracellular signals (as reviewed in Boatright et al., 2003). 
Initiator Caspases 8 and 10 form part of the extracellular apoptotic pathway, whereby 
extracellular signals bind to death receptors on the cell surface. For example the binding of 
Fas ligand to the Fas death receptor leads to the recruitment and activation of Caspase 8 
(Boatright et al., 2003). The intrinsic apoptotic pathway is regulated by initiator Caspase 9, 
which is activated by the release of mitochondrial Cytochrome C (Ashkenazi, 2002; 
Boatright et al., 2003) .  
 The androgen-dependent G1 arrest of LNCaP in response to increased exogenous 
FUS expression is accompanied by a large increase in the sub-G1 population. This 
population was confirmed to contain apoptotic cells, since cleavage of PARP (Brooke et 
al., 2011) and Caspase 3 and 7 activity (Figure 3.7A), both markers of apoptosis, were 
increased in response to increased FUS expression. Thus, FUS promotes apoptosis in 
prostate cancer cells. Investigation into the mechanism by which FUS induces apoptosis 
suggest that apoptotic induction is not via the extrinsic apoptotic initiator Caspase 8, since 
activation of executioner Caspases 3 and 7 was detected prior to activation of Caspase 8 
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(Figure 3.7A and B). Further investigation into the activity of additional initiator Caspases 
8, 9 and 10 in response to increased exogenous FUS levels would be required to gain a 
greater understanding of the mechanism(s) by which FUS regulates the LNCaP apoptotic 
pathway.  
 In support of the role of FUS as both an inhibitor of the G1/S cell cycle checkpoint 
and initiator of apoptosis, multiple proteins have been identified with dual apoptotic 
promoting activity and cell cycle checkpoint inhibition, including Regulator of Fibroblast 
Growth Factor 2 Transcription (RFT) (Kano et al., 2004). FACS analysis demonstrated that 
increased expression of RFT in the human brain cancer cell line U87MG inhibited the 
G1/S transition prior to initiation of apoptosis. Western blot analysis indicated increased 
RFT expression induced p53 expression and also increased phosphorylation of p53 at 
serine 15, which is associated with p53 activation (Kano et al., 2004). p53 is a transcription 
factor that is activated upon DNA damage and regulates expression of cell cycle 
regulators to  inhibit progression through the G1/S check point. For example p53 up-
regulates expression of p21CIP1 which has been shown to inhibit CDK2 activation in some 
cell lines (as reviewed in Balint & Vousden, 2001; el-Deiry et al., 1993; Kano et al., 2004). 
Furthermore, p53 down-regulates expression of the CDK2 activating phosphatase 
Cdc25A, contributing further to inhibition of progression through the G1/S check point 
(Rother et al., 2007). p53 also activates apoptosis via induction of pro-apoptotic factors 
including Bcl-2-Associated X Protein (BAX) (Miyashita & Reed, 1995) and p53 Up-
regulated Modulator of Apoptosis (PUMA )(Nakano & Vousden, 2001). The analysis of p53 
expression and phosphorylation status in LNCaP cells in response to increased FUS 
expression may provide further insight into the mechanism(s) of FUS-mediated initiation of 
apoptosis. 
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4.Results-Part 2 
FUS is a novel repressor of ligand-dependent Androgen Receptor 
transcriptional activity 
 
 The ligand-dependent transcriptional activity of the Androgen Receptor (AR) is 
modulated by co-regulatory proteins, which associate with the AR to enhance 
transcriptional activity (co-activators) or repress transcriptional activity (co-repressors) 
(Heemers & Tindall, 2007; Heinlein & Chang, 2002; Wang et al., 2005a). Transcriptional 
co-regulatory proteins are necessary for the efficient modulation of androgen regulated 
gene (ARG) expression (Wang et al., 2005a), and aberrant AR co-regulator expression 
has been proposed as a mechanism by which prostate cancer cells gain a selective 
growth advantage and progress to androgen refractory disease (Chmelar et al., 2007; 
O'Malley & Kumar, 2009). For example, the expression of Steroid Receptor Co-activator 1 
(SRC-1), a member of the p160 AR co-activator family, has been shown to be up-
regulated in androgen-independent prostate cancers that progressed after androgen 
deprivation treatment (Gregory et al., 2001a). 
 FUS has been shown to negatively regulate androgen-dependent LNCaP cell cycle 
progression, since increased exogenous FUS expression inhibits the G1/S cell cycle 
transition and induces apoptosis, whereas the reduction of endogenous FUS expression 
enhances androgen-dependent LNCaP proliferation (Brooke et al., 2011). GST interaction 
studies demonstrate that FUS interacts directly with the steroid receptors, for example, 
human ERα and rat GR (Powers et al., 1998), and furthermore, GST interaction studies 
demonstrated that FUS also interacts with  the AR (unpublished data from Dr Charlotte 
Bevan’s laboratory, Figure 1.23). The interaction of FUS with steroid receptors and the 
involvement of FUS in repression of AR-mediated LNCaP growth leads to the hypothesis 
that FUS may attenuate the activity of the AR directly.  
 
4.1 FUS over-expression represses ligand-dependent AR transcriptional activity 
 To investigate the effect of FUS upon AR activity, COS-1 cells were transiently co-
transfected with a human AR expression plasmid (pSVAR), an androgen responsive 
luciferase reporter (TAT-GRE-E1B-LUC or PROBASIN-PROM-LUC), a β-galactosidase 
expression plasmid (PDM-LACZ-βGAL) and increasing amounts of a FUS expression 
plasmid (pSG5-FUS). Cells were harvested after 24 hours treatment with 10nM 
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mibolerone (a synthetic androgen) or ethanol vehicle control. Cell lysates were assayed 
for luciferase activity, which was normalized to β-galactosidase activity to correct for 
transfection efficiency. Results are expressed as a percentage of luciferase activity in the 
presence of mibolerone and in the absence of pSG5-FUS (Figure. 4.1A and B).  
 FUS reduced the ligand-dependent AR transcriptional activity as measured on the 
TAT-GRE-E1B-LUC androgen responsive luciferase reporter by up to 69% (Figure 4.1A), 
and reduced the ligand-dependent transcriptional AR activity as measured on the 
PROBASIN-PROM-LUC androgen-responsive luciferase reporter to ethanol vehicle 
control background luciferase levels (Figure 4.1B). The FUS-mediated repression of 
ligand-dependent AR activity was observed using both PROBASIN-PROM-LUC and TAT-
GRE-E1B-LUC androgen responsive luciferase reporter plasmids, suggesting it is not a 
promoter specific effect. The over-expression of FUS from transiently transfected pSG5-
FUS in COS-1 was confirmed by Western blot analysis of cells that had been transiently 
transfected with increasing amounts of pSG5-FUS for 48 hours prior to harvesting, 
showing a dose-dependent increase in FUS expression with increasing amount of 
transfected pSG5-FUS (Figure 4.1C).    
 A limitation of investigating the effect of FUS on AR transcriptional activity in the 
AR-negative COS-1 cell line is that transient transfection of AR is required, which is thus 
over-expressed from a non-chromatinized template. To overcome this, the prostate cancer 
cell line PC3wtAR (created by the stable transfection of PC3 cells with wild type human 
AR) was transiently transfected with the AR responsive luciferase reporter TAT-GRE-E1B, 
a β-galactosidase expression plasmid (PDM-LACZ-βGAL) and increasing amounts of 
pSG5-FUS. Cells were harvested after 24 hours treatment with 10nM mibolerone or 
ethanol control, and lysates assayed as for Figure 4.1. FUS reduced the ligand-dependent 
AR transcriptional activity by up to 52% with 400ng pSG5-FUS (Figure 4.2). Thus, FUS is 
able to repress the ligand-dependent transcriptional activity of both transiently and stably 
expressed exogenous AR. 
 
4.2 FUS represses the activity of the Glucocorticoid and Oestrogen-α  Receptors, 
but not the Progesterone Receptor 
 Since FUS has been shown by Powers et al., to interact with the steroid receptors 
human ERα and rat GR (Powers et al., 1998), the effect of FUS upon the transcriptional 
activity of GR, ERα and PR in COS-1 cells was investigated. COS-1 cells were transiently 
transfected with expression plasmids for either human ERα, PR or GR, and co-transfected 
(A)  TAT-GRE-E1B-LUC (B)   PROBASIN-PROM-LUC 
%
 lu
ci
fe
ra
se
 a
ct
iv
ity
 
0 
20 
40 
60 
80 
100 
120 
0 50 100 200 400 
pSG5-FUS (ng) 
** ** 
** ** 
%
 lu
ci
fe
ra
se
 a
ct
iv
ity
 
Figure 4.1. The effect of FUS over-expression upon the Androgen Receptor (AR) 
transcriptional activity in COS-1. Cells were transiently transfected with 50ng of a human AR 
expression plasmid (pSVAR), 100ng of a β-galactosidase plasmid (PDM-LACZ-βGAL), increasing 
amounts of FUS expression plasmids (pSG5-FUS) as indicated and 1µg of the AR responsive 
luciferase reporter plasmid (A) TAT-GRE-E1B-LUC or (B) PROBASIN-PROM-LUC. Cells were 
incubated for 24 hours with 10nM mibolerone or ethanol vehicle control, harvested and lysed. Cell 
lysates were assayed for luciferase activity and normalized with β-galactosidase data.  Results were 
expressed as a percentage of the AR activity after 24 hours of ligand treatment (10nM mibolerone) 
in the absence of FUS. Results are the mean of 3 independent experiments repeated in duplicate 
±1stardard error.** = P<0.005 (Student’s T test). (C) Western blot analysis of FUS over-
expression in COS-1. Cells were transiently transfected with increasing amounts of pSG5-FUS as 
indicated. Cells were harvested and lysed 48 hours after transfection. Cell lysates were resolved by 
SDS-PAGE and subjected to Western blot analysis, and protein blots probed with antibodies 
specific for FUS and β-actin as indicated. 
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Figure 4.2. The effect of FUS over-expression upon Androgen Receptor (AR) transcriptional 
activity in the PC3wtAR prostate cancer cell line. Cells were transiently transfected with 250ng 
of an AR responsive luciferase reporter plasmid (TAT-GRE-E1B-LUC), 25ng of a β-galactosidase 
plasmid (PDM-LACZ-βGAL) and increasing amounts of FUS expression plasmid (pSG5-FUS) as 
indicated. Cells were incubated for 24 hours with 10nM mibolerone or ethanol vehicle control, 
harvested and lysed. Cell lysates were assayed for luciferase activity and normalized with β-
galactosidase data.  Results were expressed as a percentage of the AR activity after 24 hours of 
ligand treatment (10nM mibolerone) in the absence of FUS. Results are the mean of 3 
independent experiments repeated in duplicate ±1stardard error. * = P<0.05 ** = P<0.005 
(Student’s T test). 
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with a luciferase reporter plasmid responsive to the corresponding receptor (for PR and 
GR the TAT-GRE-E1B reporter plasmid was used and ERE-LUC reporter plasmid for 
ERα), and increasing amounts of pSG5-FUS. Cells were harvested after 24 hours 
treatment with the appropriate hormone, and lysates assayed as for Figure 4.1A. 
 FUS reduced the ligand-dependent transcriptional activity of GR and ERα. A dose-
dependent decrease in the ligand-dependent transcriptional activity of GR was observed 
with increasing pSG5-FUS, with a maximal 25% reduction in GR transcriptional activity 
with 400ng pSG5-FUS, whereas a significant decrease in ERα activity by 22% was only 
observed with 400ng-pSG5-FUS (Figure 4.3A and B). However, FUS over-expression had 
no significant effect upon PR activity (Figure 4.3C).  
 
4.3 Over-expression of TET family members TAF15 and EWS increased the ligand-
dependent transcriptional activity of the AR 
 Having seen that FUS repressed the ligand-dependent transcriptional activity of AR, 
similar transient transfection assays were carried out to assess the effect of over-
expression of the remaining TET family members, TAF15 and EWS, on AR transcriptional 
activity. The expression plasmid pSG5-TAF15 was generated by the sub-cloning of TAF15 
(variant 2) by PCR amplification from plasmid pTL37-TAF15, kindly provided by Dr Laszlo 
Tora (Jobert et al., 2009) (see chapter 2, section 2.3.3), whilst the EWS expression 
plasmid, pCMV5-HA-EWS, expressing EWS variant 2, was a kind gift from Dr Philip 
Cohen (Klevernic et al., 2009).  
 COS-1 cells were transiently co-transfected with a human AR expression plasmid 
(pSVAR), an androgen responsive luciferase reporter plasmid (TAT-GRE-E1B-LUC), a β-
galactosidase expression plasmid (PDM-LACZ-βGAL) and increasing amounts of 
expression plasmids for either EWS (pCMV5-HA-EWS) or TAF15 (pSG5-TAF15). Cells 
were harvested after 24 hours treatment with 10nM mibolerone or ethanol control, and 
lysates assayed and data plotted as for Figure 4.1A. In contrast to FUS, both EWS and 
TAF15 increased ligand-dependent AR transcriptional activity. A dose-dependent increase 
in the ligand-dependent AR transcriptional activity was observed with increasing pSG5-
TAF15, with a maximal AR transcriptional activity of 398% (Figure 4.4A), whereas an 
increase in AR ligand-dependent activity was only observed with 400ng pCMV5-HA-EWS, 
increasing AR transcriptional activity to 216% (Figure 4.4B).  
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Figure 4.3. The effect of FUS over-expression on Glucocorticoid (GR), Oestrogen-α (ERα) 
and Progesterone (PR) Receptor transcriptional activity in COS-1. Cells were transiently 
transfected with 50ng of expression plasmids for human (A) GR (pSG5-GR), (B) ERα (pSG5-ERα) 
and (C) PR (PSG5-PR), and co-transfected with 100ng of a corresponding receptor responsive 
luciferase reporter (TAT-GRE-E1B-LUC for PR and GR, and ERE-LUC for ERα), β-galactosidase 
plasmid (PDM-LACZ-βGAL) and increasing amounts of FUS expression plasmid (pSG5-FUS) as 
indicated. Cells were treated with 10nM of receptor specific ligand for 24 hours (progesterone used 
for PR, dexamethasone for  GR and  17β-Oestradiol for ERα), harvested and lysed. Cell lysates 
were assayed for luciferase activity and normalized with β-galactosidase data. Results were 
expressed as a percentage of the receptor activity after 24 hours of ligand treatment in the 
absence of FUS. Results are the mean of 3 independent experiments repeated in duplicate 
±1stardard error. * = P<0.05 ** = P<0.005 (Student’s T test). 
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Figure 4.4. The effect of TET (TLS/FUS, EWS and TAF15) family member over-expression 
upon Androgen Receptor (AR) transcriptional activity in COS-1. Cells were transiently co-
transfected with 50ng of a human AR expression plasmid (pSVAR), 100ng of a β-galactosidase 
plasmid (PDM-LACZ-βGAL),1 µg of a  AR responsive luciferase reporter plasmid (TAT-GRE-E1B-
LUC) and increasing amounts of either pSG5-TAF15 (A) or pCMV5-HA-EWS (B) as indicated. 
Cells were incubated for 24 hours with 10nM mibolerone or ethanol vehicle control prior to 
harvesting and lysis. Cell extracts were assayed for luciferase activity, and normalized with β-
galactosidase data. Results were expressed as a percentage of the AR activity after 24 hours of 
ligand treatment in the absence of FUS. Results are the mean of 3 independent experiments 
repeated in duplicate ±1SE. * = P<0.05 ** = P<0.005 (Student’s T test). Western blot analysis of 
EWS (C) and TAF15 (D) over-expression in COS-1 cells. Cells were transiently transfected with 
increasing amounts of either pCMV5-HA-EWS or pSG5-TAF15 as indicated. Cells were harvested 
and lysed 48 hours after transfection. Cell lysates were  resolved by SDS-PAGE and subjected to 
Western blot analysis, probing with antibodies specific for EWS, TAF15 and β-actin as indicated.  
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 The over-expression of EWS and TAF15 from transiently transfected pCMV5-HA-
EWS and pSG5-TAF15 was confirmed by Western blot analysis of COS-1 cells transiently  
transfected with increasing amounts of pCMV5-HA-EWS or pSG5-TAF15 for 48 hours 
prior to harvesting, showing an increase in EWS and TAF15 expression with increasing 
amounts of transfected pCMV5-HA-EWS (Figure 4.4C) and pSG5-TAF15 (Figure 4.4D) 
respectively.    
 
4.4 Increased exogenous FUS expression decreases endogenous AR target gene 
expression in LNCaP cells 
 Previous experiments demonstrating the inhibition of AR ligand-dependent 
transcriptional activity by FUS (Figure 4.1 and 4.2) have utilized exogenous FUS over-
expression from transiently transfected and non-chromatinized plasmid pSG5-FUS. 
Therefore, the androgen responsive prostate cancer cell line LNCaP-FUS, which 
expresses exogenous FUS from a chromatinized template under the control of a 
doxycycline inducible promoter (characterized in Chapter 3), was used to investigate the 
effect of increased exogenous FUS expression from a chromatinized template on the 
ligand-dependent transcriptional activity of AR on endogenous ARGs.  
 LNCaP-FUS cells were androgen deprived for 72 hours prior to treatment with 
10nM doxycycline and either 10nM mibolerone or ethanol vehicle control. Cells were 
harvested 24 or 48 hours after ligand treatment, the RNA was extracted and cDNA reverse 
transcribed. Quantitative real time PCR (qRT-PCR) was used to confirm doxycycline-
dependent increased expression of FUS in LNCaP-FUS (relative to L19 expression). A 2-
fold increase in FUS expression was observed upon doxycycline treatment in the 
presence of ethanol, and 16-fold increase in FUS expression upon doxycycline treatment 
in the presence of mibolerone for both 24 and 48 hours time points (Figure 4.5A). 
 Next the effect of increased exogenous FUS expression on the transcription of 
known androgen-regulated genes (ARGs) Kallikrein-2 (KLK2) (Young et al., 1992), 
Differentiation-Related Gene-1 (DRG1) (Ulrix et al., 1999), Prostate Specific Antigen (PSA) 
(Riegman et al., 1991) and Transmembrane Protease Serine-2 (TMPRSS2) (Lin et al., 
1999) was assessed by qRT-PCR (Figure 4.5B-E). All of the ARGs examined showed a 
mibolerone-dependent increase in expression in the absence and presence of increased 
exogenous FUS expression (doxycycline treatment). However, the mibolerone-dependent 
expression of all ARGs examined were significantly decreased in the presence of 
increased exogenous FUS expression (doxycycline treatment) at 24 and 48 hours of
Figure 4.5. Quantitative real time PCR (qRT-PCR) analysis of androgen regulated gene (ARG) 
expression in the LNCaP-FUS cell line. cells were androgen deprived for 72 hours and then 
treated for either 24 hours or 48 hours ± 10nM doxycycline (DOX) and 10nM mibolerone, or ethanol 
vehicle control. Cells were harvested, RNA extracted and cDNA reverse transcribed. The over-
expression of FUS was confirmed by qRT-PCR using FUS specific primers (A). The RNA expression 
of the ARGs TMPRSS2 (B), PSA (C), KLK2 (D) and DRG1 (E) was determined by qRT-PCR using 
gene specific primers. Data was plotted relative to L19 RNA expression, which was also determined 
by qRT-PCR. Results are the mean of 2 experiments repeated in triplicate ±1SE. ** = P<0.005 and * 
= P<0.05 (Student’s T test).  
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mibolerone treatment (Figure 4.5B-E), with the exception of PSA, for which a significant 
decrease in expression was only detected after 24 hours of mibolerone treatment (Figure 
4.5D). TMPRSS2 showed the greatest reduction in mibolerone-dependent expression in 
the presence of increased exogenous FUS expression (doxycycline treatment) with a 47% 
reduction at 24 hours and 63% reduction at 48 hours treatment with mibolerone. This data 
suggests that FUS decreases endogenous AR target gene expression. 
 
4.5 Knock-down of endogenous FUS expression by siRNA increased androgen-
dependent expression of TMPRSS2 
 Having seen that elevated levels of FUS expressed from transiently and stably 
transfected templates inhibited androgen-dependent AR transcriptional activity from a 
reporter construct and genomic loci respectively, it was hypothesized that reduced 
endogenous FUS expression may enhance AR transcriptional activity. To investigate this 
hypothesis a reciprocal experiment was performed whereby ARG expression in the 
presence of reduced endogenous FUS expression in LNCaP cells was examined by qRT-
PCR. This was achieved by the transient transfection of LNCaP cells with siRNA FUS 
(characterization of the transient transfection of LNCaP cells with siRNA FUS and 
scrambled control siRNA can be found in Figure 3.8). 
 LNCaP cells were transiently transfected with either 10nM siRNA FUS or scrambled 
siRNA for 72 hours prior to treatment with 10nM mibolerone or ethanol vehicle control for 4 
or 8 hours, after which cells were harvested, RNA extracted and cDNA reverse 
transcribed. The knock-down of FUS RNA expression was confirmed by qRT-PCR, with 
approximately 60% reduction in FUS expression for all treatment conditions (Figure 4.6A). 
Next, the effect of decreased endogenous FUS expression on the transcription of the 
known ARGs KLK2, DRG1, TMPRSS2 and PSA was determined by qRT-PCR, (Figure 
4.6B-E), performed using template cDNA generated from LNCaP cells treated as in Figure 
4.6A. The siRNA transfected LNCaP cells were assayed for ARG expression by qRT-PCR 
at 4 and 8 hours post-ligand treatment to ensure that the AR mibolerone-dependent 
transcriptional activity was not saturated, aiding in the detection of possible repressed AR 
transcriptional activity, since ARG expression was being examined after reduction of a 
hypothesized AR repressor. 
 For all ARGs examined by qRT-PCR, an increase in RNA expression was observed 
at 4 and 8 hours treatment with mibolerone in LNCaP cells transiently transfected with
Figure 4.6. Quantitative real time PCR (qRT-PCR) analysis of androgen regulated gene (ARG) 
expression in LNCaP cells treated with siRNA FUS. Cells were transfected with 25nM siRNA FUS 
or control scrambled siRNA for 72 hours in androgen-deprived media. Cells were treated ± 10nM 
mibolerone as indicated for 4 or 8 hours. Cells were harvested, RNA extracted and cDNA reverse 
transcribed. The knock-down of FUS was confirmed by qRT-PCR using FUS specific primers (A). 
The RNA expression of the ARGs TMPRSS2 (B), PSA (C), KLK2 (D) and DRG1 (E) was determined 
by qRT-PCR using gene specific primers. Data was plotted relative to L19 RNA expression, which 
was also determined by qRT-PCR. Results are the mean of 2 experiments repeated in triplicate 
±1SE. ** = P<0.005 and * = P<0.05 (Student’s T test).  
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siRNA scrambled and siRNA FUS (Figure 4.6B-E). However, in siRNA FUS transfected 
LNCaP cells a significant decrease in RNA expression was observed for KLK2 and DRG1 
after 8 hours treatment with mibolerone and ethanol (Figure 4.6B and C), whereas a 
significant decrease in PSA and TMPRSS2 RNA expression was observed after 4 hours 
treatment with mibolerone and ethanol treatment (Figure 4.6D and E). Conversely, 
TMPRSS2 RNA expression was significantly increased after 8 hours treatment with 
ethanol and mibolerone in siRNA FUS transfected LNCaP cells (Figure 4.6E). This data 
suggests that endogenous FUS may exert differential roles in the transcriptional regulation 
of ARGs.  
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4.6 Discussion 
4.6.1 FUS is a novel repressor of AR transcriptional activity 
 Previous experiments examining the effect of increased exogenous FUS levels on 
cell cycle progression showed that FUS is a negative regulator of prostate cancer growth. 
FUS inhibited androgen-dependent LNCaP cell cycle progression and promoted G1 arrest, 
in part by altering the expression of G1/S cell cycle check point regulatory proteins Cyclin 
D1, CDK6 and p27KIP. Furthermore, reduced endogenous FUS expression enhanced 
androgen-dependent proliferation of LNCaP cells (Brooke et al., 2011). GST studies have 
shown that FUS interacts with several nuclear receptors, for example ERα, (Powers et al., 
1998), and unpublished data from Dr Charlotte Bevan’s laboratory indicates that FUS 
interacts with the AR DNA binding domain and both the AF1 and AF2 domains (Figure 
1.23).  
 AR transcriptional activity is modulated by the recruitment of transcriptional co-
regulatory proteins including co-activators and co-repressors, which can bring about their 
modulatory effect either by intrinsic histone acetyl transferase (HAT) activity, histone 
deacetylase (HDAC) activity or via recruitment of co-factors with such activity (Heinlein & 
Chang, 2002). For example, Steroid Receptor Co-activator 1 (SRC-1) has been shown to 
interact directly with AR and potentiate receptor activity via the recruitment of proteins with 
HAT activity, including CREB Binding Protein (CBP) and p300 (Powell et al., 2004).   
 Thus it is hypothesized that FUS may inhibit androgen-dependent cell cycle 
progression, in part, by directly targeting the AR and attenuating its activity. In support of 
this hypothesis, over-expression of FUS inhibited the ligand-dependent transcriptional 
activity of both transiently transfected AR (in the COS-1 cells) and stably transfected AR 
(in the prostate cancer cell line PC3wtAR) (Figures 4.1 and 4.2 respectively). Furthermore, 
this repression was evident on both the TAT-GRE-E1B-LUC and PROBASIN-PROM-LUC 
androgen responsive luciferase reporter plasmids (Figure 4.1). Thus the FUS-mediated 
repression of AR ligand-dependent transcriptional activity is not a consequence of the 
transient transfection of AR, nor a cell line or luciferase reporter specific effect.  
 FUS appears to have differential regulatory effects upon the transcriptional activity 
of human steroid nuclear receptors. FUS over-expression had no effect upon PR 
transcriptional activity, but did reduce the transcriptional activity of both GR and ERα by 
approximately 20% in COS-1 cells (Figure 4.4).  This however was much less than its 
effect on AR activity, which is reduced by approximately 70% in both COS-1 and PC3wtAR 
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cell lines (Figure 4.1 and 4.2). The transcriptional activity of the steroid nuclear receptors 
AR, PR and GR in COS-1 cells was measured from the TAT-GRE-E1B-LUC reporter 
plasmid, which contains a classical glucocorticoid response element (GRE) sub-cloned 
from the promoter of Tyrosine Aminotransferase (Verrijdt et al., 2002), to which the class I 
steroid nuclear receptors AR, GR and PR bind. The observed differential ligand-dependent 
transcriptional activity of AR, PR and GR measured on the TAT-GRE-E1B-LUC reporter 
plasmid in the presence of increasing FUS expression is unlikely to be due to the GRE 
sequence since AR, PR and GR will all bind to this sequence, although the relative 
receptor binding affinities to the plasmid GRE are unknown. Therefore, the differential FUS 
repressive capacity for steroid nuclear receptors is unlikely to be a response element 
specific effect, but a steroid receptor specific effect. The class II steroid nuclear receptor 
ERα does not bind to GREs (Verrijdt et al., 2003), therefore the transcriptional activity of 
ERα was measured on the luciferase reporter plasmid ERE-LUC which contains an 
oestrogen response element (ERE). 
 
4.6.2 FUS represses endogenous AR target gene expression 
 The LNCaP-FUS cell line, in which FUS expression is under the control of a 
doxycycline inducible promoter (as characterized in Figure 3.2), was employed as a more 
physiologically relevant system for examining the FUS-mediated repression of AR 
transcriptional activity, since FUS is exogenously expressed from a chromatinized 
template and also both the AR  and ARG are endogenously expressed. 
 The quantification of FUS RNA expression in the LNCaP-FUS cell line 
demonstrated that the induction of exogenous FUS expression at both 24 and 48 hours by 
doxycycline treatment was greatest in the presence of mibolerone compared to ethanol 
vehicle control treatment, increasing FUS expression by approximately 90% (Figure 4.5A). 
The enhanced exogenous FUS expression may be due to the proliferative stimulation 
induced upon mibolerone treatment, since the LNCaP-FUS cells were growth quiescent 
due to androgen deprivation for 72 hours prior to co-treatment with doxycycline and either 
mibolerone or ethanol.  
 The RNA expression of the known ARGs KLK2, DRG1, PSA and TMPRSS2, in the 
presence or absence of increased exogenous FUS expression (doxycycline treatment) in 
the LNCaP-FUS cell line, was used as a measure of AR transcriptional activity. In 
agreement with the literature (Lin et al., 1999; Riegman et al., 1991; Ulrix et al., 1999; 
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Young et al., 1992) these ARGs were up-regulated in response to androgen. In the 
presence of increased exogenous FUS expression (doxycycline treatment) the 
mibolerone-dependent induction of KLK2, DRG1, PSA and TMPRSS2 were decreased at 
both 24 and 48 hours of doxycycline treatment (Figure 4.5B-E). This provides further 
evidence to support the hypothesized FUS-mediated repression of AR ligand-dependent 
transcriptional activity. 
  
4.6.3 Reduced endogenous FUS levels has differential effects upon endogenous 
ARG expression 
 The reduction of endogenous FUS expression in LNCaP cells by siRNA was used 
to gain further insight into the FUS-mediated repression of AR transcriptional activity. From 
the observed decrease in ARG expression in response to increased exogenous FUS 
(Figure 4.5), it was hypothesized that depletion of FUS by siRNA may reduce the FUS-
mediated repression of the AR and therefore increase the transcriptional activity of this 
receptor.  
 Contrary to this hypothesis, siRNA FUS decreased expression of PSA and 
TMPRSS2 after 4 hours treatment with mibolerone or ethanol, and also decreased 
expression of the KLK2 and DRG1 after 8 hours treatment with mibolerone or ethanol 
(Figure 4.6). However, in support of the hypothesis, siRNA FUS significantly increased 
TMPRSS2 expression after 8 hours treatment with ethanol or mibolerone (Figure 4.6). 
Therefore, it is only the observed increase in expression of TMPRSS2 upon FUS over-
expression (Figure 4.5) and knock-down (only after 8 hours of mibolerone treatment) 
(Figure 4.6) that supports the hypothesized role of endogenous FUS as a negative 
regulator of AR transcriptional activity.  
 In support of the observed FUS-mediated transcriptional repression of the ARG 
TMPRSS2, FUS is reported to selectively repress gene transcription. For example non-
coding RNA (ncRNA) transcribed from the 5’ regulatory regions of Cyclin D1 binds to FUS 
and directs  this factor to the Cyclin D1 promoter where it inhibits the HAT activity of CBP 
and p300 (Wang et al., 2008). Furthermore, Brooke et al., demonstrated that upon 
reduction of FUS expression by siRNA, the expression of Cyclin D1 is up-regulated in 
LNCaP cells (Brooke et al., 2011). FUS is also reported to repress the transcription of RNA 
Polymerase III regulated genes, whereby FUS binds to the promoters of such genes and 
inhibits transcription, possibly via interaction and inhibition of the general transcription 
factor TATA Binding Protein (TBP) (Tan & Manley, 2010).  
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 The FUS knock-down data suggests FUS has differential regulatory effects upon 
several ARGs. In support of the role of FUS as a transcriptional activator, FUS is reported 
to act in synergy with Protein Arginine Methyltransferase (PRMT1) to activate the 
transcription of Survivin. FUS is arginine methylated by PRMT1, and this methylation 
activates FUS transcriptional activation activity at the Survivin promoter (Du et al., 2011). 
Also, FUS is reported to be a transcriptional activator of Nuclear Factor–κB family protein 
p-65 (NF-κB-p65) mediated transcription, since FUS enhances expression of NF–κB p65-
regulated gene Inter-Cellular Adhesion Molecule 1 (ICAM-1) in transcription reporter 
assays (Uranishi et al., 2001). 
 The dual transcriptional regulatory role of FUS may explain the differential ligand-
dependent transcriptional regulation of ARGs observed upon the reduction of FUS by 
siRNA in LNCaP cells (Figure 4.6). However, the observed decrease in expression of the 
ARGs KLK2, PSA, DRG1 and PSA upon increased exogenous FUS expression (Figure 
4.5) and also knock-down of FUS by siRNA are contradictory results, and the reason for 
this is unknown. The siRNA FUS used reduced FUS levels by only 60%, and repeating the 
examination of ARG expression in response to a greater reduction in FUS by using a more 
efficient siRNA FUS may help to reconcile this difference.   
 
4.6.4 FUS may inhibit ARG expression by interacting with the AR 
 The direct interaction of FUS with the AR is supported by GST interactions studies, 
which suggest a strong interaction with the DNA binding domain of the AR (unpublished 
data from Dr Charlotte Bevan’s laboratory Figure 1.23). Furthermore, Powers et al. have 
mapped the interaction of FUS with nuclear receptor DNA binding domains, including that 
of the ERα (Powers et al., 1998). This may suggest that FUS is able to inhibit the 
transcriptional activity of the AR by directly interacting with the DNA binding domain and 
inhibiting the binding of AR to androgen response elements, thereby inhibiting ARG 
expression, as observed in Figure 4.5. Therefore, the interaction of FUS with the AR and 
the mechanism(s) by which FUS inhibits AR activity requires further investigation.   
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5. Results-Part 3 
Investigation into the mechanism(s) by which FUS represses Androgen 
Receptor activity 
 
 FUS is a negatively regulated androgen target gene with the capacity to repress 
Androgen Receptor (AR) ligand-dependent transcriptional activity and inhibit androgen 
dependent growth in LNCaP cells (Brooke et al., 2011). These properties are unique to FUS 
within the TET family, suggesting an important role in androgen-regulated signalling.  
 AR transcriptional activity is modulated by co-regulatory proteins, including co-
activators that enhance AR transactivation and co-repressors that inhibit AR transactivation 
(Heemers & Tindall, 2007; Wang et al., 2005a). It is therefore hypothesized that FUS is a co-
repressor of the AR. Investigation into the mechanism(s) by which FUS influences the 
transactivation potential of the AR may provide further insight into the regulation of the AR 
signalling axis, which is maintained in prostate cancer development and progression, and is 
often aberrantly activated in hormone refractory prostate cancer (Feldman & Feldman, 
2001). Alterations in co-regulator expression is one such mechanism by which the AR may 
be aberrantly activated in hormone refractory prostate cancer (Feldman & Feldman, 2001; 
O'Malley & Kumar, 2009). Therefore, increased knowledge of the mechanism(s) by which 
co-regulators affect the AR signaling axis may lead to the discovery of drug targets for 
hormone refractory prostate cancer.  
 
5.1 Generation and validation of pM-GAL4-FUS expression plasmids  
 To investigate which regions of FUS contribute to repression of AR activity, full 
length FUS and shorter FUS domains were sub-cloned into the pM-GAL4-EMPTY plasmid 
by PCR amplification from template plasmid (pSG5-FUS) to generate GAL4 DNA binding 
domain (DBD) fused FUS expression plasmids A-F (Figure 5.1A). Successful in-frame 
sub-cloning of all pM-GAL4-FUS plasmids was confirmed by DNA sequencing.   
 FUS has a predicted nuclear export signal located at amino acids 514-526 and a 
nuclear import signal located at amino acids 289-298 (Dormann et al., 2010; Lanson et al., 
2011). Fluorescent confocal microscopy was performed to determine the expression and 
cellular location of GAL4-FUS proteins. COS-1 cells were transiently transfected with pM-
GAL4-FUS (FULL-E) plasmids, fixed and permeablized 24 hours after transfection. The 
cells were probed with GAL4-DBD specific antibody and Alexa Fluor 488-conjugated 
secondary antibody. Nuclear DNA staining was achieved by addition of 4’-6-Diamidino-2-
Figure 5.1. Schematic representing the FUS domains sub-cloned 5? of GAL4 DNA binding 
domain (DBD) to create plasmids pM-GAL4-FUS (FULL-E). Full length FUS and shorter FUS 
domains were PCR amplified from template plasmid pSG5-FUS and sub-cloned into plasmid pM-
GAL4-EMPTY, generating FUS and shorter FUS domains downstream and in frame with amino 
acids 1-147 of the GAL4 DBD. The FUS amino acid numbers cloned into plasmid pM-GAL4-
EMPTY are indicated below. The location of the FUS RNA recognition domain (RRM) and zinc 
finger binding domain (ZnF) is also indicated. 
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phenylindole (DAPI). GAL4-DBD tagged proteins were detected in COS-1 cells transfected 
with all pM-GAL4-FUS plasmids, and the GAL4-DBD tagged proteins were located in the 
nucleus as shown by overlap with the DAPI staining (Figure 5.2). Evidence for the specific 
staining of GAL4-DBD is provided by the observation that untransfected cells within each 
condition had no detectable Alexa Fluor 488 staining (Figure 5.2). 
 
5.2 FUS contains an intrinsic transcriptional activation domain 
 FUS was initially identified in chromosomal translocations found in multiple 
liposarcomas and acute myeloid leukemia, wherein the NH2-terminus of FUS is fused to 
the DBD of transcription factors including CCAAT Enhancer Binding Protein Homologous 
Protein (CHOP) and ETS Regulated Gene (ERG). The mapping of the break points of 
these fusion proteins identified a potent NH2-terminal activation domain in FUS (amino 
acids 1-267) (Crozat et al., 1993; Prasad et al., 1994), and this isolated NH2-terminal 
domain is able to activate transcription from a luciferase reporter construct when 
expressed in the HepG2 human liver carcinoma cell line (Zinszner et al., 1994).  
 To investigate the intrinsic transcriptional activity of full length FUS and shorter FUS 
domains, in trans, a transcriptional activation assay was performed. COS-1 cells were 
transiently co-transfected with a luciferase reporter plasmid (pGL2-LEXA-GAL4-LUC) 
containing both LEXA and GAL4 DNA binding elements in the promoter, and plasmids 
expressing either GAL4-DBD alone (pM-GAL4-EMPTY) as a control or GAL4-DBD tagged 
full length FUS or shorter domains (pM-GAL4-FUS FULL-E) (Figure 5.3A). Cell lysates 
were assayed for luciferase expression as described for Figure 4.1A, and luciferase 
activity in the presence of pM-GAL4-EMPTY set as 100%. Co-transfection with plasmid 
LEX-VP16, expressing the LEXA-DBD fused to the potent transcription activation factor 
VP16 (Sadowski et al., 1988), increased luciferase activity, serving as a positive control for 
this assay (Figure 5.3B).  
 Plasmids pM-GAL4-FUS D and F had no significant effect upon transcription 
(Figure 5.3B). Plasmids pM-GAL4-FUS FULL, B1, B2, B3, and E showed a modest 
increase in luciferase activity compared to the large increase in luciferase activity observed 
with  constructs FUS A and C, increasing luciferase activity to approximately 48000% and 
3600% respectively (Figure 5.3B).  
 FUS therefore appears to have a potent NH2-terminus activation domain contained 
within amino acids 1-366, and COOH-terminal extension abrogates this domain activity, for 
example GAL4-FUS C (amino acids 1-449) had a 16-fold lower luciferase activity than 
FULL 
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B3 
 
Merge GAL4 DBD DAPI 
Figure 5.2 (1 of 2). Intracellular localization of pM-GAL4-FUS by immunofluorescent 
confocal microscopy. COS-1 cells were transfected with 200ng of plasmid pM-GAL4-FUS (FULL-
B3) as indicated. Cells were harvested 24 hours after transfection and fixed for immuno-staining. 
Cells were permeabilized and stained with an antibody specific for GAL4 DNA binding domain 
(DBD) followed by Alexa Fluor 488 labeled secondary antibody. DNA was stained with DAPI. The 
images were captured and processed using a confocal laser-scanning microscope (magnification 
x100 and scale bar =10 µm).  
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Figure 5.2 (2 of 2). Intracellular localization of pM-GAL4-FUS by immunofluorescent 
confocal microscopy. COS-1ells were transfected with 200ng of plasmid pM-GAL4-EMPTY or 
pM-GAL4-FUS (C-F) as indicated. Cells were harvested 24 hours after transfection and fixed for 
immuno-staining. Cells were permeabilized and stained with an antibody specific for GAL4 DNA 
binding domain (DBD) followed by Alexa Fluor 488 labeled secondary antibody. DNA was stained 
with DAPI. The images were captured and processed using a confocal laser-scanning microscope 
(magnification x100 and scale bar =10 µm).  
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Figure 5.3. Characterization of the transcriptional activity of FUS domains. (A) Schematic of 
experimental setup. (B) COS-1 cells were transiently co-transfected with 100ng of β-galactosidase 
expression plasmid PDM-LACZ-βGAL, 1µg of luciferase reporter plasmid pGL2-LEXA-GAL4-LUC 
and either 200ng of pM-GAL4-EMPTY, pM-GAL4-MAD or pM-GAL4-FUS  plasmids (FULL-E) (as 
indicated in adjacent diagram). Cells were lysed 48 hours after transfection, and lysates were 
assayed for luciferase activity and normalized with β-galactosidase activity results. Results were 
expressed as a percentage of luciferase activity in the presence of pM-GAL4-EMPTY (value for 
which is show by red line). Results are the mean of 3 independent experiments repeated in 
quadruplicate ±1SE. **= P<0.005 (Student’s T test).  
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GAL4-FUS A (amino acids 1-366). This suggests there may be a transcriptional repression 
domain within FUS amino acids 366-449 (Figure 5.3B).  
 
5.3 FUS contains intrinsic transcription repression domains 
 Although FUS has transcriptional activation domains (Figure 5.3B), FUS acts as an 
overall repressor of AR activity (Figure 4.1 and 4.2). Therefore, a trans-repression assay 
was performed to identify any potential intrinsic repressor domains. The ability of full length 
FUS and shorter domains to repress, in trans, the potent transcription activation factor 
VP16 (Sadowski et al., 1988) was measured (as described by Christian et al., 2004). This 
assay is similar to the trans-activation assay described in section 5.2, with the additional 
co-transfection of the LEXA-DBD fused to the potent transcription activator VP16 (plasmid 
LEXA-VP16), which is present throughout the assay. Plasmid LEXA-VP16 was co-
transfected with the GAL4-DBD fused FUS constructs and a luciferase reporter containing 
both GAL4 and LEXA response elements (Figure 5.4A). The ability of FUS constructs 
(FULL-E) to repress VP16 induced transcriptional activity was measured by luciferase 
activity assays as previously described (section 2.5.1), and the observed activity in the 
presence of LEXA-VP16 and pM-GAL4-EMPTY was set as 100% (Figure 5.4B).  
 Plasmid pM-GAL4-MAD (Max Dimerization Protein 1 (MAD) amino acids 250-278), 
expressing a known transcriptional repressive domain (Dr Greg Brooke, unpublished) 
served as a positive control, significantly decreasing the lucifersae activity of LEXA-VP16 
(Figure 5.4B). Luciferase activity was also decreased upon transfection with plasmids pM-
GAL4-FUS FULL, D and F, with the greatest decrease in luciferase activity observed for 
FUS domains D and F, reducing luciferase activity to approximately 34% and 20% 
respectively (Figure 5.4B). Conversely, transfection with plasmids pM-GAL4-FUS B1, B2, 
B3 and E showed a modest increase in luciferase activity compared to transfection with 
pM-GAL4-FUS A and C which increased luciferase activity to approximately 2800% and 
800% respectively (Figure 5.4B), supporting the data in Figure 5.3B where FUS domains A 
and C exhibit intrinsic potent transcriptional activation activity. 
 Comparison of the repressive activity of FUS constructs D, E and F, suggests that 
COOH-terminal amino acids 367-526 are essential for FUS-mediated transcriptional 
repressive activity, since deletion of amino acids 367-425 containing a FUS R/G rich 
domain (Figure 1.14) results in loss of repressive capacity. Therefore, amino acids 367-
425 appear to be essential but not sufficient for FUS COOH-terminal transcriptional 
repressive activity, since FUS B3 (amino acids 367-425) has transcriptional activation 
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Figure 5.4. Characterization of the transcriptional repressive potential of FUS domains. (A) 
Schematic of experimental setup. (B) COS-1 cells were transiently cotransfected with 100ng of β-
galactosidase expression plasmid PDM-LACZ-βGAL, 1µg of a luciferase reporter plasmid pGL2-
LEXA-GAL4-LUC, 100ng of plasmid LEXA-VP16 and either 200ng of plasmid pM-GAL4-EMPTY, 
pM-GAL4-FUS (FULL-E) or pM-GAL4-MAD. Cells were lysed 48 hours after transfection, and 
lysates were assayed for luciferase activity and normalized with β-galactosidase activity results. 
Data is expressed as a percentage of luciferase activity in the presence of LEXA-VP16 and pM-
GAL4-EMPTY plasmids (value for which is show by red line). Results are the mean of 3 
independent experiments repeated in quadruplicate ±1SE. * = P<0.05 and **= P<0.005 (Student’s 
T test).  
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activity. Hence FUS appears to have both a NH2-terminal intrinsic transcription activation 
and COOH-terminal transcriptional repression domain.  
 
5.4 FUS domains can both activate and repress the ligand-dependent transcriptional 
activity of AR  
 Having shown that full length FUS can repress the ligand-dependent transcriptional 
activity of AR (Figure 4.1), and given that both a transcriptional repression and activation 
domain have been identified within FUS (Figure 5.3B and 5.4B), the effect of shorter FUS 
domains on AR ligand-dependent transcriptional activity was investigated. Luciferase 
reporter assays were performed to measure the transcriptional activity of the AR on an 
androgen responsive luciferase reporter (TAT-GRE-E1B-LUC) in the presence of the 
GAL4-DBD fused FUS domains (Figure 5.5A) as previously described in Figure 4.1A. 
Results are expressed as a percentage of luciferase activity after 24 hours treatment with 
mibolerone in the absence of pSG5-FUS or pM-GAL4-FUS plasmids.  
 Co-transfection with 400ng of pM-GAL4-FUS or pSG5-FUS reduced AR activity to 
approximately 29% and 26% respectively and there was no statistical difference between 
the two plasmids (Figure 5.5B), demonstrating that the addition of the GAL4-DBD domain 
to FUS does not affect the AR repressive capacity of FUS. 
 All FUS constructs, apart from construct FUS B2, had a significant effect upon AR 
activity compared to PM-GAL4-EMPTY (p≤0.05), with FUS constructs FULL, A, B1, B3, C 
and D decreasing AR activity and FUS constructs E and F increasing receptor activity to 
approximately 227% and 166% respectively (Figure 5.5B). There is no statistical difference 
between the repressive capacity of plasmids pM-GAL4-FUS FULL and plasmids pM-
GAL4-FUS A and C, reducing AR activity to approximately 29%, 34% and 24% 
respectively (Figure 5.5B). Conversely, plasmids pM-GAL4-FUS B1, B2, B3 and D showed 
reduced AR repressive capacity compared to pM-GAL4-FUS FULL, reducing AR activity to 
approximately 63%, 91%, 73%, and 38% respectively (Figure 5.5B).  
 These results confirm that full length FUS is able to repress the ligand-dependent 
activity of the AR. The shorter FUS domains have different effects upon the ligand-
dependent activity of the AR, with NH2-terminal amino acids 1-366 (inclusive of the RNA 
recognition motif (RRM)) required for maximal repression, whereas the COOH-terminal 
426-526 amino acids appear to enhance the ligand-dependent transcription activity of the 
AR.  
 
Plasmid(s) transfected 0 50 100 150 200 250 
% luciferase activity 
Figure 5.5. The effect of FUS truncations upon Androgen Receptor (AR) ligand-dependent 
transcriptional activity in COS-1. (A) Schematic of experimental setup. (B) Cells were transiently 
co-transfected with 50ng of AR expression plasmid pSVAR, 100ng of β-galactosidase expression 
plasmid PDM-LACZ-βGAL, 1µg of an AR responsive luciferase reporter plasmid TAT-GRE-E1B-
LUC and 400ng of pM-GAL4-FUS (FULL-E) as indicated in adjacent diagram, pSG5-FUS, pM-
GAL4-EMPTY or pSG5-EMPTY. Cells were incubated for 24 hours with 10nM mibolerone or 
ethanol prior to lysis. Cell lysates were assayed for luciferase activity and normalized with β-
galactosidase data. Results were expressed as a percentage of AR activity after 24 hours of 10nM 
mibolerone  in the absence of pSG5-FUS or pM-GAL4-FUS (value indicated by red line, and 
dashed line distinguishes between pSG5-FUS and pM-GAL4-FUS transfections). Results are the 
mean of 3 independent experiments repeated in duplicate ±1stardard error. ** = P<0.005 
(Student’s T test). 
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 The RRM alone is unable to repress the activity of AR (construct FUS B2, amino 
acids 288-366). However, deletion of the RRM from construct D which has AR repressive 
activity, generates constructs E and F (amino acids 426-526 and 367-526 respectively) 
which enhance AR activity, suggesting the RRM may be essential, although not sufficient, 
for FUS NH2-terminal mediated repression of the AR (Figure 5.5B).  
 
5.5 FUS associates with the AR  
 Glutathione-S-Transferase (GST) pull down studies identified FUS as a binding 
partner of nuclear receptors including Retinoid-α and Thyroid Receptor and steroid 
receptors ERα and GR (Powers et al., 1998). Deletion studies of GST-fused nuclear 
receptors suggest that FUS binds to the nuclear receptor DBD and flanking regions 
(Powers et al., 1998). In support of Powers et al., GST interaction studies demonstrated a 
strong association between FUS and the AR-DBD, and a weaker interaction with AF2-LBD 
and the AF2-LBD-HINGE in the presence of bicalutamide. A weak interaction with AF1 
was also observed (unpublished data from Dr Charlotte Bevan’s laboratory Figure 1.23).  
 Given that full length FUS and shorter FUS domains can differentially modify the 
ligand-dependent transcriptional activity of AR (Figure 5.5B), a mammalian 2-hybrid 
interaction assay was performed to determine which domains of FUS interact with full 
length AR. COS-1 cells were transiently co-transfected with a luciferase reporter plasmid 
containing GAL4 DNA binding elements in the promoter (5GAL-TATA-LUC), a VP16 fused 
human AR expression plasmid (VP16-AR) as ‘prey’, a GAL4-DBD fused FUS expression 
plasmid (pMGAL4-FUS FULL-F) or pM-GAL4-EMPTY as ‘bait’ (Figure 5.6A). Co-
transfection with a plasmid expressing a known AR interaction amino acid motif ‘FXXLF’ 
fused with GAL4-DBD (pM-GAL4-FXXLF) served as a positive ‘bait’ control. The 
transfected cells were harvested after 24 hours incubation with either 10nM mibolerone or 
1µM bicalutamide (an AR antagonist), or ethanol vehicle control. Cells were assayed for 
luciferase activity as described for Figure 4.1 and results are expressed as a percentage 
of luciferase activity in the presence of pM-GAL4-EMPTY and mibolerone.  
 Co-transfection of the AR positive interacting motif FXXLF plasmid (pM-GAL4-
FXXLF) showed a significant mibolerone-dependent increase in luciferase activity (Figure 
5.6B). This assay is not as informative as it could be, since it is not possible to distinguish 
between activity caused by intrinsic FUS transcriptional activity and that due to FUS 
Figure 5.6. Mammalian 2-hybrid interaction assay between full length Androgen Receptor 
(AR) and either full length FUS or shorter FUS domains in COS-1. (A) Schematic of 
experimental set up. (B) Cells were transiently co-transfected with 1ug of luciferase reporter 
plasmid 5-GAL-TATA-LUC, 100ng of β-galactosidase expression plasmid PDM-LACZ-βGAL, 100ng 
of plasmid VP16-AR and 200ng of pM-GAL4-FUS plasmids (as depicted in adjacent figure), 
pMGAL4-EMPTY or pM-GAL4-FXXLF. Cells were harvested after incubation for 24 hours with 
10nM mibolerone, 1µM bicalutamide or ethanol as vehicle control. Cell were lysed and assayed for 
luciferase activity, and normalized with β-galactosidase results and expressed as a percentage of 
luciferase activity in the presence of pM-GAL4-EMPTY and VP16-AR in the presence of 
mibolerone. Results are the mean of 3 independent experiments repeated in duplicate ±1SE. 
Significant differences between ethanol treatment and mibolerone or bicalutamide are shown, 
where * = P<0.05 ** = P<0.005 (Student?s T test).  
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interaction with AR-VP16 in the absence of ligand. However a ligand-dependent change in 
luciferase activity does suggest ligand-dependent interaction with VP16-AR.  
 A large increase in luciferase activity was observed for FUS domains A and C (pM-
GAL4-FUS A and C), in the presence of all treatment conditions. This is likely due to the 
intrinsic transcriptional activation activity of these domains (Figure 5.3B), which may mask 
an enhancement in luciferase production due to interaction with VP16-AR. However, there 
is a significant mibolerone-dependent increase in luciferase activity with FUS domain A 
(pM-GAL4-FUS A), and a significant decrease in luciferase activity upon bicalutamide 
treatment of FUS domain C (Figure 5.6B).  
 FUS domains B1, B2 and D (pM-GAL4-FUS B1, B2 and D) show a mibolerone-
dependent increase in luciferase activity, whereas bicalutamide treatment resulted in 
similar luciferase activity levels to that observed with ethanol treatment (Figure 5.6B). 
However, no increase in luciferase activity was observed upon transfection with FUS FULL 
and FUS domain B3, E and F (pM-GAL4-FUS FULL, B3, E and F) in the presence of 
mibolerone, suggesting these constructs do not interact with the AR (Figure 5.6B).  
 This data suggests a ligand-dependent interaction between FUS and the AR, which 
is dependent upon the RRM domain, since deletion of this domain diminished interaction 
with the AR.  
 
5.6 FUS represses the AR transcriptional activity in part via AR domains Tau1, Tau5 
and the AR ligand binding domain (LBD) 
 Unpublished GST interaction studies from Dr Bevan’s laboratory indicate FUS 
interacts with the AF1, AF2 and DBD of the AR (Figure 1.23) and a mammalian 2-hybrid 
assay suggest the association of FUS and the AR (Figure 5.6B). Deletion constructs of the 
AR were therefore used to determine the functional domains of the AR that are important 
for the FUS-mediated repression of AR transcriptional activity.  
 To investigate the importance of FUS association with the AR ligand binding 
domain (containing the AF2) upon FUS-mediated repression of the AR, reporter assays 
were performed to measure the activation of an androgen responsive luciferase reporter 
plasmid (TAT-GRE-E1B-LUC) in the presence of the constitutively active human AR 
expression plasmid lacking the LBD (ARΔLBD) (Jenster et al., 1991) and increasing 
amounts of a FUS expression plasmid (pSG5-FUS). Cells were assayed for luciferease 
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activity after 48 hours as described for Figure 4.1 and results expressed as a percentage 
of ARΔLBD activity in the absence of pSG5-FUS (Figure 5.7A).  
 FUS is able to repress the activity of ARΔLBD, with a maximal 37% reduction in 
luciferase activity with 400ng of pSG5-FUS (Figure 5.7B). FUS is able to repress full length 
AR by 69% (Figure 4.1A) and although these two data sets are not directly comparable, 
the reduction in FUS repressive potency on ARΔLBD suggests that FUS interaction with 
the LBD is required for maximal AR repression.  
 To investigate the importance of the association of FUS with the AR AF1 domain on 
the FUS-mediated repression of the AR, deletion constructs of the AF1 were utilized. The 
AF1 domain appears to be the predominant AR activation function as demonstrated by 
deletion studies, where deletion of AF2 (containing the ligand binding domain) results in a 
constitutively active AR receptor fragment with analogous activity to ligand activated full 
length AR (Jenster et al., 1991; Zhou et al., 1994). Jenster et al., have defined two 
transcription activation units (Tau) within the AF1, firstly Tau1 (amino acids 100-370) which 
is necessary for full length AR activation, and secondly Tau5 (amino acids 360-529) which 
is required for autonomous activation function of ARΔLBD (Jenster et al., 1995). To 
investigate the importance of Tau1 and Tau5 upon FUS-mediated AR repression, reporter 
assays were performed to measure activation of an androgen responsive luciferase 
reporter (TAT-GRE-E1B-LUC) in the presence of AR Tau deletion plasmids ARΔτ1 or 
ARΔτ5 (as depicted in Figure 5.8A) and increasing amounts of a FUS expression plasmid 
(pSG5-FUS). Cells were treated and assayed for luciferase activity as described for Figure 
4.1. Results are expressed as a percentage of full length AR (plasmid pSVAR) luciferase 
activity after 24 hours treatment with mibolerone in the absence of pSG5-FUS (Figure 
5.8B).  
 In agreement with Jenster et al., deletion of Tau1 in plasmid ARΔτ1 reduced the 
ligand-dependent transcriptional activation capacity of the AR by almost 60% (Figure 5.8B) 
(Jenster et al., 1995). However, in contrast to Jenster et al., who reported a 40% reduction 
in ligand-dependent activity of AR upon transfection of ARΔτ5 in HeLa cells (Jenster et al., 
1995), no significant difference in AR ligand-dependent transcription activity was observed 
between pSVAR and ARΔτ5 (Figure 5.8B). This discrepancy in construct activity may be 
due to different cell line and luciferase reporter plasmid usage. 
 To allow for comparison between the different AR constructs, the data was 
expressed as a percentage of luciferase activity upon co-transfection with either pSVAR, 
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Figure 5.7. The effect of FUS upon the transcriptional activity of the Androgen Receptor (AR) 
lacking the ligand binding domain (ARΔLBD) in COS-1 cells. (A) Representative diagram of full 
length AR and ARΔLBD constructs. (B) Cells were transiently co-transfected with 50ng of 
expression plasmid ARΔLBD, 1µg of a luciferase reporter plasmid TAT-GRE-E1B-LUC, 100ng of a 
β-galactosidase expression plasmid PDM-LACZ-βGAL and increasing amounts of the FUS 
expression plasmid pSG5-FUS. Cells were lysed 48 hours after transfection and cell lysates 
assayed for luciferase activity and normalized to β-galactosidase activity. Data was expressed as a 
percentage of AR activity in the absence of pSG5-FUS. Results are the mean of 3 independent 
experiments repeated in duplicate ±1SE. * = P<0.05 (Student’s T test). 
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Figure 5.8. The effect of FUS upon the activity of the Androgen Receptor (AR) lacking 
transcriptional activation domain 1 (AR∆τ1) and transcriptional activation domain 5 (AR∆τ5), 
in COS-1 cells. (A) The structure of AR expressed from expression plasmids pSVAR, AR∆τ1 and 
AR∆τ5. (B) Cells were transiently co-transfected with either 50ng of AR expression plasmids 
pSVAR, AR∆τ1 or AR∆τ5 as indicated, 1µg of AR responsive luciferase reporter (TAT-GRE-E1B-
LUC), 100ng of a β-galactosidase expression plasmid PDM-LACZ-βGAL and increasing amounts 
of a FUS expression plasmid pSG5-FUS as indicated. Cells were incubated for 24 hours with 
10nM mibolerone or ethanol vehicle control prior to lysis. Cell lysates were assayed for luciferase 
activity, and normalized with β-galactosidase activity. (B) Data was expressed as a percentage of 
full length AR activity in the absence of pSG5-FUS after 24 hours treatment with 10nM mibolerone. 
(C) To allow for comparison between AR constructs the data was expressed as a percentage of AR 
activity (full length, ∆τ1 and ∆τ5) in the absence of pSG5-FUS. Results are the mean of 3 
independent experiments repeated in duplicate ±1SE. * = P<0.05 ** = P<0.005 (Student?s T test). 
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ARΔτ1 or ARΔτ5 in the absence of pSG5-FUS (Figure 5.8C). Transfection of 200ng and 
400ng of pSG5-FUS reduced the ligand-dependent transcription activity of pSVAR by 
approximately 45% and 65% respectively (Figure 5.9C). Deletion of Tau1 or Tau5 
significantly reduced the AR repressive capacity of FUS. Co-transfection with 200ng of 
pSG5-FUS had no significant effect upon the ligand-dependent transcription activity of 
ARΔτ1, and reduced ARΔτ5 ligand-dependent transcription activity by approximately 20% 
(Figure 5.8C), and co-transfection with 400ng pSG5-FUS reduced ARΔτ1 and ARΔτ5 
ligand-dependent luciferase activity by approximately 50% and 40% respectively (Figure 
5.8C). Thus the AR repressive capacity of FUS is reduced upon deletion of either Tau1 or 
Tau5. This suggests that both Tau1 and Tau5 within the AF1 domain are important for 
maximal AR repressive activity of FUS.  
 
5.7 FUS interacts with AR transcriptional co-activators  
 FUS is reported to interact with and repress the HAT activity of the transcription co-
activator proteins CBP and p300 (Wang et al., 2008). AR signalling is dependent upon the 
HAT activity of CBP and p300, since selective inhibition of both CBP and p300 abrogated 
the androgen-dependent transcription from an AR responsive luciferase reporter plasmid 
(Huang et al., 2003). Furthermore, chromatin immunoprecipitation studies demonstrated 
both CBP and p300 are recruited to the androgen receptor transcription complex formed at 
the promoter of the androgen regulated gene PSA (Prostate Specific Antigen) (Huang et 
al., 2003; Kang et al., 2002; Shang et al., 2002), and both CBP and p300 have been 
shown to interact with the AR (Aarnisalo et al., 1998; Fu et al., 2000). 
 The interaction of FUS and shorter FUS domains with known AR transcriptional co-
activator proteins ARA70, SRC-1, CBP and p300 (reviewed in (Culig et al., 2004; Xu et al., 
2009) was investigated. Transcription assays were performed to measure the activation of 
a luciferase reporter plasmid containing GAL4 DNA binding elements in the promoter 
(5GAL-TATA-LUC) in the presence of the GAL4-DBD fused FUS domains and 
transcriptional cofactors p300 (cMVB-p300), CBP (pSIR-SV-MC-CBP-HA), ARA70 (pSG5-
ARA70), SRC-1 (pSG5-SRC-1) or pSG5-EMPTY as empty plasmid control (Figure 5.9A). 
Cells were assayed for luciferase activity after 48 hours as described for Figure 4.1A. 
Results are expressed as a percentage of luciferase activity in the absence of co-activator 
expression plasmids and in the presence of plasmids pSG5-EMPTY and pM-GAL4-
EMPTY. Co-transfection with pM-GAL4-EMPTY served as a negative control in this assay, 
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Figure 5.9. The association of FUS with transcriptional co-activators CBP, SRC-1, ARA70 
and p300 in COS-1. (A) Schematic of experimental set up. (B) Cells were transiently co-
transfected with 1µg luciferase of reporter plasmid 5-GAL-TATA-LUC, 100ng of β-galactosidase 
expression plasmid PDM-LACZ-βGAL and either 200ng of pM-GAL4-FUS plasmid (FULL-E) (as 
depicted) or pM-GAL4-EMPTY. In addition cells were co-transfected with 200ng of co-activator 
expression plasmids pRSIR-SV-MC-CBP-HA, pSG5-SRC-1, pSG5-ARA70, cMVB-p300 or pSG5-
EMPTY. Cells were harvested and lysed 48 after transfection. Cell lysates were assayed for 
luciferase activity, and normalized with β-galactosidase activity. Results and expressed as a 
percentage of luciferase activity in the presence of pM-GAL4-EMPTY and pSG5-EMPTY. Results 
are the mean of 2 independent experiments repeated in duplicate ±1SE. Statistical difference 
shown between pM-GAL4-FUS in the presence of pSG5-EMPTY or coactivator expression 
plasmid, where * = P<0.05 ,** = P<0.005  and NS=not significant (Student?s T test). 
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and no significant increase in luciferase activity was detected upon co-transfection of this 
with the co-activator expression plasmids (Figure 5.9B).  
 No significant increase in luciferase activity was detected upon co-transfection with 
expression plasmids for transcription co-activators and full length FUS and the shorter 
FUS domains D, E and F (Figure 5.9B), suggesting these constructs do not interact with 
the co-activators. In agreement with previous experiments (Figure 5.3B and 5.4B), 
plasmids FUS A and C auto-activate the 5-GAL-LUC luciferase reporter plasmid, however 
there is a significant increase in luciferase activity compared to pSG5-EMPTY upon co-
transfection of FUS domain A and C with co-activator ARA70, and FUS domain A with 
SRC-1 and p300 (Figure 5.9B). Therefore, the FUS NH2-terminus associates with known 
AR transcriptional co-activators ARA70, SRC-1 and p300.  
 
5.8 The FUS-mediated repression of AR is independent of histone deacetylase 
(HDAC) class I and II activity 
 Co-repressors have been demonstrated to reduce nuclear receptor activity, in part, 
via recruitment of HDAC activity. HDACs promote local repressive chromatin conformation 
by removal of acetyl groups from lysine residues of histones, promoting chromatin 
condensation and transcription silencing (reviewed in (Glass & Rosenfeld, 2000). For 
example, the AR transcriptional co-repressor ARR19 has been shown to interact directly 
with the AR and recruit HDAC4. Furthermore, chromatin immunoprecipitation studies 
revealed the AR, HDAC4 and ARR19 are co-recruited to an androgen response element 
in the promoter of an androgen responsive reporter plasmid in vitro (Jeong et al., 2004). A 
further example is Nuclear Receptor Co-repressor (NCoR) which represses AR 
transcriptional activity via recruitment of HDAC3 (Li et al., 2000). 
 The HDAC class I and II specific inhibitor trichostatin A (Yoshida et al., 1990), class 
I and class IIa specific inhibitors valproic acid (Gottlicher et al., 2001; Gurvich et al., 2004), 
class I inhibitor sodium butyrate (Sealy & Chalkley, 1978) and class III inhibitor 
nicotinamide (Bitterman et al., 2002; Imai et al., 2000) were utilized to determine whether 
the FUS-mediated repression of AR ligand-dependent transcriptional activity is dependent 
upon HDAC activity. Reporter assays were performed in COS-1 cells to measure the 
activation of an androgen responsive luciferase reporter (TAT-GRE-E1B-LUC) by 
transiently transfected AR, in the presence of HDAC inhibitors. Cells were treated for 24 
hours with 10nM mibolerone or ethanol vehicle control, and simultaneously co-treated with 
either 5mM valproic acid, sodium butyrate, nicotinamide or 100nM trichostatin A. HDAC 
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inhibitors were administered to the cells at concentrations reported to impair endogenous 
HDAC activity and to be non-toxic to cells (Bitterman et al., 2002; Earel et al., 2006; 
Gamble et al., 2007; Ma et al., 2010; Phiel et al., 2001). Cells were assayed for luciferase 
activity as described for Figure 4.1A. Results are expressed as a percentage of luciferase 
activity after 24 hours treatment with 10nM mibolerone in the absence of HDAC inhibitors 
(Figure 5.10A).  
 All of the HDAC inhibitors increased ligand-dependent luciferase activity in the 
presence of 10nM mibolerone (Figure 5.10A), confirming that at the concentrations used 
HDAC inhibitors were able to inhibit HDAC activity and increase the ligand-dependent 
transcriptional activity of the AR. Furthermore, Western blot analysis of cell lysates from 
the experiment shown in Figure 5.10A showed an increase in global Histone H3 
acetylation upon treatment with valproic acid, sodium butyrate and trichostatin A. No 
change in global H3 acetylation was observed upon treatment with nicotinamide (Figure 
5.10B).  
 To determine whether the FUS-mediated repression of AR is dependent upon 
HDAC activity, COS-1 cells were co-transfected as in Figure 5.10A with the addition of a 
FUS expression plasmid (pSG5-FUS). To account for the differential activity of AR in the 
presence of HDAC inhibitors (Figure 5.10A), data was expressed as a percentage of 
luciferase activity after 24 hours of treatment with 10nM mibolerone in the absence of 
pSG5-FUS and the presence of individual HDAC inhibitors as indicated. The addition of 
200ng pSG5-FUS in the absence of HDAC inhibitors reduced the ligand-dependent 
luciferase activity of the AR to approximately 32% (Figure 5.10C). No significant difference 
in FUS repressive capacity of AR transcriptional activity was detected upon addition of any 
of the HDAC inhibitors tested (Figure 5.10C), indicating the FUS-mediated repression of 
AR transcriptional activity is HDAC class I and II-independent. However, due to the 
absence of a positive control demonstrating nicotinamide inhibits HDAC III activity, it is not 
proven that the FUS-mediated repression of AR activity is HDAC class III independent.   
 To explore further the role of HDAC activity in FUS-mediated repression, the FUS 
transcriptional repressive constructs D and F identified previously (Figure 5.4) were 
assayed for their ability to repress the potent transcriptional activator VP16 in the presence 
of HDAC inhibitors in a trans-repression assay (as described by Christian et al., 2004 and 
Figure 5.4). The addition of HDAC inhibitors had a differential effect upon luciferase 
activity in the presence of pM-GAL4-EMPTY (Figure 5.11B). To account, for this the data 
was expressed as a percentage of luciferase activity in the presence of LEXA-VP16 and
(A) 
Figure 5.10. (A) The effect of histone deacetylase (HDAC) inhibitors on FUS-mediated 
repression of androgen receptor (AR) transcriptional activity in COS-1 cells. (A) Cells were 
transiently co-transfected with 50ng of the AR expression vector pSVAR, 100ng of β-galactosidase 
expression vector PDM-LACZ- βGAL and 1µg of the AR responsive luciferase reporter TAT-GRE-
E1B-LUC. Cells were incubated for 24 hours with 10nM mibolerone or ethanol and co-incubated 
with HDAC inhibitors, trichostatin A (100nM), nicotinamide (5mM), sodium butyrate (5mM) or 
valproic acid (5mM). Cells were harvested after 24 hours of treatment, and cell lysates were 
assayed for luciferase activity, and normalized with β-galactosidase data. Results were expressed 
as a percentage of AR activity after 24 hours treatment with 10nM mibolerone in the absence of 
HDAC inhibitors. (B) Lysates from experiment (A) where cells were co-treated with ethanol and the 
indicated HDAC inhibitor in the absence of pSG5-FUS were collected after luciferase and β-
galactosidase assays were performed. Lysates were resolved by SDS-PAGE and Western blot 
analysis performed, immuoblotting with antibodies specific for β-actin and acetyl H3 (specific for H3 
acetylation at K9 and K14). (C) Cells were transfected as in (A), with additional co-transfection of 
200ng pSG5-FUS. To account for the differential effect of HDAC inhibitors on AR ligand-dependent 
activity, data was expressed as a percentage of AR activity after 24 hours treatment with 10nM 
mibolerone in the absence of pSG5-FUS and in the presence of individual HDAC inhibitors. Results 
are the mean of 3 independent experiments repeated in duplicate ±1stardard error, where ns= non 
significant and ** = P<0.005 (Student?s T test).  
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Figure 5.11. The effect of histone deacetylase (HDAC) inhibitors on the intrinsic repression 
domains of FUS in COS-1. (A) Schematic of the experimental setup. (B) Cells were transiently 
co-transfected with 100ng of β-galactosidase plasmid PDM-LACZ-βGAL, 1µg of reporter construct 
plasmid pGL2-LEXA-GAL4-LUC, and 50ng of plasmid LEXA-VP16 and either 100ng of plasmids 
pM-GAL4-EMPTY or pM-GAL4-FUS (FULL, D and F). Cells were incubated for 24 hours with 
either HDAC inhibitor trichostatin A (100nM), nicotinamide (5mM), sodium butyrate (5mM) or 
valproic acid (5mM) prior to lysis. Cell lysates were assayed for luciferase activity and luciferase 
activity normalized with β-galactosidase activty. Data is expressed as a percentage of luciferase 
activity in the presence of LEXA-VP16 and pM-GAL4-EMPTY plasmids 24 hours after ethanol 
vehicle control treatment. (C) Data from (B) was re-plotted to account for the differential effect of 
HDAC inhibitors on pMGAL4-EMPTY luciferase activity, where data is expressed as a percentage 
of luciferase activity in the presence of LEXA-VP16 and pM-GAL4-EMPTY 24 hours after treatment 
with HDAC inhibitors or ethanol. Results are the mean of 3 independent experiments repeated in 
quadruplicate ±1SE. * = P<0.05. 
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pM-GAL4-EMPTY after 24 hours treatment with HDAC inhibitor or ethanol as vehicle 
treatment control (Figure 5.11C). In agreement with data in Figure 5.4, full length FUS and 
shorter FUS domains D and F (pM-GAL4-FUS FULL, D and F) possess intrinsic 
transcriptional repressive activity, repressing in trans the VP16 dependent luciferase 
activity to approximately 31%, 17% and 16% respectively (Figure 5.11C). The 
transcriptional repressive capacity of pMGAL4-FUS D and F was unaffected by the 
addition of HDAC inhibitors. However, the ability of full length FUS (pM-GAL4-FULL) to 
inhibit, in trans, the transcriptional activity of VP16, was reduced in the presence of 5mM 
nicotinamide, increasing luciferase activity from 31% to 42% (Figure 5.11C), indicating that 
in this system, class III HDACs may be involved in the repression of AR activity by full 
length FUS, although in the absence of a positive control to demonstrate nicotinamide is 
active, this is not proven for class III HDACs. 
 
5.9 FUS may not be recruited to the androgen-regulated genes TMPRSS2 and PSA 
 FUS can repress transcription via recruitment to gene promoters, including the 
Cyclin D1 promoter, where it has been shown to inhibit the HAT activity of CBP and p300 
(Wang et al., 2008). Furthermore, FUS is recruited to several RNA Polymerase III-
regulated promoters where it represses transcription, possibly via interaction with TATA-
Binding Protein (TBP) (Tan & Manley, 2010). Having shown that increased exogenous 
FUS expression decreases the expression of the androgen-regulated gene (ARG) 
Transmembrane Protease Serine-2 (TMPRSS2) (Figure 4.5), and decreased endogenous 
FUS expression increased TMPRSS2 expression in LNCaP cells (Figure 4.6), it was 
hypothesized that FUS may repress the ligand-dependent transcriptional activity of the AR 
at promoter regions of ARGs. To investigate this hypothesis chromatin 
immunoprecipitation was performed in the LNCaP-FUS cell line, where FUS is under the 
control of a doxycycline-inducible promoter (as characterized in Figure 3.2), to examine 
whether FUS is recruited to TMPRSS2 androgen response elements and whether 
increased exogenous FUS expression alters AR recruitment at these regions. LNCaP-FUS 
cells were androgen-deprived in the presence or absence of 10nM doxycycline for 72 
hours prior to treatment with 10nM mibolerone or vehicle control ethanol for 2 hours and 
then chromatin immunoprecipitation was performed.  
 To examine FUS and AR recruitment at the TMPRSS2 promoter, the recovered 
DNA was used as a template for quantitative real time PCR (qRT-PCR) using primers 
specific for five putative androgen response elements (I-V) identified by Wang et al., 
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located between -770 and -13545 base pairs upstream of the TMPRSS2 transcription start 
site (Figure 5.12A) (Wang et al., 2007). These TMPRSS2 androgen response elements 
were identified by sequence homology to known AR-binding motifs, and subsequent AR 
chromatin immunoprecipitation analysis in LNCaP cells confirmed AR recruitment to 
TMPRSS2 androgen response element V (located at -13545 base pairs) in the presence 
of androgen (Wang et al., 2007). In agreement with Wang et al., AR recruitment was 
detected at TMPRSS2 androgen response element V (Figure 5.12F), and AR association 
was not detected at TMPRSS2 androgen response element II and III (Figure 5.12C and 
D). In contrast to Wang et al., AR recruitment was also detected at androgen response 
element IV and to a lesser extent at response element I (Figure 5.12E and B) (Wang et al., 
2007). Co-treatment of LNCaP-FUS cells with 10nM mibolerone and 10nM doxycycline 
increased the association of AR at TMPRSS2 androgen response elements I, IV and V 
(Figure 5.12B, E and F). In the absence of mibolerone, no increase in AR binding was 
evident following treatment with doxycycline. Also, no evidence of FUS association with 
any TMPRSS2 androgen response elements (I-V) was observed (Figure 5.12B-F).  
 In addition to TMPRSS2, increased exogenous FUS expression in LNCaP-FUS 
cells also reduced the ligand-dependent transcription of the ARG Prostate specific Antigen 
(PSA) (Figure 4.5). To determine whether FUS is recruited to the PSA promoter, where it 
may mediate its transcriptional repressive activity, qRT-PCR was performed using primers 
specific for the characterized enhancer androgen response element located approximately 
4000 base pairs upstream of the PSA transcription start site (Shang et al., 2002) (Figure 
5.13A), and also primers for a non-androgen response binding element region 
approximately 2000 base pairs upstream were used as a negative control (Figure 5.13A). 
In agreement with Shang et al., ligand-dependent AR recruitment was detected at the PSA 
enhancer region and no binding was evident at the negative region (Figure 5.13B) (Shang 
et al., 2002). This binding was further enhanced in the presence of increased exogenous 
FUS expression (doxycycline treatment) (Figure 5.13B). However, FUS association with 
PSA enhancer androgen response element and negative region was not detected (Figure 
5.13B).  
 
5.10 FUS-mediated inhibition of AR ligand-dependent transcription activity is 
inhibited by plasmid pTER-EMPTY 
 The FUS-mediated transcriptional repression of Cyclin D1 is dependent upon non-
coding RNA (ncRNA) transcribed from regulatory regions within the Cyclin D1 promoter.
ARE V ARE IV ARE III 
TMPRSS2 
ARE II ARE I 
-13545 bp -12871 bp -9719 bp -9080 bp -770 bp -1 bp 
0 
20 
40 
60 
80 
100 
120 
R
el
at
iv
e 
en
ric
hm
en
t 
- doxycycline  
+ doxycycline 
0 
2 
4 
6 
8 
10 
12 
IgG Mouse IgG Rabbit FUS AR 
Mibolerone: -  -  + + -  -  + + -  -  + + -  -  + + 
IP: 
R
el
at
iv
e 
en
ric
hm
en
t 
(B) TMPRSS 2 ARE I 
IP: IgG Mouse IgG Rabbit FUS AR Mibolerone: -  -  + + -  -  + + -  -  + + -  -  + + 
(C) TMPRSS 2 ARE II 
0 
2 
4 
6 
8 
R
el
at
iv
e 
en
ric
hm
en
t 
- doxycycline  
+ doxycycline 
IP: 
0 
2 
4 
6 
8 
10 
12 
14 
IgG Mouse IgG Rabbit FUS AR 
Mibolerone: -  -  + + -  -  + + -  -  + + -  -  + + 
R
el
at
iv
e 
en
ric
hm
en
t 
(D)TMPRSS 2 ARE III 
- doxycycline  
+ doxycycline 
IP: IgG Mouse IgG Rabbit FUS AR Mibolerone: -  -  + + -  -  + + -  -  + + -  -  + + 
(E) TMPRSS 2 ARE IV (F) TMPRSS 2 ARE V 
0 
20 
40 
60 
80 
R
el
at
iv
e 
en
ric
hm
en
t 
IP: IgG Mouse IgG Rabbit FUS AR Mibolerone: -  -  + + -  -  + + -  -  + + -  -  + + 
- doxycycline  
+ doxycycline 
- doxycycline  
+ doxycycline 
(A) 
Figure 5.12. Assessment of androgen receptor (AR) and FUS recruitment to the promoter of 
TMPRSS2 in LNCaP-FUS cells by chromatin immunoprecipitation. (A) Diagram representing 
putative androgen response elements (AREs) I-IV, and validated ARE V in the TMPRSS2 
promoter. (B-F) LNCaP-FUS were androgen deprived for 72 hours in the presence or absence of 
10nM doxycycline. Cells were then treatment with 10nM or ethanol vehicle control for 2 hours. 
Cells were fixed, harvested and lysed and chromatin sheared by sonication. Cross linked 
chromatin was immunoprecipitation for 1 hour using 2µg of rabbit polyclonal AR and monoclonal 
mouse FUS specific antibodies for each treatment condition. Immunoprecipitation was also 
performed for each treatment condition using 2µg of species matched IgGs as control. Precipitated 
DNA was amplified by quantitative real time PCR using primers specific for TMPRSS2 AREs I-IV 
as indicated. Results are the mean of one experiment repeated in duplicate ± 1 stardard deviation, 
* = P<0.05 (Student?s T test).  
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Figure 5.13. Assessment of androgen receptor (AR) and FUS recruitment to the promoter of 
PSA in LNCaP-FUS cells by chromatin immunoprecipitation. (A) Diagram depicting the 
enhancer androgen response element (ARE) and negative ARE regions of the PSA promoter. (B) 
LNCaP-FUS cells were androgen deprived for 72 hours in the presence or absence of 10nM 
doxycycline. Cells were then treatmened with 10nM or ethanol vehicle control for 2 hours. Cells 
were fixed, harvested and lysed and chromatin sheared by sonication. Cross-linked chromatin was 
immunoprecipitation for 1 hour using 2µg of rabbit polyclonal AR and monoclonal mouse FUS 
specific antibodies for each treatment condition. Immunoprecipitation was also performed for each 
treatment condition using 2µg of species matched immunoglobulins (IgGs) as control. Precipitated 
DNA was amplified by qRT-PCR using primer specific for PSA enhancer ARE and ARE negative 
regions as indicated. Results are the mean of one experiment repeated in duplicate ±1 stardard 
deviation, * = P<0.05 (Student?s T test).  
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FUS binds to ncRNA, which relieves an inhibitory NH2/COOH-terminal intra-molecular 
interaction. The ncRNA, due to its homology with the target sequence, tethers FUS to the 
Cyclin D1 promoter, where it binds to and inhibits the HAT activity of CBP and p300 (Wang 
et al., 2008). Thus the ability of FUS to regulate Cyclin D1 expression is allosterically 
regulated by ncRNA. Since FUS is able to repress the ligand-dependent activity of the AR 
(Figure 4.2 and 4.6), this leads to the hypothesis that ncRNA may be involved in FUS-
mediated repression of AR target gene transcription. 
 To investigate this hypothesis the pTER RNA expression plasmid containing a 25 
base pair RNA oligonucleotide sequence (published by Wang et al., 2008) containing the 
‘GGUG’ motif to which FUS binds (Lerga et al., 2001) (plasmid pTER-GGUG created by Dr 
G Brooke, unpublished) was transfected into COS-1 cells and the ability of FUS to repress 
AR transcriptional activity measured using luciferase transcription assays as described for 
Figure 4.1. Data is expressed as a percentage of luciferase activity in the absence of 
pSG5-FUS and presence of pSG5-EMPTY or pTER plasmids after 24 hours treatment 
with 10nM mibolerone (Figure 5.14). 
 Confirming the findings of Figure 4.1, in the absence of pTER-GGUG and pTER-
EMPTY FUS repressed the ligand-dependent transcriptional activity of AR with a 
maximum 73% repression of luciferase activity upon co-transfection of 400ng of pSG5-
FUS (Figure 5.14). Co-transfection of plasmid pTER-EMPTY or plasmid pTER-GGUG 
inhibited this FUS-mediated repression of AR activity, with no significant change in 
luciferase activity, with the exception of a slight decrease in the ligand-dependent activity 
of AR by 22% upon co-transfection with 100ng pSG5-FUS and pTER-GGUG (Figure 
5.14). It is unclear why the empty pTER plasmid also blocks the FUS-mediated repression 
of AR, but it can be hypothesized that the short pieces of RNA that will be transcribed from 
the empty plasmid (i.e. the multicloning site) may also contain a sequence to which FUS 
binds.  
Figure 5.14. The effect of non-coding RNA upon the FUS-mediated repression of Androgen 
Receptor (AR) transcriptional activity in COS-1. Cells were transiently co-transfected with 50ng 
of AR expression vector pSVAR, 100ng of β-galactosidase expression plasmid PDM-LACZ-βGAL, 
1 µg of AR responsive luciferase reporter plasmid TAT-GRE-E1B-LUC and increasing amounts of 
pSG5-FUS. Cells were additionally co-transfected with either 100ng of plasmids pTER-EMPTY, 
pTER-GGUG or pSG5-EMPTY where indicated. Cells were incubated for 24 hours with 10nM 
mibolerone or ethanol as vehicle control prior to lysis. Cell lysates were assayed for luciferase 
activity and luciferase activity normalized to β-galactosidase data. Results were expressed as a 
percentage of the AR activity after 24 hours of 10nM mibolerone treatment in the absence of 
pSG5-FUS. Results are the mean of 3 independent experiments repeated in duplicate ±1stardard 
error. * = P<0.05 ** = P<0.005 (Student’s T test). 
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5.11 Discussion 
5.11.1 FUS contains a transcriptional activation and repression domain 
 Reporter assays using GAL4-DBD fused FUS constructs demonstrated that FUS 
contains an NH2-terminal transcriptional activation domain within amino acids 1-366 (Figure 
5.3B). This domain contains FUS amino acids 1-266 that are found in oncogenic fusion with 
transcription factors including CHOP (Crozat et al., 1993). The observed FUS NH2-terminal 
transcriptional activation function supports the findings of several other groups who 
demonstrated that the FUS NH2-terminal contains a transcription activation domain using 
reporter assays (Prasad et al., 1994; Sanchez-Garcia & Rabbitts, 1994; Uranishi et al., 
2001; Zinszner et al., 1994).  
 Reporter assays were also performed to determine whether FUS has intrinsic 
transcriptional repression activity. The FUS constructs D and F were able to repress, in 
trans, the transcriptional activity of the potent transcription factor VP16, indicating the FUS 
COOH-terminal amino acids 367-526 contain a transcriptional repression domain (Figure 
5.4B). 
 Interestingly, full length FUS activated transcription in the trans-activation assay, 
increasing luciferase activity to approximately 170% (Figure 5.3B), and also repressed 
transcription in the trans-repression assay, reducing VP16-induced luciferase activity to 
approximately 55% (Figure 5.4B). The luciferase reporter construct pGL2-LEXA-GAL4-LUC 
was used in both transcription assays. One possible explanation for the observed dual 
transcriptional activity in the trans-repression and trans-activation assays is that full length 
FUS may at the GAL4 response element have a weak transcriptional activation potential on 
the pGL2-LEXA-GAL4-LUC luciferase reporter construct, as observed in the trans-activation 
assay. This FUS activation complex may inhibit the recruitment of the LEXA-VP16 
transcriptional activation complex in the trans-repression assay, possibly by steric hindrance, 
resulting in the relative transcriptional repressive activity of FUS FULL construct. 
 The observed transcriptional repressive activity of NH2-terminal FUS amino acids 1-
366 and transcriptional activation activity of COOH-terminal amino acids 367-526 suggests 
that the transcriptional activity of FUS may also be regulated by the allosteric conformation 
of FUS. To explore this, the trans-repression and trans-activation assays could be performed 
in the presence and absence of the GGUG RNA oligonucleotide, which is known to interrupt 
the intramolecular FUS NH2/COOH-terminal interaction and activate the FUS repressive 
capacity of Cyclin D1 transcription (Wang et al., 2008).  
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 In order to gain greater mechanistic understanding of the intrinsic transcriptional 
activity of FUS, further mapping of transcriptional activity domains is also required. The use 
of smaller FUS domains in both the trans-repression and trans-activation assays may 
indicate smaller candidate domains whose functions could be explored by deletion or site 
directed mutagenesis within full length FUS. The alignment of TET family protein sequences 
using the CLUSTAL 2.1 multiple amino acid sequence alignment program tool 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Larkin et al., 2007) identified FUS amino acids 
258-267 ‘DRGGFNKFGG’, located in the NH2-terminus of FUS 5’ of the RRM domain, as 
being highly conserved between all TET members, where amino acids are either identical 
between all three TET family members or share a conserved substitution of an amino acid of 
similar properties (Figure 5.15). This conservation suggests this motif may be functionally 
important, and would be a sensible location at which to begin to examine intrinsic 
transcriptional activity of FUS via site directed mutagenesis.  
 
5.11.2. The FUS NH2-terminal represses AR transcriptional activity, whilst the FUS 
COOH-terminal activates AR transcriptional activity          
 The NH2-terminal amino acids 1-366 in FUS construct A are necessary to achieve AR 
repression levels equal to that of full length FUS (Figure 5.5B). The RRM domain is likely to 
be important for this activity, since deletion of the RRM from COOH-terminal constructs of 
FUS revealed an AR activation domain within the FUS COOH-terminal amino acids 426-526 
(Figure 5.5B).  
 Interestingly, FUS amino acids 1-366 also demonstrated intrinsic transcriptional 
activation activity (Figure 5.3B), and Wang et al., showed NH2-terminal FUS amino acids 1-
211 interact with transcriptional co-activators p300 and CBP and inhibit their HAT activity at 
the Cyclin D1 promoter (Wang et al., 2008). Therefore, it may be possible that the FUS 
activation domain represses AR activity via competition for essential transcriptional co-
activators at a physical or functional level, including CBP and p300, which are known AR co-
activators (Aarnisalo et al., 1998; Fu et al., 2000). In support of this, FUS NH2-terminal 
amino acids 1-366 were also shown to interact with the known AR co-factors SRC-1 and 
ARA70 (Figure 5.9B).   
 In contrast to the FUS NH2-terminal, the FUS COOH-terminal amino acids 426-526 in 
construct FUS E activated the transcriptional activity of the AR (Figure 5.5B). This AR 
activation domain is contained within the FUS transcriptional repression domain (amino 
acids 367-526) (Figure 5.4B). A mammalian 2-hybrid assay did not detect a mibolerone-
TET protein: 
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Conservation: 
Figure 5.15. Identification of highly conserved amino acid sequence in the TET protein 
family using CLUSTALW2 alignment program. CLUSTALW2  multiple protein sequence 
alignment was performed (http://www.ebi.ac.uk/Tools/msa/clustalw2/) between TET family 
protein sequences (FUS variant 1, EWS variant 2 and TAF15 variant 2). Amino acids for TET 
family members are represented by the single amino acid code and amino acid number also 
indicated. Amino acids are colour coded according to physiochemical properties, where blue 
represent acidic amino acids, magenta represents basic amino acids, red represents small, 
hydrophobic and aromatic amino acids and green represents hydroxyl, amine and basic amino 
acids. CLUSTALW2 alignment tool inserts gaps to give maximal conservation. Identically 
conserved amino acids are represented by ?*? and conservation between amino acids groups 
of similar properties is represented by ?:?. ClustalW and ClustalX version 2 (2007) Larkin MA 
et al., Bioinformatics 2007 23(21): 2947-2948. 
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dependent interaction with construct FUS E (Figure 5.6B), nor did this construct interact with 
AR co-activators CBP, ARA70, p300, and SRC-1 (Figure 5.9B). This suggests the 
enhancement of AR activity is unlikely to be due to association of this FUS domain with the 
AR or enhanced AR co-activator recruitment. Further investigation to elucidate this 
mechanism of AR activation could involve expanding the interaction studies between 
construct FUS E and AR co-activators and basal transcription machinery. It may be possible 
that construct FUS E is stabilizing the AR ligand-bound AR conformation, or facilitating 
translocation of AR to the nucleus. Further interaction studies including immunoprecipitation 
could be performed to explore further the interaction of construct FUS E with the AR in the 
absence of LEXA and GAL4-DBD tagged proteins as used in the mammalian 2-hybrid 
assay, in case these may distort AR conformation. 
  
5.11.3 Full length FUS and shorter FUS domains differentially interact with the AR 
 In addition to inhibiting the ligand-dependent activity of AR (Figure 4.1 and 5.5B), 
FUS is also reported to bind to nuclear receptors, including ERα, and this interaction has 
been mapped to the DBD (Powers et al., 1998). Furthermore, GST interaction studies 
demonstrated the interaction of FUS with the AR DBD and identified a novel interaction of 
FUS with domains AF2 in the presence of the AR antagonist bicalutaimide and a weak 
treatment-independent interaction with the AF1 domain (Figure 1.23, unpublished data from 
Dr Charlotte Bevan laboratory). Therefore, FUS may inhibit the ligand-dependent activity of 
AR by interaction with the AR directly, either by inhibiting AR-DNA interaction via binding to 
the AR DBD, or by disrupting AR co-activator recruitment by binding to AF1 and AF2 
domains. A mammalian 2-hybrid interaction assay was performed to further investigate AR 
interaction with full length FUS and shorter FUS domains, the result of which suggested the 
RRM is necessary for a ligand-dependent interaction with full length AR (Figure 5.6B). 
However, due to the intrinsic transcriptional activation activity of FUS domains (as 
demonstrated in Figure 5.3B), this assay may not distinguish between luciferase activity due 
to intrinsic transcriptional activity of FUS or VP16-mediated luciferase activity due to 
interaction with AR, unless a significant increase or decrease in luciferase was detected 
upon ligand treatment, as observed for FUS constructs A, B1, B2, C an D  (Figure 5.6B). 
This suggests these domains do interact with the AR in a ligand-dependent manner (Figure 
5.6B). More informative would be to perform the mammalian 2-hybrid assay in the presence 
and absence of VP16-AR, enabling a more quantitative and direct comparison of FUS 
domain intrinsic transcriptional activity and VP16-AR mediated activity.   
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 It is interesting to note that the addition of bicalutamide did not stimulate the 
interaction of FUS constructs with VP16-AR (Figure 5.6B) in contrast to the observed 
bicalutamide-induced association with AR domains AF2 and AF2-HINGE in the GST 
interaction assay (Figure 1.23, unpublished data from Dr Charlotte Bevan’s laboratory). A 
possible explanation for this is that bicalutamide is an anti-androgen and molecular 
simulation modelling suggests bicalutamide binds to the AR ligand pocket and distorts the 
AF2 helix 12, preventing co-activator recruitment (Osguthorpe & Hagler, 2011). Bicalutamide 
has also been shown to enhance the recruitment of AR co-repressors, including NCoR and 
SMRT, to promoter of ARGs (Kang et al., 2004; Shang et al., 2002). Therefore, bicalutamide 
represses AR transcriptional activity and thus may inhibit VP16-AR-dependent luciferase 
activity in the mammalian 2-hybrid assay.   
 Co-immunoprecipitation assays were performed in an attempt to confirm the 
interaction of FUS and AR observed in the GST interaction assay, whereby endogenous AR 
was immunoprecipitated from LNCaP lysates and the AR-associated proteins analysed by 
Western blot analysis with a FUS specific antibody. Reverse co-immunoprecipitation was 
also performed with an AR specific antibody. Both co-immunoprecipitation experiments were 
unsuccessful due to the presence of FUS in the IgG control, suggesting that FUS may be 
non-specifically pulled-down by the IgG.  The use of a more stringent wash buffer may help 
to overcome this non-specific FUS pull-down. Recently however, Halie et al., have 
demonstrated that FUS and the AR are found in the same protein complex in LNCaP cells by 
co-immunoprecipitation (Haile et al., 2011), confirming the FUS-AR interaction observed in 
the GST interaction assay.  
 
5.11.4 Full length AR is necessary for maximal FUS-mediated repression of AR 
activity 
 The deletion of either of the NH2-terminal activation domains, Tau1 or Tau5, or the 
ligand binding domain (AF2) reduced the FUS-mediated repression of AR activity in 
transcription assays (Figure 5.8C and 5.7B), demonstrating that full length AR is necessary 
for maximal FUS-mediated repression of the AR. Interaction of FUS with these deleted AR 
domains may be necessary for maximal FUS-mediated repressive activity.  
 
5.11.5 FUS NH2-terminal interacts with transcriptional co-activators 
 The interaction of FUS domain A with p300 (Figure 5.9B) supports the findings of 
Wang et al., who reported p300 to interact with the NH2-terminal FUS amino acids 1-211 
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(Wang et al., 2008). In contrast to these findings, however, interaction of FUS with CBP was 
not detected. This may reflect a difference in cell lines used and further interaction studies 
would be required to investigate this. A novel interaction between FUS NH2-terminal amino 
acids 1-366 with SRC-1 and ARA70 was also detected (Figure 5.9B). Wang et al., also 
demonstrated that the interaction of FUS with co-activators is dependent upon the 
conformation of FUS, which is allosterically regulated by ncRNA (Wang et al., 2008) (as 
described previously in section 1.10.1.3). This ncRNA-regulated interaction of FUS with co-
activators may also extend to SRC-1 and ARA70, since they share a common FUS 
interaction domain (Figure 5.9B).   
 Interestingly, no interaction was detected between full length FUS and co-activators 
(Figure 5.9B), and this may be due to the absence, or low levels, of ncRNA required to 
disrupt the FUS NH2/COOH-terminal intramolecular interaction. Wang et al., reported that 
the ncRNA responsible for allosteric modulation of FUS and subsequent activation of co-
activator binding, is transcribed at very low levels from the Cyclin D1 promoter in response 
to DNA damage in RAW 264.7 cells. For example, Cyclin D1 ncRNA expressing region D 
increases from 2 copies to 4 copies per cell upon ionizing irradiation (Wang et al., 2008). 
The ncRNA to which FUS binds may therefore be limiting in COS-1 cells, under which 
circumstances the FUS intramolecular NH2/COOH-terminal interaction may be the 
predominant FUS conformation, thus preventing NH2-terminal co-activator binding. 
  
5.11.6 FUS-mediated AR repression is class I and II HDAC independent 
 Co-repressors modulate the activity of transcription factors, in part, via HDAC 
recruitment, promoting condensed chromatin conformation by the removal of histone acetyl 
groups (Abbas & Gupta, 2008; Glass & Rosenfeld, 2000). However, the intrinsic 
transcriptional repressive capacity of FUS was not relieved upon the addition of HDAC class 
I and II inhibitors in the trans-repression assay, suggesting a HDAC class I and II-
independent mechanism of FUS-mediated transcriptional repression (Figure 5.11C). The 
addition of nicotinamide, a HDAC class III inhibitor, significantly relieved the transcriptional 
repression activity of full length FUS in the trans-repression assay (Figure 5.11C). This 
suggests that the class III HDACs may be involved in some of the repressive actions of FUS. 
However, Western blot analysis was unable to detect nicotinamide-dependent increased 
acetyl-H3 (Figure 5.10B). Therefore, in the absence of a positive control it is not possible to 
confirm the involvement of HDAC class III in FUS-mediated repression. Furthermore, 
nicotinamide did not relieve the FUS-mediated repression of the AR (Figure 5.10C). Recent 
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studies report down regulation of the class III HDAC, Sirtuin 1 (SIRT1), in the presence of 
50µM nicotinamide after 48 hours (Peck et al., 2010). Therefore, the use of nicotinamide at 
the lower concentration of 50µM compared to 5mM used as for Figure 5.10 and 5.11, and 
the probing of Western blot of assay lysates with a SIRT1 antibody, may provide a positive 
control for nictotinamide-mediated HDAC class III inhibition. A lower concentration of 
nicotinamide may also relieve the transcriptional repressive activity of full length FUS in the 
trans-repression assay and also reduce the FUS-mediated repression of the AR, which was 
not affected by 24 hour incubation with 5mM nicotinamide (Figure 5.10).  
 
5.11.7 FUS was not detected at TMPRSS2 androgen response elements 
 Transcription of the androgen-regulated gene TMPRSS2 is negatively-regulated by 
FUS, since increased exogenous FUS expression decreased TMPRSS2 expression 
(Figure 4.5), and decreased endogenous FUS expression increased TMPRSS2 
expression in LNCaP cells (Figure 4.6). FUS is also known to negatively-regulate the 
transcription of RNA Polymerase III regulated genes and Cyclin D1 by promoter 
recruitment (Tan & Manley, 2010; Wang et al., 2008). It was therefore hypothesized that 
FUS may inhibit TMPRSS2 transcription via direct recruitment to the TMPRSS2 promoter. 
Since TMPRSS2 is an androgen-regulated gene, the recruitment of FUS to potential 
androgen response elements was examined in the presence of increased exogenous FUS 
expression in LNCaP cells. The recruitment of AR to androgen response elements was 
also examined, since FUS has been shown to interact with the AR DNA binding domain 
(Figure 1.23) and may physically block the binding of AR to the TMPRSS2 androgen 
response element. In agreement with chromatin immunoprecipitation studies by Wang et 
al., the AR was recruited to TMPRSS2 putative androgen response element V, however 
additional AR recruitment was also detected at putative androgen response elements I 
and IV (Figure 5.12), which Wang et al., did not observe (Wang et al., 2007). A significant 
increase in AR recruitment at TMPRSS2 androgen response element V was detected in 
the presence of increased FUS expression (doxycycline treatment), and this warrants 
validation by further chromatin immunoprecipitation studies.   
 Chromatin immunoprecipitation was unable to detect the recruitment of FUS to the 
TMPRSS2 promoter androgen response elements in LNCaP-FUS cells (Figure 5.12). 
Wang et al., have shown that recruitment of FUS to the Cyclin D1 promoter is dependent 
upon ncRNA transcribed from the promoter of Cyclin D1 (Wang et al., 2008). In addition to 
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allosterically modifying FUS to relieve an inhibitory NH2/COOH-terminal FUS interaction, 
ncRNA is also believed to direct FUS recruitment to the ncRNA ‘expressing’ regions of the 
Cyclin D1 promoter (Wang et al., 2008). Therefore, recruitment of FUS to the TMPRSS2 
promoter may be ncRNA-dependent. The identification of ncRNA transcribed from the 
promoter of TMPRSS2 may indicate possible FUS binding sites and the hypothesized 
ncRNA-mediated repression of TMPRSS2 transcription by FUS warrants further 
investigation. 
 
5.11.8 FUS domain summary 
 In summary, reporter assays confirm the presence of an intrinsic transcriptional 
activation domain contained within FUS NH2-terminal amino acids 1-366. This domain also 
interacts with the known AR co-regulators SRC-1, ARA70 and p300 and represses the 
transcriptional activity of AR. Interestingly, the AR transcriptional repression domain is also 
the FUS intrinsic transcriptional activation domain. A novel transcriptional repression 
domain was also identified within FUS COOH-terminal amino acids 367-526 (Figure 5.16), 
and this domain contains within it an AR transcriptional activation domain.  
 In support of GST studies (Figure 1.23, unpublished data from Dr Charlotte Bevan’s 
laboratory), a mammalian-2 hybrid assay revealed FUS interacts with the AR, and the FUS 
RRM is essential for the ligand-dependent interaction of FUS with the AR. This AR 
interaction domain overlaps with the AR repression domain (amino acids 1-366). The 
significance of these results will be discussed in chapter 6.  
R/G rich RRM ZnF G rich S/Y/G/Q rich R/G rich 
1                                  165          265 288         366         426   449        526 
FUS 
Activation domain: 
 
Repression domain: 
 
Co-activator interaction: 
 
AR interaction: 
 
AR activation domain: 
 
AR repression domain: 
Figure 5.16. FUS domain activity summary diagram.  A schematic representation of the FUS 
protein structure including the RNA recognition motif (RRM) and zinc finger domain (ZnF). The 
amino acid domain boundaries  and domain activities are indicated below.  
Amino acids: 
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6. Final Conclusions 
 
 The Androgen Receptor (AR) regulates the growth, development and function of 
the prostate gland and is expressed in prostate cancer tumours and throughout 
development to hormone-refractory tumour growth (as reviewed in Taplin & Balk, 2004). 
Androgen blockade is the primary treatment for prostate tumours that cannot be surgically 
removed, and this is achieved by either surgical castration and/or inhibiting the AR using 
anti-androgens. However, this treatment invariably fails, after a median 18-24 months, as 
the tumours become hormone-refractory and continue to grow in the presence of low 
‘castrate’ androgen concentrations (Tammela, 2004). The proposed mechanisms of 
androgen deprivation therapy failure and progression to hormone refractory prostate 
cancer include AR amplification and/or over-expression, AR gain of function mutation and 
co-factor deregulation which result in hyper-sensitization of the AR to androgens (as 
reviewed in Feldman & Feldman, 2001; Knudsen & Scher, 2009). Therefore, the 
identification of novel androgen-regulated targets that mediate the androgen-dependent 
growth response in prostate cells may provide useful targets for prostate cancer therapy 
and/or potential markers for disease progression. 
 
FUS is an androgen down-regulated target and regulates androgen-dependent cell 
cycle progression 
 Androgens exert their proliferative effect on prostate cells via regulation of the 
expression of G1/S regulatory proteins to facilitate transition through the G1/S check point, 
including the up-regulation of Cyclin D1 and p21CIP and the down-regulation of CDK 
inhibitor p27KIP (Knudsen et al., 1998). The mechanism(s) by which androgens, via the AR, 
mediate this regulation remain largely unknown, and the identification of androgen targets 
with cell cycle regulatory activity may provide mechanistic insight into the androgen-
regulation of cell cycle progression.  
 FUS is a member of the TET family of RNA binding proteins, and is implemented in 
many physiological processes, including transcriptional regulation, splicing and mRNA 
transport (as reviewed in Tan & Manley, 2009). FUS expression is down-regulated in 
response to androgens in the prostate cancer cell line, LNCaP. This suggested that FUS 
may be involved in androgen signalling and its down-regulation may be necessary for 
androgen-dependent growth in prostate cancer cells. In support of this, increased 
exogenous FUS expression inhibited androgen-dependent cell cycle progression, leading 
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to G1 arrest and induction of apoptosis in LNCaP cells. FUS mediates inhibition of the 
androgen-dependent cell cycle, in part, via the modulation of the expression of G1/S 
regulatory checkpoint proteins including the down-regulation of Cyclin D1 and CDK6 and 
the up-regulation of p27KIP. The observed FUS-mediated repression of Cyclin D1 supports 
the findings of Wang et al., who demonstrated that FUS is a negative regulator of Cyclin 
D1 transcription (Wang et al., 2008).  
 Furthermore, Brooke et al. demonstrated that FUS is recruited to the promoter of 
Cyclin D1 in LNCaP cells and dissociates from the promoter after 2 hours treatment with 
mibolerone (Brooke et al., 2011) (Appendix). Therefore, FUS may repress Cyclin D1 
expression via promoter recruitment. It is possible that androgens not only mediate the 
down-regulation of the novel cell cycle repressor FUS at the protein level, but also initiate 
a more rapid release of FUS-mediated repression of the cell cycle by causing the 
dissociation of FUS from the Cyclin D1 promotor, thus enabling androgen stimulation of 
Cyclin D1 expression and progression through the G1/S cell cycle check point.  
 The down-regulation of FUS by androgens, and the FUS-mediated promotion of 
G1/S cell cycle arrest and apoptosis in prostate cancer cells, in part, via modulation of cell 
cycle regulatory proteins demonstrates that FUS is a key regulator of androgen-dependent 
cell cycle progression and has properties of a novel tumour suppressor. In support of this, 
Brooke et al. demonstrated that FUS represses the growth of LNCaP tumour xenografts in 
nude mice, whereby increased exogenous FUS expression induced tumour shrinkage and 
apoptosis. Furthermore, immunohistochemistry studies demonstrated that FUS expression 
is inversely correlated with increasing prostate tumour Gleason grade (a measure of 
prostate cancer progression and aggressiveness), and patients with higher FUS levels had 
longer survival times and were less likely to have bone metastases (Brooke et al., 2011).  
 This work indicates that a feed-forward regulatory mechanism may exist, whereby 
androgens stimulate the growth of prostate cells via the AR, whilst simultaneously inducing 
the down-regulation of an AR cell-cycle repressor, FUS. Release of the FUS-mediated 
inhibition of the G1/S cell cycle checkpoint enables androgen-dependent cell cycle 
progression and increased proliferation. 
 
FUS is a novel repressor of AR transcriptional activity 
 Glutathione-S-Transferase (GST) studies (Figure 1.23, unpublished result from Dr 
Charlotte Bevan’s labratory) demonstrated that FUS interacts with the AR DNA binding 
domain (DBD), supporting the observations of Powers et al., that FUS interacts with 
 185 
nuclear receptor DBDs (Powers et al., 1998). The GST studies also revealed a ligand-
independent interaction with the AR activation function (AF) 1 domain and a bicalutamide-
dependent interaction with the AF2 domain. Furthermore, the mammalian 2-hybrid assay 
revealed a ligand-dependent interaction between FUS and the AR, and this required the 
FUS RNA recognition motif (RRM). The physical interaction of FUS with the AR suggests 
that FUS may also modulate the androgen signalling axis by directly targeting the AR 
itself. In support of this hypothesis, transient transcription assays demonstrated that FUS 
over-expression suppressed the ligand-dependent activity of the AR in multiple cells lines. 
These effects were not a consequence of transient transfection, since over expression of 
FUS from a chromatinized template was able to repress endogenous AR activity as 
measured by quantitative real time PCR (qRT-PCR) of known androgen target genes such 
as Prostate Specific Androgen (PSA) and Kallikrein 2 (KLK2).  
 Accordingly, it was hypothesized that the reduction of endogenous FUS expression 
would increase expression of androgen regulated genes, however siRNA had an opposing 
effect upon the expression of the androgen regulated genes in LNCaP cells since 
decreased ligand dependent-expression was observed for PSA, KLK2 and Differentiation-
Related Gene-1 (DRG1). The androgen regulated gene Transmembrane Protease Serine-
2 (TMPRSS2) was the exception, since its expression increased following FUS knock-
down. Since the siRNA FUS used only reduced FUS expression by 60%, performing the 
experiment with a more potent siRNA oligonucleotide may give a more accurate insight 
into FUS regulation of androgen-regulated genes. However, this data does support 
negative regulation of the expression of TMPRSS2, which supports the hypothesis that 
FUS is a repressor of AR transcriptional activity under some circumstances at least. 
 This apparent paradoxical regulation of androgen-regulated gene expression may 
be explained by the fact that FUS is a multi-functional protein with both transcriptional 
activation and repression activities, and exerts its transcriptional repressive effects via 
multiple mechanisms. For example, FUS represses transcription of Cyclin D1 via a non-
coding RNA (ncRNA) dependent mechanism, whereby ncRNA transcribed from the Cyclin 
D1 promoter binds and allosterically modulates FUS, enabling recruitment to the Cyclin D1 
promoter, where the FUS NH2-terminal domain interacts with co-activators CBP and p300 
and inhibits their histone acetyl transferase activity (Wang et al., 2008). FUS has also 
been shown to act as a transcriptional repressor by disrupting transcription factor 
recruitment to DNA, for example FUS associates with the DNA binding domain of 
transcription factor RUNX, and inhibits the transcription of RUNX-regulated genes possibly 
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via inhibition DNA binding (Li et al., 2010). FUS can also act as a transcipional co-
activator, for example it interacts with the trans-activation domain of p65, a member of the 
Nuclear Factor κB (NF-κB) family, and co-activates transcription from a NF-κB reporter 
plasmid. Furthermore, increased FUS expression also up-regulated expression of the p65 
regulated gene ICAM-1 (Uranishi et al., 2001). 
 The observed differential regulation of androgen-regulated gene expression in 
response to FUS knock-down, and its reported transcriptional regulatory activity of multiple 
FUS target proteins, suggests mechanisms may exist to enable specific regulation of 
androgen-regulated genes by FUS. For example, the novel mechanism by which ncRNA 
transcribed from the promoter of Cyclin D1 enables the transcriptional repressive capacity 
of FUS at the Cyclin D1 promoter (Wang et al., 2008). Therefore, it is possible that 
allosteric regulation of FUS transcriptional activity by gene specific ncRNA may be one 
mechanism by which FUS achieves differential and specific transcriptional regulation of 
androgen-regulated genes.  
 It is an interesting observation that androgens down-regulated the expression of 
FUS, yet FUS mediates repression of the AR in the presence of ligand. One possible 
explanation is that since AR activity is dependent upon the balance between co-activator 
and co-repressor activity, the FUS down-regulation in response to androgen may permit 
additional regulation of the AR transcriptional activity. Also, little is known about the 
regulation of FUS expression, and it is possible that despite the presence of androgen, 
additional stimuli may increase FUS expression and enable FUS-mediated repression of 
the AR in the presence of androgen, serving as an additional regulatory mechanism of AR 
transcriptional activity or possible involvement in the termination of the androgen 
response. 
  
FUS may be important for anti-androgen action 
 Bicalutamide is an anti-androgen and in the absence of structural data showing 
bicalutamide bound to wild-type AR, data simulation modelling suggests that bicalutamide 
binds to the ligand-binding domain of AR in a site adjacent to the ligand binding pocket 
and distorts helix 12 to prevent co-activator recruitment (Osguthorpe & Hagler, 2011). 
Bicalutamide also promotes recruitment of co-repressor NCoR and SMRT to the 
promoters of androgen-regulated genes (Shang et al., 2002). Therefore, the bicalutamide-
dependent FUS-AR interaction suggests that FUS may be an important factor in the anti-
androgen mediated inhibition of AR transactivation. If so, FUS expression levels could also 
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be an important factor in patient response to anti-androgen therapy, since the observed 
decrease in FUS expression in high Gleason grade tumours may contribute towards less 
efficient repression of the AR in the presence of bicalutamide and subsequent therapy 
failure. As a consequence, the bicalutamide-dependent AR-FUS interaction warrants 
further investigation. For example it would be interesting to investigate by chromatin 
immunoprecipitation whether FUS and the AR are co-recruited to the regulatory regions of 
AR target genes in the presence of bicalutamide and other anti-androgens.  
 
FUS may repress AR activity by competing for co-activator activity 
 During investigation of the mechanism(s) by which FUS represses AR activity, 
mapping of the intrinsic transcriptional repression and activation domains demonstrated 
that FUS contains an intrinsic transcriptional activation domain in the NH2-terminus and a 
transcriptional repression domain within the COOH-terminus. Interestingly, transcription 
assays also demonstrated that the AR activation domain within FUS is the region critical 
for FUS intrinsic repression activity. This suggests that FUS may repress AR activity via 
competition for AR co-activator activity at a physical or functional level. In support of this, 
the FUS NH2-terminal intrinsic activation domain is also the FUS co-activator recruitment 
domain, as demonstrated by Wang et al., who reported recruitment of co-activators CBP 
and p300 to the FUS NH2-terminal domain (Wang et al., 2008). Furthermore, transcription 
assays confirmed the interaction of the FUS NH2-terminal domain with p300 and identified 
novel interaction with AR co-activators SRC-1 and ARA70. FUS may mediate AR 
repression via direct competition for AR co-activator binding, and this squelching of a 
limited pool of AR co-regulators could result in decreased AR transactivation. 
 FUS may also compete for AR co-activator activity by direct interaction with the AR 
and inhibition of co-activator recruitment, since GST interaction studies demonstrated FUS 
binds to the AF1 domain, which is the principal domain for AR recruitment of co-activators 
including SRC-1 (Bevan et al., 1999). In support of this, FUS-mediated repression of the 
AR is reduced upon deletion of the AF1 transcription activation units (Tau) Tau1 and Tau5 
which are key interaction sites for co-activators including the p160 co-activator family 
(Bevan et al., 1999; Christiaens et al., 2002). The hypothesized FUS-mediated repression 
of the AR via functional or direct competition for AR co-activator binding sites could be 
further explored by transient transfection assays to examine whether it is possible to 
reverse the potential FUS-mediated squelching effect or competition with co-activator 
binding by over-expression of an AR co-activator such as SRC-1.  
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 Interestingly, the intrinsic transcriptional repression of full length FUS may be HDAC 
III-dependent since this intrinsic repressive activity was relieved upon the addition of 
HDAC III inhibitor nicotinamide. However, the FUS-mediated repression of AR is HDAC 
class I, II and III independent since sodium butyrate, valporic acid, tricostatin A and 
nicotinamide had no effect upon the FUS-dependent repression of AR. This further 
supports the hypothesis that FUS-mediated AR repression is not due to the intrinsic 
repressive activity of FUS, and rather points to competition for AR co-activator activity or 
inhibition of AR co-activator binding as potential mechanisms by which FUS mediates 
transcriptional repression of the AR.   
 
FUS does not appear to repress AR activity via recruitment to androgen regulated 
elements 
 Wang et al. demonstrated that FUS repressed transcription of Cyclin D1 via ncRNA-
dependent recruitment to the Cyclin D1 promoter, where FUS inhibited p300 and CBP 
histone acetyl transferase activity (Wang et al., 2008). Chromatin immunoprecipitation 
studies did not detect FUS at TMPRSS2 androgen response elements, which suggests 
that FUS does not repress TMPRSS2 expression via recruitment to androgen response 
elements. However, FUS binding ncRNAs transcribed from the TMPRSS2 promoter have 
not been identified. Therefore, if FUS promoter recruitment is ncRNA-dependent, 
identification of ncRNA coding regions may provide potential FUS recruitment sites where 
FUS could exert its transcriptional repressive activity. Furthermore, distal nuclear steroid 
receptor binding elements upstream of transcriptional start sites are able to interact with 
proximal promoter regions via chromosomal looping (Carroll et al., 2005). For example, 
chromatin immunoprecipitation combined with chromosomal conformation capture (termed 
ChIP-3C) demonstrated that an oestrogen response element 144kb upstream of the 
transcriptional start site of the oestrogen regulate gene Nuclear Receptor Interacting 
Protein 1 (NRIP-1) interacts with a response element in the promoter of NRIP-1 (Carroll et 
al., 2005). Therefore, distal androgen response elements up stream of TMPRSS2 should 
also be investigated as possible locations for FUS recruitment, where FUS may exert its 
transcriptional repressive activity.  
 FUS may also repress AR transcriptional activity via inhibition of AR recruitment to 
androgen response elements upstream of the transcriptional start site of androgen-
regulated genes. In support of this mechanism, GST interaction studies demonstrated that 
FUS interacted with the AR DBD, which could result in steric inhibition of DNA binding. 
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However, chromatin immunoprecipitation studies did not detect decreased AR recruitment 
to TMPRSS2 androgen response elements upon increased exogenous FUS expression in 
the LNCaP cell line, suggesting that FUS did not inhibit AR recruitment to DNA. This 
supports the findings of Powers et al., who reported that FUS binding to the DNA binding 
domain of the Thyroid Receptor did not inhibit receptor interaction with the thyroid 
response element in vitro (Powers et al., 1998).  
 Interestingly, in LNCaP cells expressing doxycycline-inducible FUS cDNA, 
chromatin immunoprecipitation studies detected increased AR recruitment to TMPRSS2 
androgen response elements I, IV and V in the presence of doxycycline. However, the AR 
has been shown to cycle on and off the promoters of the androgen-regulated genes in 
response to ligand, for example the AR has a binding cycle of approximately 90 minutes at 
the KLK2 and PSA promoters (Kang et al., 2002). Furthermore, the use of proteasome 
inhibitors demonstrated that proteasomal-dependent degradation of the AR is necessary 
for subsequent rounds of transcription (Kang et al., 2002). Therefore, it may be possible 
that FUS inhibits the release of the AR from the promoter of TMPRSS2, and this may 
subsequently affect AR transcriptional activity.   
 
Future work 
 In addition to the future work already suggested, additional experiments could be 
performed to further explore the role of FUS in androgen signalling:   
 
Cell cycle studies 
• To further investigate the mechanism(s) by which FUS regulates cell cycle 
progression more stable cell lines could be made with FUS under the control of a 
doxycycline inducible promoter. For example, the stable over expression of FUS in 
the AR negative PC3 cell line would enable investigation into the importance of the 
AR in FUS-mediated inhibition of cell cycle progression. Furthermore, it would be 
interesting to examine the cell cycle regulatory role of FUS in different tumour types, 
for example the breast cancer cell line MCF-7.  
 
• To investigate the effect of increased FUS expression on LNCaP cells that were 
already under going cell cycle in response to androgen, LNCaP-FUS cells could be 
treated with mibolerone prior to induction of exogenous FUS expression by 
doxycycline treatment.  The harvesting of the cells for FACS analysis at 8, 16 and 
 190 
24 hours post doxycycline treatment would enable the effect of increasing FUS 
expression on cycling cells to be analyzed. 
 
• The mechanism(s) by which FUS induces inhibition of the androgen-dependent 
G1/S cell cycle progression in LNCaP cells could be explored further by expanding 
the number of cell cycle regulatory proteins examined for changes in expression in 
response to increased exogenous FUS expression to include p21CIP, which is a 
regulator of the G1/S cell cycle transition. p21CIP is a direct androgen target, and its 
expression is up-regulate by androgen in prostate cells (Lu, 1999) where it is 
hypothesized to stimulate Cyclin D1/CDK4 complex formation (Balk & Knudsen, 
2008). The observed FUS-dependent inhibition of the G1/S cell check point and the 
p21CIP-mediated regulation of the G1/S cell cycle transition suggests p21CIP 
expression is an interesting target to examine in response to increased FUS 
expression in LNCaP cells. 
 
Apoptosis studies 
• The mechanism(s) by which FUS induces apoptosis in LNCaP cells could be further 
studied by the generation of stable LNCaP cell lines expressing shorter FUS 
domains under the control of a doxycycline inducible promoter, enabling 
identification of potential FUS domains that induce apoptosis. 
 
• mRNA mircroarray analysis of the LNCaP-FUS cell line in response to mibolerone 
and in the presence or absence of doxcycline may help to identify FUS-regulated 
genes and provide further insight into the mechanism(s) of FUS-mediated 
regulation of the AR signalling pathway, inhibition of androgen-dependent cell cycle 
progression and induction of apoptosis. 
 
Chromatin immunoprecipitation studies 
• To further investigate the mechanism(s) by which FUS represses the androgen-
dependent expression of TMPRSS2 ChIP studies could be expanded to investigate 
whether FUS mediates this repression via recruitment to the TMPRSS2 promoter. 
ChIP analysis could be repeated using a FUS specific antibody that recognizes a 
different FUS epitope, the use of which may enhance the sensitivity of the assay. 
The TMPRSS2 promoter should also be examined for additional distal AREs where 
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FUS may also be recruited, since chromosomal confirmation capture ChiP has 
recently demonstrated recruitment of the oestrogen receptor to an oestrogen 
response element located 144Kb upstream of the transcriptional start site of the 
oestrogen regulated gene NRIP-1 (Carroll et al., 2005).  
 
• The recruitment of FUS to the Cyclin D1 promoter and the repression of Cyclin D1 
transcription is ncRNA-dependent (Wang et al., 2008). The identification ncRNA 
transcribed from the TMPRSS2 promoter may indicate possible FUS recruitment 
sites within the TMPRSS2 promoter and these ncRNA transcribing sites could be 
examined for FUS recruitment using ChiP analysis.  
 
Final summary 
 FUS is an androgen down-regulated target and a key link to AR-dependent cell 
cycle progression. It inhibits androgen-dependent cell cycle progression in prostate cancer 
cells via the modulation of G1/S cell cycle check point regulatory proteins to facilitate G1 
arrest, and also interacts with the AR and is a novel co-regulator of AR transcriptional 
activity. FUS is a known transcriptional regulatory protein and uses multiple mechanisms 
to mediate such effects, including the novel ncRNA-dependent repression of Cyclin D1. 
Investigation into the mechanism(s) by which FUS represses the AR revealed that FUS 
has an NH2-terminal transcriptional activation and co-activator interacting domain, which is 
also the AR repression domain. Therefore, FUS may inhibit AR transactivation via 
competition for AR co-activator activity (Figure 6.1). The ability of FUS to repress AR 
activity, inhibit androgen-dependent growth and promote apoptosis in prostate cancer cells 
suggests that increased FUS expression may be a possible therapeutic strategy for the 
treatment of prostate cancer and the investigation into signalling pathways that up-regulate 
FUS expression may provide potential drug targets. 
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8. Appendix 
Mo lecu lar and C e llu lar Pathob io logy
FUS/TLS Is a Nove l Med iator of Androgen-Dependent
C e ll-Cyc le Progress ion and Prostate C ancer Growth
Greg N . Brooke1, Rache l L. Culley1, D . A lwyn Dart1, David J. Mann2, Luke Gaughan6, Stuart R. McCracken6,
Cra ig N . Robson6, Brad ley Spencer-Dene3, S imon C . Gamb le1, Sue M . Powe ll1, Rob in Wa it4, Jonathan Waxman1,
Marjorie M . Wa lker5, and Charlotte L. Bevan1
Abstra ct
Progression of prostate cancer is highly dependent upon the androgen receptor pathway, such that knowledge
of androgen-regulated proteins is vital to understand and combat this disease. Using a proteomic screen,
we found the RNA-binding protein FUS/TLS (Fused in Ewing's Sarcoma/Translocated in Liposarcoma) to be
downregulated in response to androgen. FUS has recently been shown to be recruited by noncoding RNAs to the
regulatory regions of target genes such as cyclin D1, in which it represses transcription by disrupting complex
formation. Here we show that FUS has some characteristics of a putative tumor suppressor, as its overexpression
promoted growth inhibition and apoptosis of prostate cancer cells, whereas its knockdown increased cell
proliferation. This effect was reproducible in vivo, such that increasing FUS levels in tumor xenografts led to
dramatic tumor regression. Furthermore, FUS promoted conditions that favored cell-cycle arrest by reducing the
levels of proliferative factors such as cyclin D1 and Cdk6 and by increasing levels of the antiproliferative Cdk
inhibitor p27. Immunohistochemical analysis revealed that FUS expression is inversely correlated with Gleason
grade, demonstrating that patients with high levels of FUS survived longer and were less likely to have bone
metastases, suggesting that loss of FUS expression may contribute to cancer progression. Taken together, our
results address the question of how androgens regulate cell-cycle progression, by demonstrating that FUS is
a key link between androgen receptor signaling and cell-cycle progression in prostate cancer. Cancer Res; 71(3);
914–24.  2010 AACR.
Introduct ion
Prostate cancer is almost invariably dependent upon the
androgen receptor (AR) pathway, which when activated sti-
mulates cell proliferation. Several factors involved in cell-cycle
progression are regulated in response to androgen — for
example, cyclin D1, which is upregulated (1–3). Non–organ-
confined prostate cancer is treated with analogues of luteiniz-
ing hormone releasing hormone (LHRH), which block andro-
gen production, and/or antiandrogens, which bind to the AR
and hold it in an inactive state. Although initially successful,
these treatments consistently fail and the tumors progress to a
more aggressive hormone-refractory stage for which few
therapeutic options exist. Expression of the AR is maintained
in this refractory stage and much evidence exists to suggest
that the receptor is still driving growth (4). Downstream
targets of the AR involved in cell growth are therefore impor-
tant in terms of further characterising this disease and iden-
tifying new therapeutic targets.
FUS (Fused in Ewing's Sarcoma), also known as TLS
(Translocated in Liposarcoma), is a member of the TET family,
along with Ewing's Sarcoma (EWS) and TATA-binding pro-
tein-associated factor TAF15/TAFII68 (5). These family mem-
bers, which are structurally and functionally related, are
defined by the presence of an N-terminal SYGQ-rich region,
a C2/C2 zinc finger motif, an RNA-recognition motif and at
least 1 RGG-repeat region (6). FUS was originally identified in
human myxoid and round cell liposarcomas as an oncogenic
fusion with the stress-induced DNA-binding transcription
factor CHOP (CCAAT enhancer-binding homologous protein;
ref. 7, 8). FUS is a multifunctional protein, being implicated in
pre-mRNA splicing (9), chromosome stability (10), cell spread-
ing (11), and transcription (12, 13). Recently, FUS has been
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shown to be directed to the regulatory regions of target genes
by single stranded noncoding RNA (ncRNA) transcripts teth-
ered to DNA; repressing transcription by binding to and
inhibiting complexes bound to such elements (12). This
suggests that ncRNAs, via recruitment of RNA-binding pro-
teins such as FUS, can act cooperatively as selective ligands to
regulate transcription.
Here we show that FUS is an AR target protein down-
regulated in response to androgen. Overexpression of FUS
significantly retards androgen-induced prostate cancer cell
growth in vitro and in vivo, regulates the expression of several
factors involved in cell-cycle progression (for example, cyclin
D1), and induces G1 arrest and apoptosis. FUS therefore
exhibits certain characteristics of a tumor suppressor. Immu-
nohistochemistry performed upon human tissue arrays
demonstrated that FUS expression is inversely correlated with
prostate tumor grade, and that patientswith high levels of FUS
have longer survival rates and are less likely to have bone
metastases and hence we surmise that loss of FUS expression
is important in disease progression.
Materia ls and Methods
Ce l l culture
LNCaP cells (ATCC CRL-1740) were obtained in 2003 from
American Type Culture Collect ion, where they are verified
phenotypically and by short tandem repeat profiling, frozen
in liquid nitrogen, and fresh aliquots defrosted for use every
4 to 6 months. Cell were grown in RPMI 1640 media as
described previously (14) and their identity further verified
at least every 1 to 2 months by testing for morphology
(m icroscopic inspection), AR expression (immunoblott ing),
hormone sensit ivity (reporter or PSA assay), and myco-
plasma contamination (MycoA lert; Lonza). The LNCaP-
TR2 (15) and LNCaP-FUS lines were grown in RPMI 1640
media supplemented with 10% TET-free fetal calf serum
(C lontech), in the presence of the relevant antibiotics for
selection purposes. Seventy-two hours before exposure to
ligand, media were replaced with phenol red-free RPMI,
supplemented with 2 mmol /L L-glutamine, 100 U/mL peni-
cillin, 100 mg/mL streptomycin (Sigma-A ldrich) and 5%
charcoal-stripped FBS (Labtech Internat ional).
2D-SDS PAGE
Four samples were prepared per experimental condition.
Cells were incubated with ligand for 16 hours before lysis and
proteins separated by 2D-SDS PAGE as previously described
(14). Gels were stained using Sypro-ruby (GE Healthcare) and
spots detected using PDQuest version 8 (Bio-Rad). Spots found
to be significantly regulated between treatments were excised
and sequenced using mass spectrometry as previously
described (16).
Generation of stable ce l ls inducibly expressing FUS ce l l
l ine
For insertion of FUS in to the pCDNA4-TO plasmid, FUS
was amplified by PCR with the addition of BamHI and XhoI
restriction sites (for 50-GGA TCC ATG GCC TCA AAC GAT
TAT ACC C-30 , rev 50- CTC GAG TTA ATA CGG CCT CTC CCT
GC-30). Both the plasmid and PCR product were digested with
BamHI and XhoI before ligation and subsequently verified by
sequencing. The pCDNA4-TO-FUS plasmid was stably trans-
fected in to the LNCaP-TR2 line as previously described (15,
17).
Deplet ion of FUS leve ls using siRNA
FUS levels were reduced in LNCaP cells, using a Dharmacon
On-Target siRNA pool (L-009497-00-0005; Thermo Scientific)
as previously described (18). To calculate percentage knock-
down, densitometry was performed using Image J (NIH). FUS
levels were normalized to b-actin and expressed as a percen-
tage of FUS levels following treatment with scrambled siRNA.
Real-t ime quantitat ive PCR
Cells were treated for the indicated times and RNA har-
vested using Qiashredders and RNEasy kits (Qiagen Ltd.). F ive
hundred nano grams of RNA was reverse transcribed using the
SuperScript F irst-Strand Synthesis System (Invitrogen). Gene
expression was quantified using quantitative real-time PCR on
a Taqman 7900HT (Applied Biosystems; ref. 18).
Western blott ing
Cells were lysed in RIPA buffer and protein concentration
determined by DC protein assay (Bio-Rad). F ifteen micro
grams of protein was separated on a 10% SDS polyacrylamide
gel and electrophoretically transferred (Transblot; Bio-Rad)
onto nitrocellulose membrane. Membranes were blocked for
30 minutes in PBS–0.5% Tween containing 5% nonfat milk
powder followed by a 1 hour incubation with primary anti-
body against: FUS (4H11), cyclin E1 (HE-12), CDK2 (M2), and
p27(C-19) were from Santa Cruz Biotechnology; b-actin (AC-
15) and cyclin D1 (ab24249) were from Abcam; cleaved PARP
(Asp214) was from Cell Signaling Technology; retinoblastoma
(554162) was from BD Biosciences; phosphospecific antibody
for retinoblastoma Rb-pSer807/811 was from Sigma-Aldrich
(R6400; Sigma-Aldrich); cyclin A2 (E23-1) was a kind gift from
Dr Gordon Peters (CRUK LRI). Membranes were washed 3
times with PBS–Tween and incubated for a further hour with
the relevant secondary antibody (Dako). Three washes with
PBS-T and 1 wash with PBS were performed before chemilu-
minescent detection using ECL-PLUS (GE Healthcare).
Ce l l-cycle analysis
Cells were washed with PBS, trypsinized, and pelleted (1,200
rpm, 5 minutes). After 2 washes with PBS, cells were fixed in
70% ethanol (overnight at 4  C). Cells were washed 3 times
with PBS before incubation for 1 hour with 50 mg/mL
propidium iodide and 50 mg/mL RNAse A in PBS. FACS
analysis was carried out using a Becton-Dickinson FACS
Calibur machine using linear scale representation of forward
and side scatter during flow analysis. A total of 10,000 events
were measured per sample.
Growth and caspase assays
LNCaP-FUS and the parental LNCaP-TR2 cells were seeded
at 1,000 per well on a 96-well plate in ‘strippingmedia ’ and left
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for 24 hours. Cells were treated with and without mibolerone
and with and without doxycyline for the indicated times.
Changes in cell proliferation were quantified using WST1
assay (Roche), following the manufacturers instructions.
Simultaneous plates were assayed for evidence of caspase
3/7 activity using Caspase-Glo assays (Promega) and activity
normalized for cell proliferation.
Chromatin immunoprecip itat ion
LNCaP cells were grown to approximately 70% and serum
starved for 72 hours. Cellswere treated 0, 2, or 24 hourswith 10
nmol/L mibolerone before cross-linking with formaldehyde
(Sigma) for 10minutes at RT. Chromatin immunoprecipitation
(ChIP) was performed using the Millipore Chromatin Immu-
noprecipitation K it (Millipore) following the manufacturer's
instructions, with the exception that a protein A/G sepharose
mix was used. DNA was recovered by phenol–chloroform
extraction and real-time quantitative PCR was used to quan-
titate enrichment of regions of the CCND1 promoter. A:
for - 50-CTCCACCTCACCCCCTAAATC-30 , rev - 50-AGAGCC-
CAAAAGCCATCC-30; C: for - 50-CCGACTGGTCAAGGTAG-
GAAG-30 , rev: 50-ACAACCCCTGTGCAAGTTTC-30 ; D: for -
50-GGGACCCTCTCATGTAACCA-30 , rev - 50GAGCCGGCATA-
ATTCAGAAC30 (12).
Tissue microar ray and immunohistochemist ry
Immunohistochemistry was performed using 3 tissue
microarrays (TMA) of benign and malignant prostate biopsies
derived from transrectal biopsy, transurethral resection, and
radical prostatectomy as previously described (19). All mate-
rials were used in accordance with approval granted by the
Northumberland, Tyne and Wear NHS Strategic Health
Authority Research Ethics Committee (reference 2003/11;
The Freeman Hospital). The final study included 321 cancer
biopsies and 69 benign biopsies. Antigen retrieval was
achieved by immersion in 10 mmol/L citric acid buffer
(pH 6.0), followed by microwaving for 15 minutes (at 1,000
W) in a pressure cooker. Sections were immunostained with a
rabbit polyclonal antibody against FUS (Santa Cruz Biotech-
nology) on a DAKO autostainer using Vectastain ABC kits
(Vector Labs), according to the manufacturer's protocol. Sec-
tions known to stain positively were included in each batch,
and negative controls were prepared by replacing the primary
antibody with TBS buffer. FUS expression was scored blindly
for epithelial nuclear intensity of staining and number of
epithelial nuclei positive per field, in each biopsy core. Slides
were scanned using a Scanscope GL scanner (Aperio) and
analyzed using Spectrum software (Aperio). For statistical
analysis, samples were split into low or high intensity/number
of positive nuclei (low ¼ 0, 1 and high ¼ 2, 3).
In vivo xenograft mode l
About 2  106 LNCaP-FUS cellsmixed with an equal volume
of matrigel (BD Biosciences) were injected subcutaneously
into the flanks of castrated male balb/c nude mice (Harlan
Laboratories). Animals received bi-daily testosterone replace-
ment injections until the tumors were established, following
which the mice were split into experimental groups:  dox-
ycycline and  testosterone. Tumors were measured using
calipers and relative tumor volume (RTV) calculated as pre-
viously described (20). After sacrifice, tumors were resected
and immunohistochemistry performed as previously
described (20) using antibodies specific for phospho-histone
H3 (Ser10; Millipore), active caspase 3 (AF835; R&D Systems),
and cleaved PARP (Asp214; Cell Signaling Technology).
Resu lts
FUS is downregulated by androgen treatment
To identify targets regulated by the androgen receptor, a
2D-proteomic screen was performed on the AR positive
LNCaP prostate cancer cell line, which is dependent on
androgen for growth, treated with mibolerone (a synthetic
androgen) or vehicle for 16 hours. Proteins were separated
using 2D SDS-PAGE, stained with Sypro-Ruby and spots found
to have a significant change in density in response to androgen
excised and identified using mass spectrometry. A spot found
to be downregulated in response to androgen, running at
around 75 kDa and pI 9.4, was identified as FUS (F ig. 1A). To
confirm androgen regulation of FUS expression, the LNCaP
line was treated with androgen for 0 to 72 hours and immu-
noblotting performed (F ig. 1B). FUS expression was found to
be reduced by more than 90% after 72 hours of stimulation
with androgen. This regulation appears to be at least partly at
the RNA level, as qRT-PCR demonstrated a significant
decrease in FUS over a 72-hour time course (56% reduction
at 72 hours; F ig. 1C). As a control, expression of the known
androgen regulated gene prostate specific antigen (PSA) was
measured and increased transcription in response to andro-
gen was confirmed. C-jun has been previously shown to
regulate FUS degradation (21), and hence we investigated
whether this posttranscriptional regulation was also impor-
tant in the androgen induced downregulation of FUS. In
accordance with this hypothesis, and in agreement with the
work of Perrotti and colleagues (21), we found that c-jun
expression was androgen-dependent, with upregulation of
c-jun protein evident within 8 hours of androgen treatment
(Supplementary F ig. 1A), preceding the decrease in FUS.
However, reducing c-jun levels by siRNA or treating cells with
the protease inhibitor lactacystin did not affect the androgen-
induced downregulation of FUS (Supplementaryl F ig. 1B and
1C). We therefore surmise that the androgen-dependent reg-
ulation of FUS is independent of c-jun and proteasomal
degradation and is instead predominantly regulated at the
transcriptional level.
FUS represses LNCaP growth
Because androgen treatment results in both prostate cell
proliferation and a reduction in FUS expression, we tested the
hypothesis that FUS is a suppressor of growth. To investigate
this, we created a stable cell line to allow doxycycline-indu-
cible overexpression of FUS. Addition of doxycycline led to an
increase in FUS expression, with maximal expression at 10
nmol/L and within 24 hours (Supplementary F ig. 2). Light
microscopy revealed that this exogenous FUS expression
results in cell rounding within 4 days and a marked reduction
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in cell number by day 6 (F ig. 2A, top). To quantify this, growth
assays were performed over the same timecourse. In the
absence of ligand, little proliferation was evident, whereas
addition of mibolerone resulted in a 6-fold increase in pro-
liferation after 8 days (F ig. 2A, bottom). Exogenous FUS
expression in the presence of ligand resulted in a decrease
in cell number, with fewer cells present after 8 days than were
seeded. To ensure that these effects were not an artifact of
F igure 1. FUS is downregulated in
response to androgen. LNCaP
ce lls were exposed to mibolerone
(MIB) or vehic le (ethanol, EtOH). A ,
lysates were separated by 2D ge l
e lectrophoresis and prote ins
visua lized using SyproRuby
sta ining. S ignificant d ifferences in
spot intensity between trea tments
were identified using PDQuest
v6.2.1 (B io-Rad) and prote in
identities determined using mass
spectrometry. B , LNCaP ce lls
were treated for the ind icated
times, lysates separated by SDS-
PAGE , and immunob lotting
performed . Densitometry was
performed upon 3 independent
samp les and data norma lized to
b-actin and expressed re lative to 0
hours. C , LNCaP ce lls were
treated for the ind icated times w ith
ligand , RNA harvested , and rea l-
time quantitative PCR performed .
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doxycycline treatment, growth assays were performed on the
parental cells (LNCaP-TR2), which were unaffected by dox-
ycycline treatment, demonstrating that the inhibition of
androgen-stimulated growth is as a result of FUS overexpres-
sion (F ig. 2A). To investigate the effect of FUS upon cell-cycle
progression, cells were propidium iodide (PI) stained and
analyzed using FACS. In agreement with previous studies
(for example, 2, 14), in the absence of ligand LNCaP cells
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F igure 2. FUS b locks androgen-
dependent prostate ce ll growth.
A , the LNCaP-FUS line was
treated w ith and w ithout
doxycyc line (DOX) and w ith
mibolerone (MIB) and images
taken w ith a phase contrast
microscope at the ind icated times
(bars, 100 mm). The effect of FUS
overexpression upon androgen-
induced ce ll proliferation was
quantified using WST1 assays.
WST1 assays were a lso
performed upon the parenta l line ,
LNCaP-TR2. B , at the ind icated
time point, ce lls were fixed ,
sta ined w ith PI, and ce ll-cyc le was
ana lyzed by FACS . Data were
ana lyzed using F lowJo v8.8.6
(TreeStar). C , the 4 days FACS
data were reana lyzed to exc lude
the sub-G1 pool. D , LNCaP ce lls
were transfected w ith scramb led
siRNA or siRNA to target FUS and
incubated for 3 days before
treatment w ith d ifferent doses of
ligand . Ce lls were left for 3 or
6 days follow ing treatment w ith
mibolerone (MIB) before WST1
growth assays were performed .
t test *, P < 0.05; **,
P < 0.005; ***, P < 0.0005.
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were found to arrest in G1 phase (F ig. 2B and C). Addition of
ligand resulted in cells progressing through to S/G2/M. In the
presence of mibolerone, exogenous FUS resulted in a large
increase sub-G1 peak (from 1.9% of cells to 4.3% at 4 days and
from 2.7% to 31% at 8 days; Supplementary Table 1 and
F ig. 4A). Analysis of the FACs data with the sub-G1 population
removed (to avoid skewing the data) revealed that exogenous
FUS expression (addition of doxycycline) blocks the action of
androgen, resulting in an increase in cells in G1 and reducing
the percentage of cells progressing to S and G2/M (F ig. 2C).
FACS analysis of the parental LNCaP-TR2 showed no change
in cell-cycle profile in response to doxycycline (F ig. 2C and
Supplementary F ig. 2), confirming that these differences are as
a result of increased FUS levels.
To establish the role of FUS in androgen-induced growth we
performed the reciprocal experiment, reducing FUS expres-
sion using transiently transfected siRNA. LNCaP cells were
transfected with siRNA, successful knockdown was confirmed
at the levels of RNA (93%) and protein (74%; Supplementary
F ig. 4), and growth analyzed at days 3 and 6 in response to
different concentrations of mibolerone (F ig. 2D). After 3 days,
reduction of FUS expression resulted in a significant increase
in growth at the highest concentration (10 nmol/L) of ligand.
After 6 days this growth-promoting effect was significant at
both 1 nmol/L and 10 nmol/L mibolerone.
FUS regulates the expression of factors involved in ce l l-
cycle progression
Previously it has been shown that FUS is a negative
regulator of cyc lin D1 expression in RAW264.7 cells (12).
We were therefore interested to see whether increasing FUS
expression in the LNCaP line altered the expression of ce ll-
cycle regulators, either direct ly or (as cyclin D1 is also
androgen-regulated; refs. 22–24) perhaps via preventing
androgen-induced changes, which could potentially explain
G1 accumulat ion and growth inhibition. Western blotting of
lysates from the LNCaP-FUS line demonstrated that increas-
ing FUS leve ls altered the expression levels of several factors
involved in G1 progression (F ig. 3A). Specifically, cyclin D1
and CDK6 levels were decreased in response to FUS over-
expression, whereas the level of the k inase inhibitor p27 was
increased. Litt le change was observed in levels of the other
ce ll-cycle regulators investigated and levels of the AR were
also found to remain unchanged. This indicates that the
effects of FUS on growth are at least in part due to it
promot ing G1 arrest, possibly via regulat ion of cyclin D1,
CDK6 and p27.
Wang and colleagues have previously demonstrated that
FUS binds, via noncoding RNA, to the regulatory regions of
cyclin D1 and blocks transcription (12). In agreement with
their study, the regulation of cyclin D1 by FUS in these
prostate cancer cells appears to be at the transcriptional level,
as overexpression or knockdown of FUS respectively reduces
or enhances androgen-induced cyclin D1 expression at the
RNA level (F ig. 3B). Furthermore, we performed ChIP on the
CCND1 promoter to analyze FUS recruitment to 2 regions
demonstrated by Wang and colleagues to express ncRNA
(regions A and D) and 1 negative region that has been shown
not to express ncRNA (region C; ref. 12; F ig. 3D). FUS was
found to bind to regions A and D but not C, and binding was
only evident in the absence of androgen, supporting our
hypothesis that, in prostate cancer cells, FUS regulates cyclin
D1 expression via recruitment to the CCND1 promoter and
this is modulated by androgen treatment.
FUS induces apoptosis
We have shown that increasing FUS expression in cells
cycling in response to androgen results in an increase in the
sub-G1 population, which suggests an increase in apoptosis
(F ig. 4A and Supplementary Table 1). To confirm whether FUS
can influence rates of apoptosis, caspase 3/7 activity was
measured (F ig. 4B). Exogenous expression of FUS resulted
in an increase in caspase 3/7 activity of 2.9-fold at 4 days and
34-fold at 8 days in the mibolerone-treated cells. No such
doxycycline-induced increase in caspase activity was evident
for the parental LNCaP-TR2 upon androgen treatment. We
also investigated the downstream apoptotic marker of PARP
cleavage. Western blotting demonstrated a ligand- and FUS
overexpression-dependent increase in cleaved PARP (F ig. 4C),
which was evident after 4 days treatment. Hence, it appears
that increasing FUS expression results in an increase in cell
death due to activation of apoptotic pathways.
FUS blocks tumor growth in vivo
Having demonstrated FUS to be a repressor of androgen-
dependent proliferation in culture, we went on to investigate
the role of FUS in prostate tumor progression in vivo. The
LNCaP-FUS line was subcutaneously injected into both flanks
of castrated male nude BALB/c mice. Animals were given bi-
daily injections of testosterone until tumors had reached an
average size of approximately 250 mm3, upon which (day 0)
animals were split into experimental groups of  testosterone
and  doxycycline (F ig. 5A). In the absence of testosterone
tumors did not increase in size during the course of the
experiment, in fact some regression was seen, whereas tes-
tosterone promoted a significant increase in growth (t test,
7 days P < 0.05). Addition of doxycycline to testosterone-
treated mice led to a significant reduction in tumor volume
compared with testosterone alone (P < 0.05 at 7 days), with
tumor volumes falling to sizes comparable to those in animals
receiving no testosterone.
To test whether the effects of FUS overexpression are
reversible, mice that were treated with testosterone and
doxycycline were monitored for an extended period (F ig. 5B).
At day 13 doxycycline was withdrawn and the tumors were
found to grow, expanding up to an average of 1.5 times
original tumor size at day 29 (P < 0.0005). Doxycycline was
reintroduced at day 30 and the RTV again regressed, this
t ime in a dramat ic fashion to approximately 50% of max-
imum size at day 37. Following animal sacrifice, immuno-
histochemistry was performed upon tumor sections to
invest igate the expression of markers of proliferation and
apoptosis. The number of cells expressing the mitotic mar-
ker phospho-histone H3 was found to be significantly
decreased following exogenous FUS expression, whereas
markers of apoptosis (active caspase 3 and cleaved PARP)
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were significantly upregulated (F ig. 5C and Supplementary
F ig. 4).
FUS expression is inverse ly cor re lated with Gleason
grade, survival , and bone metastasis
To determine whether alterations in FUS expression are
associated with prostate cancer progression, immunohisto-
chemistry was performed on prostate cancer tissue micro-
arrays (examples of staining in Supplementary F ig. 5). Sections
were scored for primary Gleason grade and epithelial cells
scored for the number of cells positive for nuclear FUS
staining per field (F ig. 6A) and the intensity of nuclear staining
(F ig. 6B). An inverse correlation of FUS expression with
Gleason grade, a determinant of aggression of prostate cancer
by histology, was found using both scoring methods for all
grades except for benign prostatic hyperplasia (BPH) versus
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primary Gleason grade 3. Analysis of patient survival and data
on the presence of bone metastases found no significant
correlation with the number of cells positive for FUS. FUS
nuclear intensity, however, showed significant correlation
with the presence of bone metastases at the time of biopsy
(data available for 77 patients with confirmed absence of bone
metastases and 37 with confirmed bone metastases), with
patients with high levels of FUS significantly less likely to
present with bone metastases (Mann–Whitney, 2-tailed P
value ¼ 0.0325). Furthermore, a significant difference in
patient survival was observed. Patients with high FUS expres-
sion show significantly longer survival than patients with low
FUS expression, with mean survival increasing from 70.8 to
91.8 months and median from 57 to 109.2 months in the high
expressers versus the low expressers (F ig. 6C and Table 1).
D iscuss ion
Prostate cancer growth is almost always dependent upon
the AR pathway and therefore identification of downstream
targets critical for growth is important for the further char-
acterization of this disease. In an attempt to identify novel
androgen-regulated targets, we performed a proteomic screen
on the LNCaP prostate cancer cell line following stimulation
with androgen. One of the proteins found to be significantly
regulated was the RNA-binding protein FUS. Addition of
androgen was found to result in a decrease in FUS expression
at the RNA and protein level. Perrotti and colleagues have
shown that FUS is regulated at the protein level by c-jun (21),
which targets the protein to the proteasome. Velasco and
colleagues reported regulation of c-jun by androgen (25), and
in support of this we saw upregulation of c-jun protein within
8 hours of androgen treatment (Supplementary F ig. 1A).
Because c-jun upregulation precedes the observed decrease
in FUS levels, we hypothesized that androgens may induce
FUS degradation via increasing c-jun. However, knockdown of
c-jun or treatment with proteasomal inhibitors did not reduce
the androgen-dependent downregulation of FUS. We there-
fore conclude that the regulation of FUS in response to
androgen is predominantly at the transcriptional level.
Because FUS levels are decreased by growth-promoting
androgen treatment we hypothesized that FUS may be a
repressor of prostate cancer growth. In stably transfected
LNCaP cells, we found exogenous FUS expression significantly
inhibits cell growth, causes G1 arrest and promotes apoptosis.
The AR is known to regulate factors important in cell-cycle
progression and appears be particularly important in G1/S
progression because androgen depletion results in G1 arrest
(24). In agreement with this we also found LNCaP cells to
arrest in G1 following removal of androgen, whereas addition
of androgen resulted in an increase in the number of cells
progressing to S and G2/M. Overexpression of FUS, however,
blocked the effects of androgen, leading to G1 arrest and
also an increase in the sub-G1 population. Increased caspase
3/7 activity and an increase in the levels of PARP cleavage
confirmed that this sub-G1 population contained apoptotic
cells. Hence, FUS appears to promote apoptosis in prostate
cancer cells.
Analysis of cell-cycle regulators revealed that manipula-
t ion of FUS levels is assoc iated with altered expression of
several factors important in G1/S transition, spec ifically
cyclin D1, CDK6, and p27. It is known that cyclin D1 and
p27 are androgen targets, and that an increase in cyclin D1
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and a decrease in p27 promote G1 transition (22-24). Our
observed reduction in the expression of this cyc lin and the
increase in p27 following exogenous expression of FUS
suggests that FUS induces G1 arrest and thus affects andro-
gen-dependent proliferat ion, at least in part, via modulat ion
of these factors. Recent ly, FUS was demonstrated to be
directly recruited to the regulatory regions of CCND1, which
encodes cyclin D1, by ncRNA which is transcribed from
various points on the 50 upstream region. This recruitment
leads to interference with transcriptional complex format ion
hence decreased expression of cyclin D1 (12). The regulat ion
of cyclin D1 in response to FUS overexpression or knockdown
was found to be at the RNA level (F ig. 3B). Furthermore, ChIP
revealed FUS binding to ncRNA-expressing regions of the
CCND1 promoter in the absence of androgen, which was
abrogated by androgen treatment. This data therefore fits
with the mechan ism of regulation proposed by Wang and
colleagues (12) and suggests that androgen withdrawal-
mediated repression of cyclin D1 expression is via alterat ions
in recruitment of FUS to the CCND1 promoter. It thus
appears that cyclin D1 is a target of both androgens
(22-24) and FUS (12; and data herein). We have shown that
FUS levels are regulated by androgens, and others have
shown that cyc lin D1 itse lf is a corepressor of the androgen
receptor (26). It is therefore possible that complex funct ional
interactions between FUS, the androgen receptor, and cyc lin
D1 that merit further investigation. Notwithstanding this,
our data demonstrate that man ipulat ion of FUS leve ls influ-
ences the levels of a number of key cell-cycle regulatory
prote ins, indicat ing that FUS may be a crit ical link between
androgen signaling and cell-cyc le progression.
Our data from both in vitro and in vivo systems demonstrate
that FUS has characteristics suggestive of a putative tumor
suppressor. FUS expression in prostate tumor samples was
inversely correlated with Gleason grade and analysis of patient
data demonstrated that those with high expression levels of
FUS had longer survival rates and were less likely to have bone
metastases (the primary cause of morbidity in prostate cancer
patients), suggesting that loss of expression may be important
in disease progression. Our study in xenograft models suggests
that this correlation is not merely circumstantial, as not only
did increasing FUS levels result in decreased tumour growth,
but this effect was also reversible because removing the
exogenous expression increased tumor growth while reexpres-
sing it halved the tumour volume within a week.
From the work presented here, we suggest that androgen
signaling downregulates FUS and that FUS subsequently
regulates factors important in cell-cycle progression. This,
combined with the finding that FUS expression is reduced
in advanced stages of prostate cancer, suggests that loss
of FUS may enhance androgen signaling and promote
prostate cell growth. Furthermore, the demonstration that
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F igure 5. Increasing FUS leve ls
b locks androgen-dependent
tumor growth in vivo . Ma le
castrated nude mice were injected
subcutaneously w ith LNCaP-FUS .
The mice were given b i-da ily
testosterone injections until
tumors had estab lished . A , mice
were sp lit into experimenta l
groups (day 0) and RTV measured
over 7 days. Tumor size was
measured using ca lipers and the
RTVs ca lculated . B , tumor size of
mice in the þ testosterone þ
doxycyc line group were
monitored for an extended time
course during which time
doxycyc line was removed (day 13)
and readm inistered (day 31). Mean
RTV  1 SE . C ,
immunohistochemistry was
performed on sections derived
from the xenograft tumors to
investigate ce lls positive for
markers of proliferation and
apoptosis. The number of positive
ce lls were counted and expressed
as a percentage of the tota l ce ll
number of ce lls in 5 randomly
chosen fie lds of view in at least 2
independent tumors (mean  SE
shown). t test *, P < 0.05;
**, P < 0.005.
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Tab le 1 . FUS expression is corre lated w ith patient surviva l
Nuc lear intens ity Surviva l time , mo
MeanA Med ian
Estimate SE 95% C I Estimate SE 95% C I
Lower bound Upper bound Lower bound Upper bound
H igh 91.798 8.299 75.531 108.065 109.200 34.360 41.854 176.546
Low 70.844 5.722 59.629 82.059 57.000 6.024 45.192 68.808
Overa ll 78.727 4.889 69.145 88.308 67.000 7.637 52.032 81.968
NOTE: The intensity of FUS sta ining was corre lated w ith patient data and med ian and mean surviva l times ca lculated .
aEstimation is limited to the largest surviva l time if it is censored .
F igure 6. FUS expression is
inverse ly corre lated w ith G leason
grade and d irectly corre lated w ith
patient surviva l.
Immunohistochemistry was
performed upon 3 human prostate
cancer tissue microarrays and
cores scored for (A), the number of
ce lls positive for FUS or (B), FUS
sta ining intensity and expressed in
re lation to grade . C , Kap lan–Me ier
graph to show the corre lation
between FUS sta ining intensity
and patient surviva l time (months).
*, P < 0.05; **, P < 0.005;
***, P < 0.0005 (chi-squared test).
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overexpression of FUS in vivo reduces tumor growth suggests
that methods to manipulate FUS expression could be useful
for the treatment of prostate cancer.
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c-jun 
FUS 
β-actin 
blot 
siRNA scram 
siRNA c-jun 
MIB 
- - + + 
- - + + 
- + - + 
EtOH 
MIB 
Lactocystin 
- + - + 
+ - - + 
- - + + 
FUS 
β-actin 
blot 
FUS 
c-jun 
β-actin 
MIB 
0 8 24 Time (hrs) 
blot - + + - - 
A 
B 
C 
Supplemental Figure 1. The down-regulation of FUS in response to androgen is 
independent of c-jun and proteasomal degradation. (A) LNCaP cells were treated with MIB 
(mibolerone) for 8 and 24 hours. Cells were harvested and c-jun and FUS levels investigated 
using immunoblotting. (B)  LNCaP cells were transfected with an siRNA pool to target c-jun. 
Cells were incubated for 72hours before ligand was added and the cells left for an additional 48 
hours. (C) LNCaP cells were treated with mibolerone for 32 hours, 10µM Lactocystin added and 
cells incubated for a further 16 hours.  
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Brooke et al. Supplemental Figure 2 
Supplemental Figure 2. Over-expression of FUS in the LNCaP-FUS line. Western 
blotting of the LNCaP-FUS line to analyze FUS expression in response to (A) differing 
doses of doxycycline (DOX) for 24hrs or (B) 10nM DOX for 0-48hrs. 
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Brooke et al. Supplemental Table 1 
Supplemental Table 1. FUS over-expression results in G1 arrest and an increase in sub-G1. 
LNCaP-FUS were treated ± doxycycline (DOX) ± mibolerone (MIB) for the indicated times.  (A) 
Cells were fixed, propidium iodide stained and cell cycle analyzed using FACs. (B) The FACs data 
was recalculated with the sub-G1 pool removed. 
  
 
EtOH 
 sub-G1 G1 S G2/M 
DOX - + - + - + - + 
4 days 4.5±0.4 4.1±0.2 90.2±0.5 90.5±0.4 1.4±0.2 1.1±0.1 4.0±0.2 4.2±0.1 
8 days 2.9±0.3 3.9±0.5 90.2±0.3 89.5±0.9 1.1±0.0 1.0±0.1 5.8±0.2 5.5±0.4 
 
 
 MIB 
 sub-G1 G1 S G2/M 
DOX  - + - + - + - + 
4 days 1.9±0.2 4.3±0.2 88.3±0.4 88.4±0.2 2.9±0.0 1.4±0.1 7.0±0.2 5.8±0.2 
8 days 2.7±1.1 31.1±2.5 78.1±0.3 56.3±2.2 4.7±0.0 3.7±0.3 14.4±1.4 8.8±0.4 
 
 
 
 
 
 EtOH 
 G1 S G2/M 
DOX  - + - + - + 
4 days 94.4±0.1 94.4±0.2 1.4±0.2 1.2±0.1 4.2±0.3 4.4±0.1 
8 days 92.9±0.2 93.2±0.5 1.1±0.0 1.1±0.1 6.0±0.2 5.7±0.4 
 
 
 MIB 
 G1 S G2/M 
DOX  - + - + - + 
4 days 89.9±0.3 92.5±0.2 2.9±0.0 1.4±0.1 7.1±0.2 6.1±0.2 
8 days 79.2±0.0 81.9±0.6 4.7±0.0 5.3±0.2 16.1±0.1 12.8±0.4 
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Brooke et al. Supplemental Figure 3 
Supplemental Figure 3. Doxycycline has little effect upon the parental LNCaP-TR2 line. 
LNCaP-TR2 were treated ± doxycycline (DOX) ± mibolerone (MIB) for the indicated times. Cells 
were fixed, propidium iodide stained and cell cycle analyzed using FACs.  
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Brooke et al. Supplemental Figure 4 
Supplemental Figure 4. FUS levels can be successfully reduced using siRNA. LNCaP cells 
were either mock, siRNA scrambled or siRNA FUS transfected and left for 3 days.  (A) RNA was 
harvested, reverse transcription performed and FUS levels analyzed using PCR. (B) FUS 
expression at the protein level was analyzed by immunoblotting. 
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Brooke et al. Supplemental Figure 5 
Supplemental Figure 5. Over-expression of FUS results in a reduction in a marker  of 
proliferation and an increase in apoptotic markers. Xenograft tumours were harvested after 4 
days of doxycycline treatment and immunohistochemistry performed to investigate the number of 
cells expressing phospho histone H3, active Caspase 3 and cleaved PARP. Bars = 100µm. 
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Brooke et al. Supplemental Figure 6 
Supplemental Figure 6. FUS expression is inversely correlated with Gleason grade. 
Immunohistochemistry was performed upon a prostate cancer tissue microarray to investigate 
FUS expression in relation to Gleason grade. Bars = 100µm. 
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